



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : C07D 401/04, 471/04 A61K 31/47, 31/435 C07D 207/09, 207/26	A1	(11) International Publication Number: WO 92/09596 (43) International Publication Date: 11 June 1992 (11.06.92)
(21) International Application Number: PCT/US91/08419 (22) International Filing Date: 12 November 1991 (12.11.91) (30) Priority data: 621,201 30 November 1990 (30.11.90) US 731,825 15 July 1991 (15.07.91) US (71) Applicant: WARNER-LAMBERT COMPANY [US/US]; 2800 Plymouth Road, Ann Arbor, MI 48105 (US). (72) Inventors: DOMAGALA, John, Michael ; 776 George- town, Canton, MI 48188 (US). KIELY, John, Steven ; 4138 Sunset Court, Ann Arbor, MI 48103 (US). SCHRO- EDER, Mel, Conrad ; 3020 Inverness, Dexter, MI 48130 (US).		(74) Agents: DAIGNAULT, Ronald, A.; Warner-Lambert Company, 2800 Plymouth Road, Ann Arbor, MI 48105 (US) et al. (81) Designated States: AT (European patent), AU, BE (Euro- pean patent), CA, CH (European patent), DE (Euro- pean patent), DK (European patent), ES (European pa- tent), FR (European patent), GB (European patent), GR (European patent), IT (European patent), JP, LU (Euro- pean patent), NL (European patent), SE (European pa- tent). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the</i> <i>claims and to be republished in the event of the receipt of</i> <i>amendments.</i>
(54) Title: INDIVIDUAL STEREOISOMERS OF 7-[3-(1-AMINOALKYL)-1-PYRROLIDINYL]-QUINOLONES AND NAPHTHYRIDONES AS ANTIBACTERIAL AGENTS (57) Abstract Individual stereoisomers of 7-[3-(1-aminoalkyl)-1-pyrrolidinyl]-quinolones and naphthyridones are described, their therap- eutic advantages as antibacterial agents, as well as a novel method for the preparation and isolation of such stereoisomers.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MN	Mongolia
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GN	Guinea	NL	Netherlands
BJ	Benin	GR	Greece	NO	Norway
BR	Brazil	HU	Hungary	PL	Poland
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LI	Liechtenstein	SU ⁺	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TG	Togo
DE*	Germany	MC	Monaco	US	United States of America
DK	Denmark				

⁺ Any designation of "SU" has effect in the Russian Federation. It is not yet known whether any such designation has effect in other States of the former Soviet Union.

-1-

INDIVIDUAL STEREOISOMERS OF
7-[3-(1-AMINOALKYL)-1-PYRROLIDINYL]-QUINOLONES
AND NAPHTHYRIDONES AS ANTIBACTERIAL AGENTS

5


BACKGROUND OF THE INVENTION

The identification and selection of an antibacterial chemotherapeutic agent for development depends on several properties. These include in vitro potency against bacteria, in vivo efficacy in animals and man, pharmacokinetic parameters such as good plasma levels and favorable metabolism, and reduced side effects and toxicity. The ideal agent should have the best blend of these properties.

Within the quinolone/naphthyridone class of antibacterials efforts are directed toward increasing in vitro and in vivo efficacy while lowering certain side effects such as phototoxicity and cytotoxicity and reducing general toxicity as well.

It is also known that within the chiral environment of living organisms, individual stereoisomers/enantiomers of drugs may show unique properties relative to the racemic mixtures. When this occurs, the optimal properties of the drug can only be obtained when the most favorable stereoisomer is utilized in its pure chiral form.

U. S. Patent 4,665,079 shows quinolones and naphthyridones by structural formula to have 7-[3-(1-aminoalkyl)-1-pyrrolidinyl]side chains. These compounds of formula A, where R_1 or R_2




35

A

-2-

are alkyl or hydrogen were revealed to have good antibacterial in vitro potency. European Patent Publication 207,420 describes such compounds having the two asymmetric centers in the C₇ side chain of the quinolone/naphthyridone and the preparation of two diastereomeric mixtures, each containing two nonseparable enantiomers of formula B and C.



15 The mixtures B and C were described to possess improved in vivo activity relative to unsubstituted compounds (Formula A, where R₁ and R₂ are hydrogen). All data reported were for the mixtures, and no method of separation of the mixtures was described. At the
20 International Congress of Antimicrobial Agents and Chemotherapy (ICAAC) in Houston, Texas, 1989, there were reported certain individual enantiomers of 1-ethyl and 1-cyclopropyl-6,8-difluoro-quinolone-3-carboxylic acids. The 3-(R)-1'-(S) stereoisomers were
25 disclosed to have the most potent activity in vitro. One stereoisomer (3R,1'S) was shown to have improved in vivo efficacy relative to an unsubstituted analog. Except for the in vitro data, no other comparisons among the pure stereoisomers were provided. The
30 method employed to prepare and isolate the individual enantiomers involved putting a chiral auxiliary, N-tosylproline, on the amine side chain and performing a separation, removing the N-tosylproline, then replacing it with a conventional protecting group.


-3-

It has now been found that overall therapeutic value, i.e. efficacy and safety, of individual enantiomers of various 7-[3-(1-aminoalkyl)-1-pyrrolidinyl]quinolones and naphthyridones cannot be predicted until all of the enantiomers are made, separated, and tested.

It has also been found, further, that the use of a chiral auxiliary, such as (S)- or (R)- α -methylbenzylamine, as a protecting group, permits separation of diastereomeric amines, thus saving two costly steps in the overall synthesis of all four stereoisomers of 7-[3-(1-aminoalkyl)-1-pyrrolidinyl]quinolones and naphthyridines.

SUMMARY OF THE INVENTION

Accordingly, the present invention includes all four novel enantiomers of the formula I



I

wherein

* denotes an asymmetric carbon atom;

X is C-H, C-F, C-Cl, C-OR, C-CF₃ or N;

R₁ is ethyl, cyclopropyl, or 2,4-difluorophenyl;

-4-

R_2 is hydrogen, alkyl of 1-4 carbon atoms or a cation;


R_3 is hydrogen, amino, or methyl;

R and R' are each independently hydrogen or alkyl of 1-3 carbon atoms, or a pharmaceutically acceptable acid addition salt thereof; with the proviso that when X is C-F, R_3 is amino or R^1 is 2,4-difluorophenyl.

The invention also includes a pharmaceutical composition which comprises an antibacterially effective amount of a compound having structural formula I and the pharmaceutically acceptable salts thereof in combination with a pharmaceutically acceptable carrier.

The invention further includes a method for treating bacterial infections in a mammal which comprises administering an antibacterially effective amount of the above defined pharmaceutical composition to a mammal in need thereof.


The invention in another aspect includes a process for the preparation of a compound of formula I which comprises reacting a compound of the formula II



II

-5-

wherein L is fluorine or chlorine or other leaving groups with an individual stereoisomer of the amine of formula III



III


wherein * denotes an asymmetric carbon atom;

R is hydrogen or alkyl of 1-3 carbon atoms; and

R'' is hydrogen, alkyl of 1-3 carbon atoms or an amino protecting group which can be removed, if necessary, according to known methods.

The invention in still another aspect includes novel stereoisomers as intermediates which are:

(a) stereoisomers of the formula III



III


wherein * denotes asymmetric carbon atoms;

R and R'' are independently hydrogen or alkyl of 1-3 carbon atoms or an amino

-6-

protecting group which can be removed
by known methods;

(b) stereoisomers of the formula IV



IV

5

wherein * and *' denote asymmetric carbon
atoms;


R is hydrogen or alkyl of 1-3 carbon
atoms; and

10

R'' is hydrogen, alkyl of 1-3 carbon
atoms, acetyl, trifluoroacetyl or
t-butyloxycarbonyl;

(c) stereoisomers of the formula V

15




V

wherein * and *' denote asymmetric carbon
atoms.

-7-

Finally, the invention includes a process for the preparation of the individual enantiomers of the formula III




III

5

wherein * denotes asymmetric carbon atoms and R and R'' are independently hydrogen or alkyl of 1-3 carbon atoms which comprises:

- (a) converting a chirally fixed pyrrolidin-5-one-3-carboxylic acid of the formula VI

10




VI

VI

wherein * and *' is either R or S by known methods to a diastereomeric pair of oximes of the formula

15


-8-



wherein * and *' are asymmetric carbon atoms;

- 5 (b) separating the diastereomers by column chromatography;
- (c) reducing each diastereomeric oxime by known means to a diastereomeric pair of amines of the formula VIII

10




- (d) separating each of these diastereomeric pairs into the individual diastereomers by column chromatography;
- 15 (e) reducing the 5-pyrrolidinone by known methods and protecting the free amino group with a suitable protecting group (such as BOC, Acetate etc.) by known methods, if desired;

-9-

- (f) removing the chiral α -methylbenzyl protecting group by hydrogenolysis, thereby liberating the four, separated diastereomers of formulae IIIa-d, and
- 5 (g) converting, if desired, by known means the resulting compounds of formula VIII or III where R is hydrogen to those where R is independently hydrogen or alkyl of 1-3 carbon atoms. The entire overall process
- 10 can be summarized in Scheme A.

-10-

SCHEME A



-11-

DETAILED DESCRIPTION AND PREFERRED EMBODIMENTS

5 The quinolones and naphthyridones of the present invention have 7-[3-(1-aminoalkyl)-1-pyrrolidinyl] as a side chain. This moiety has two asymmetric centers and thus is capable of existing in four stereoisomeric forms. These are illustrated as IIIa-d in Scheme A.

10 Of the four possible stereoisomers of the quinolones and naphthyridones of the present invention, it has been found that the 3R,1S stereoisomers are generally more potent in vitro, the 3R,1R stereoisomers being second best. However, in vivo efficacy shows the 3R,1S as the generally preferred stereoisomer with the 3S,1R and the 3R,1R
15 alternating for second best. Nevertheless, when considering overall safety and efficacy, i.e. taking potential side effects such as phototoxicity and cytotoxicity into account, the 3S,1R stereoisomers can become overall preferred.

20 Particularly valuable quinolones and naphthyridones are:

3R,1S-7-[3-(1-aminoethyl)-1-pyrrolidinyl]-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid,

25 3R,1S-7-[3-(1-aminoethyl)-1-pyrrolidinyl]-8-chloro-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid,

30 3R,1S-7-[3-(1-aminoethyl)-1-pyrrolidinyl]-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid,

35 3R,1S-5-amino-7-[3-(1-aminoethyl)-1-pyrrolidinyl]-1-cyclopropyl-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid,

-12-

- 3R,1S-7-[3-(1-aminoethyl)-1-pyrrolidinyl]-1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid,
- 5 3R,1S-5-amino-7-[3-(1-aminoethyl)-1-pyrrolidinyl]-1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid,
- 10 3R,1S-7-[3-(1-aminoethyl)-1-pyrrolidinyl]-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-8-trifluoromethyl-3-quinolinecarboxylic acid,
- 15 3R,1S-7-[3-(1-aminoethyl)-1-pyrrolidinyl]-1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-5-methyl-4-oxo-3-quinolinecarboxylic acid,
- 20 3R,1S-7-[3-(1-aminoethyl)-1-pyrrolidinyl]-1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid,
- 25 3R,1S-5-amino-7-[3-(1-aminoethyl)-1-pyrrolidinyl]-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid,
- 30 3R,1S-7-[3-(1-aminoethyl)-1-pyrrolidinyl]-1-cyclopropyl-6-fluoro-1,4-dihydro-5-methyl-4-oxo-3-quinolinecarboxylic acid,
- 35 3R,1S-7-[3-(1-aminoethyl)-1-pyrrolidinyl]-1-cyclopropyl-8-ethoxy-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid,

-13-

- 3R,1S-1-cyclopropyl-6-fluoro-1,4-dihydro-7-[3-[1-(methylamino)ethyl]-1-pyrrolidinyl]-1,8-naphthyridine-3-carboxylic acid,
- 5 3R,1S-8-chloro-1-cyclopropyl-6-fluoro-1,4-dihydro-7-[3-[1-(methylamino)ethyl]-1-pyrrolidinyl]-4-oxo-3-quinolinecarboxylic acid,
- 10 3R,1S-5-amino-1-cyclopropyl-6,8-difluoro-1,4-dihydro-7-[3-[1-(methylamino)ethyl]-1-pyrrolidinyl]-4-oxo-3-quinolinecarboxylic acid,
- 15 3R,1S-1-cyclopropyl-6-fluoro-1,4-dihydro-7-[3-[1-(methylamino)ethyl]-1-pyrrolidinyl]-4-oxo-3-quinolinecarboxylic acid,
- 20 3R,1S-1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[3-[1-(methylamino)ethyl]-1-pyrrolidinyl]-4-oxo-3-quinolinecarboxylic acid,
- 25 3R,1S-5-amino-1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[3-[1-(methylamino)ethyl]-1-pyrrolidinyl]-4-oxo-3-quinolinecarboxylic acid,
- 30 3R,1S-1-cyclopropyl-6-fluoro-1,4-dihydro-7-[3-[1-(methylamino)ethyl]-1-pyrrolidinyl]-4-oxo-8-trifluoromethyl-3-quinolinecarboxylic acid,
- 35 3R,1S-1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-5-methyl-7-[3-[1-(methylamino)ethyl]-1-pyrrolidinyl]-4-oxo-3-quinolinecarboxylic acid,
- 3R,1S-1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-7-[3-[1-(methylamino)ethyl]-1-pyrrolidinyl]-4-oxo-1,8-naphthyridine-3-carboxylic acid,

-14-

- 3R,1S-1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-7-[3-[1-(methylamino)ethyl]-1-pyrrolidinyl]-4-oxo-3-quinolinecarboxylic acid,
- 5 3R,1S-5-amino-1-cyclopropyl-6-fluoro-1,4-dihydro-7-[3-[1-(methylamino)ethyl]-1-pyrrolidinyl]-4-oxo-3-quinolinecarboxylic acid,
- 10 3R,1S-1-cyclopropyl-6-fluoro-1,4-dihydro-5-methyl-7-[3-[1-(methylamino)ethyl]-1-pyrrolidinyl]-4-oxo-3-quinolinecarboxylic acid,
- 15 3R,1S-1-cyclopropyl-8-ethoxy-6-fluoro-1,4-dihydro-7-[3-[1-(methylamino)ethyl]-1-pyrrolidinyl]-4-oxo-3-quinolinecarboxylic acid,
- 20 3R,1S-1-cyclopropyl-7-[3-[1-(ethylamino)ethyl]-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid,
- 25 3R,1S-1-cyclopropyl-7-[3-[1-(ethylamino)ethyl]-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid,
- 30 3R,1S-5-amino-1-cyclopropyl-7-[3-[1-(ethylamino)ethyl]-1-pyrrolidinyl]-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid,
- 35 3R,1S-1-cyclopropyl-7-[3-[1-(ethylamino)ethyl]-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid,

-15-

- 3R,1S-5-amino-1-cyclopropyl-7-[3-[1-(ethylamino)ethyl]-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid,
- 5 3R,1S-1-(2,4-difluorophenyl)-7-[3-[1-(ethylamino)ethyl]-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-5-methyl-4-oxo-3-quinolinecarboxylic acid,
- 10 3R,1S-1-cyclopropyl-7-[3-[1-(ethylamino)ethyl]-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-4-oxo-8-trifluoromethyl-3-quinolinecarboxylic acid,
- 15 3R,1S-1-(2,4-difluorophenyl)-7-[3-[1-(ethylamino)ethyl]-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid,
- 20 3R,1S-1-(2,4-difluorophenyl)-7-[3-[1-(ethylamino)ethyl]-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid,
- 25 3R,1S-5-amino-1-cyclopropyl-7-[3-[1-(ethylamino)ethyl]-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid,
- 30 3R,1S-1-cyclopropyl-7-[3-[1-(ethylamino)ethyl]-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid,
- 35 3R,1S-1-cyclopropyl-7-[3-[1-(dimethylamino)ethyl]-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid,

-16-

3R,1S-1-cyclopropyl-7-[3-[1-(dimethylamino)ethyl]-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid,

5 3R,1S-5-amino-1-cyclopropyl-7-[3-[1-(dimethylamino)ethyl]-1-pyrrolidinyl]-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid,

10 3R,1S-1-cyclopropyl-7-[3-[1-(dimethylamino)ethyl]-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid,

15 3R,1S-8-chloro-1-cyclopropyl-7-[3-[1-(dimethylamino)ethyl]-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid,

20 3R,1S-5-amino-1-cyclopropyl-7-[3-[1-(dimethylamino)ethyl]-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid,

3R,1S-1-cyclopropyl-7-[3-[1-(dimethylamino)ethyl]-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-8-trifluoromethyl-4-oxo-3-quinolinecarboxylic acid,

25 3R,1S-1-(2,4-difluorophenyl)-7-[3-[1-(dimethylamino)ethyl]-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid,

30 3R,1S-1-(2,4-difluorophenyl)-7-[3-[1-(dimethylamino)ethyl]-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid,

35 3R,1S-1-(2,4-difluorophenyl)-7-[3-[1-(dimethylamino)ethyl]-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-5-methyl-4-oxo-3-quinolinecarboxylic acid,

-17-

- 3R,1S-5-amino-1-cyclopropyl-7-[3-[1-(dimethylamino)ethyl]-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid,
- 5 3R,1S-1-cyclopropyl-7-[3-[1-(dimethylamino)ethyl]-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-5-methyl-4-oxo-3-quinolinecarboxylic acid,
- 10 3R,1S-1-cyclopropyl-7-[3-[1-(dimethylamino)ethyl]-1-pyrrolidinyl]-8-ethoxy-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid,
- 15 3S,1R-7-[3-(1-aminoethyl)-1-pyrrolidinyl]-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid,
- 20 3S,1R-7-[3-(1-aminoethyl)-1-pyrrolidinyl]-8-chloro-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid,
- 25 3S,1R-7-[3-(1-aminoethyl)-1-pyrrolidinyl]-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid,
- 30 3S,1R-5-amino-7-[3-(1-aminoethyl)-1-pyrrolidinyl]-1-cyclopropyl-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid,
- 35 3S,1R-5-amino-7-[3-(1-aminoethyl)-1-pyrrolidinyl]-1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid,

-18-

- 3S,1R-7-[3-(1-aminoethyl)-1-pyrrolidinyl]-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-8-trifluoromethyl-3-quinolinecarboxylic acid,
- 5 3S,1R-7-[3-(1-aminoethyl)-1-pyrrolidinyl]-1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-5-methyl-4-oxo-3-quinolinecarboxylic acid,
- 10 3S,1R-7-[3-(1-aminoethyl)-1-pyrrolidinyl]-1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid,
- 15 3S,1R-7-[3-(1-aminoethyl)-1-pyrrolidinyl]-1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid,
- 20 3S,1R-5-amino-7-[3-(1-aminoethyl)-1-pyrrolidinyl]-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid,
- 25 3S,1R-7-[3-(1-aminoethyl)-1-pyrrolidinyl]-1-cyclopropyl-6-fluoro-1,4-dihydro-5-methyl-4-oxo-3-quinolinecarboxylic acid,
- 30 3S,1R-7-[3-(1-aminoethyl)-1-pyrrolidinyl]-1-cyclopropyl-8-ethoxy-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid,
- 35 3S,1R-1-cyclopropyl-6-fluoro-1,4-dihydro-7-[3-[1-(methylamino)ethyl]-1-pyrrolidinyl]-1,8-naphthyridine-3-carboxylic acid,
- 3S,1R-8-chloro-1-cyclopropyl-6-fluoro-1,4-dihydro-7-[3-[1-(methylamino)ethyl]-1-pyrrolidinyl]-4-oxo-3-quinolinecarboxylic acid,

-19-

3S,1R-5-amino-1-cyclopropyl-6,8-difluoro-1,4-dihydro-7-[3-[1-(methylamino)ethyl]-1-pyrrolidinyl]-4-oxo-3-quinolinecarboxylic acid,

5 3S,1R-1-cyclopropyl-6-fluoro-1,4-dihydro-7-[3-[1-(methylamino)ethyl]-1-pyrrolidinyl]-4-oxo-3-quinolinecarboxylic acid,

10 3S,1R-1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[3-[1-(methylamino)ethyl]-1-pyrrolidinyl]-4-oxo-3-quinolinecarboxylic acid,

15 3S,1R-5-amino-1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[3-[1-(methylamino)ethyl]-1-pyrrolidinyl]-4-oxo-3-quinolinecarboxylic acid,

20 3S,1R-1-cyclopropyl-6-fluoro-1,4-dihydro-7-[3-[1-(methylamino)ethyl]-1-pyrrolidinyl]-4-oxo-8-trifluoromethyl-3-quinolinecarboxylic acid,

3S,1R-1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-5-methyl-7-[3-[1-(methylamino)ethyl]-1-pyrrolidinyl]-4-oxo-3-quinolinecarboxylic acid,

25 3S,1R-1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-7-[3-[1-(methylamino)ethyl]-1-pyrrolidinyl]-4-oxo-1,8-naphthyridine-3-carboxylic acid,

30 3S,1R-1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-7-[3-[1-(methylamino)ethyl]-1-pyrrolidinyl]-4-oxo-3-quinolinecarboxylic acid,

35 3S,1R-5-amino-1-cyclopropyl-6-fluoro-1,4-dihydro-7-[3-[1-(methylamino)ethyl]-1-pyrrolidinyl]-4-oxo-3-quinolinecarboxylic acid,

-20-

- 3S,1R-1-cyclopropyl-6-fluoro-1,4-dihydro-5-methyl-7-[3-[1-(methylamino)ethyl]-1-pyrrolidinyl]-4-oxo-3-quinolinecarboxylic acid,
- 5 3S,1R-1-cyclopropyl-8-ethoxy-6-fluoro-1,4-dihydro-7-[3-[1-(methylamino)ethyl]-1-pyrrolidinyl]-4-oxo-3-quinolinecarboxylic acid,
- 10 3S,1R-1-cyclopropyl-7-[3-[1-(ethylamino)ethyl]-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid,
- 15 3S,1R-8-chloro-1-cyclopropyl-7-[3-[1-(ethylamino)ethyl]-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid,
- 20 3S,1R-1-cyclopropyl-7-[3-[1-(ethylamino)ethyl]-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid,
- 25 3S,1R-5-amino-1-cyclopropyl-7-[3-[1-(ethylamino)ethyl]-1-pyrrolidinyl]-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid,
- 30 3S,1R-1-cyclopropyl-7-[3-[1-(ethylamino)ethyl]-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid,
- 35 3S,1R-5-amino-1-cyclopropyl-7-[3-[1-(ethylamino)ethyl]-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid,
- 3S,1R-1-(2,4-difluorophenyl)-7-[3-[1-(ethylamino)ethyl]-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-5-methyl-4-oxo-3-quinolinecarboxylic acid,

-21-

- 3S,1R-1-cyclopropyl-7-[3-[1-(ethylamino)ethyl]-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-4-oxo-8-trifluoromethyl-3-quinolinecarboxylic acid,
- 5 3S,1R-1-(2,4-difluorophenyl)-7-[3-[1-(ethylamino)-ethyl]-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid,
- 10 3S,1R-1-(2,4-difluorophenyl)-7-[3-[1-(ethylamino)-ethyl]-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid,
- 15 3S,1R-5-amino-1-cyclopropyl-7-[3-[1-(ethylamino)-ethyl]-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid,
- 20 3S,1R-1-cyclopropyl-7-[3-[1-(ethylamino)ethyl]-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-5-methyl-4-oxo-3-quinolinecarboxylic acid,
- 25 3S,1R-1-cyclopropyl-8-ethoxy-7-[3-[1-(ethylamino)-ethyl]-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid,
- 30 3S,1R-1-cyclopropyl-7-[3-[1-(dimethylamino)ethyl]-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid,
- 35 3S,1R-1-cyclopropyl-7-[3-[1-(dimethylamino)ethyl]-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid,
- 3S,1R-5-amino-1-cyclopropyl-7-[3-[1-(dimethylamino)-ethyl]-1-pyrrolidinyl]-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid,

-22-

3S,1R-1-cyclopropyl-7-[3-[1-(dimethylamino)ethyl]-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid,

5 3S,1R-8-chloro-1-cyclopropyl-7-[3-[1-(dimethylamino)-ethyl]-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid,

10 3S,1R-1-cyclopropyl-7-[3-[1-(dimethylamino)ethyl]-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid,

15 3S,1R-1-cyclopropyl-7-[3-[1-(dimethylamino)ethyl]-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-8-trifluoromethyl-3-quinolinecarboxylic acid,

20 3S,1R-1-(2,4-difluorophenyl)-7-[3-[1-(dimethylamino)ethyl]-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid,

3S,1R-1-(2,4-difluorophenyl)-7-[3-[1-(dimethylamino)ethyl]-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid,

25 3S,1R-1-(2,4-difluorophenyl)-7-[3-[1-(dimethylamino)ethyl]-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-5-methyl-4-oxo-3-quinolinecarboxylic acid,

30 3S,1R-5-amino-1-cyclopropyl-7-[3-[1-(dimethylamino)-ethyl]-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid,

35 3S,1R-1-cyclopropyl-7-[3-[1-(dimethylamino)ethyl]-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-5-methyl-4-oxo-3-quinolinecarboxylic acid,

-23-

- 3S, 1R-1-cyclopropyl-7-[3-[1-(dimethylamino)ethyl]-1-pyrrolidinyl]-8-ethoxy-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid,
- 5 3R, 1R-7-[3-(1-aminoethyl)-1-pyrrolidinyl]-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid,
- 10 3R, 1R-7-[3-(1-aminoethyl)-1-pyrrolidinyl]-8-chloro-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid,
- 15 3R, 1R-7-[3-(1-aminoethyl)-1-pyrrolidinyl]-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid,
- 20 3R, 1R-5-amino-7-[3-(1-aminoethyl)-1-pyrrolidinyl]-1-cyclopropyl-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid,
- 25 3R, 1R-5-amino-7-[3-(1-aminoethyl)-1-pyrrolidinyl]-1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid,
- 30 3R, 1R-7-[3-(1-aminoethyl)-1-pyrrolidinyl]-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-8-trifluoromethyl-3-quinolinecarboxylic acid,
- 35 3R, 1R-7-[3-(1-aminoethyl)-1-pyrrolidinyl]-1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-5-methyl-4-oxo-3-quinolinecarboxylic acid,

-24-

3R,1R-7-[3-(1-aminoethyl)-1-pyrrolidinyl]-1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid,

5 3R,1R-7-[3-(1-aminoethyl)-1-pyrrolidinyl]-1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid,

10 3R,1R-5-amino-7-[3-(1-aminoethyl)-1-pyrrolidinyl]-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid,

15 3R,1R-7-[3-(1-aminoethyl)-1-pyrrolidinyl]-1-cyclopropyl-6-fluoro-1,4-dihydro-5-methyl-4-oxo-3-quinolinecarboxylic acid,

20 3R,1R-7-[3-(1-aminoethyl)-1-pyrrolidinyl]-1-cyclopropyl-8-ethoxy-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid,

3R,1R-1-cyclopropyl-6-fluoro-1,4-dihydro-7-[3-[1-(methylamino)ethyl]-1-pyrrolidinyl]-1,8-naphthyridine-3-carboxylic acid,

25 3R,1R-8-chloro-1-cyclopropyl-6-fluoro-1,4-dihydro-7-[3-[1-(methylamino)ethyl]-1-pyrrolidinyl]-4-oxo-3-quinolinecarboxylic acid,

30 3R,1R-5-amino-1-cyclopropyl-6,8-difluoro-1,4-dihydro-7-[3-[1-(methylamino)ethyl]-1-pyrrolidinyl]-4-oxo-3-quinolinecarboxylic acid,

35 3R,1R-1-cyclopropyl-6-fluoro-1,4-dihydro-7-[3-[1-(methylamino)ethyl]-1-pyrrolidinyl]-4-oxo-3-quinolinecarboxylic acid,

-25-

3R,1R-1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[3-[1-(methylamino)ethyl]-1-pyrrolidinyl]-4-oxo-3-quinolinecarboxylic acid,

5 3R,1R-5-amino-1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[3-[1-(methylamino)ethyl]-1-pyrrolidinyl]-4-oxo-3-quinolinecarboxylic acid,

10 3R,1R-1-cyclopropyl-6-fluoro-1,4-dihydro-7-[3-[1-(methylamino)ethyl]-1-pyrrolidinyl]-4-oxo-8-trifluoromethyl-3-quinolinecarboxylic acid,

15 3R,1R-1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-5-methyl-7-[3-[1-(methylamino)ethyl]-1-pyrrolidinyl]-4-oxo-3-quinolinecarboxylic acid,

20 3R,1R-1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-7-[3-[1-(methylamino)ethyl]-1-pyrrolidinyl]-4-oxo-1,8-naphthyridine-3-carboxylic acid,

3R,1R-1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-7-[3-[1-(methylamino)ethyl]-1-pyrrolidinyl]-4-oxo-3-quinolinecarboxylic acid,

25 3R,1R-5-amino-1-cyclopropyl-6-fluoro-1,4-dihydro-7-[3-[1-(methylamino)ethyl]-1-pyrrolidinyl]-4-oxo-3-quinolinecarboxylic acid,

30 3R,1R-1-cyclopropyl-6-fluoro-1,4-dihydro-5-methyl-7-[3-[1-(methylamino)ethyl]-1-pyrrolidinyl]-4-oxo-3-quinolinecarboxylic acid,

35 3R,1R-1-cyclopropyl-8-ethoxy-6-fluoro-1,4-dihydro-7-[3-[1-(methylamino)ethyl]-1-pyrrolidinyl]-4-oxo-3-quinolinecarboxylic acid,

-26-

3R, 1R-1-cyclopropyl-7-[3-[1-(ethylamino) ethyl]-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid,

5 3R, 1R-8-chloro-1-cyclopropyl-7-[3-[1-(ethylamino) ethyl]-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid,

10 3R, 1R-1-cyclopropyl-7-[3-[1-(ethylamino) ethyl]-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid,

15 3R, 1R-5-amino-1-cyclopropyl-7-[3-[1-(ethylamino) ethyl]-1-pyrrolidinyl]-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid,

20 3R, 1R-1-cyclopropyl-7-[3-[1-(ethylamino) ethyl]-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid,

3R, 1R-5-amino-1-cyclopropyl-7-[3-[1-(ethylamino) ethyl]-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid,

25 3R, 1R-1-(2,4-difluorophenyl)-7-[3-[1-(ethylamino) ethyl]-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-5-methyl-4-oxo-3-quinolinecarboxylic acid,

30 3R, 1R-1-cyclopropyl-7-[3-[1-(ethylamino) ethyl]-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-4-oxo-8-trifluoromethyl-3-quinolinecarboxylic acid,

35 3R, 1R-1-(2,4-difluorophenyl)-7-[3-[1-(ethylamino) ethyl]-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid,

-27-

- 3R,1R-1-(2,4-difluorophenyl)-7-[3-[1-(ethylamino)ethyl]-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid,
- 5 3R,1R-5-amino-1-cyclopropyl-7-[3-[1-(ethylamino)ethyl]-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid,
- 10 3R,1R-1-cyclopropyl-7-[3-[1-(ethylamino)ethyl]-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-5-methyl-4-oxo-3-quinolinecarboxylic acid,
- 15 3R,1R-1-cyclopropyl-8-ethoxy-7-[3-[1-(ethylamino)ethyl]-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid,
- 20 3R,1R-1-cyclopropyl-7-[3-[1-(dimethylamino)ethyl]-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid,
- 25 3R,1R-5-amino-1-cyclopropyl-7-[3-[1-(dimethylamino)ethyl]-1-pyrrolidinyl]-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid,
- 30 3R,1R-1-cyclopropyl-7-[3-[1-(dimethylamino)ethyl]-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid,
- 35 3R,1R-8-chloro-1-cyclopropyl-7-[3-[1-(dimethylamino)ethyl]-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid,

-28-

- 3R,1R-5-amino-1-cyclopropyl-7-[3-[1-(dimethylamino)ethyl]-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid,
- 5 3R,1R-1-cyclopropyl-7-[3-[1-(dimethylamino)ethyl]-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-8-trifluoromethyl-3-quinolinecarboxylic acid,
- 10 3R,1R-1-(2,4-difluorophenyl)-7-[3-[1-(dimethylamino)ethyl]-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid,
- 15 3R,1R-1-(2,4-difluorophenyl)-7-[3-[1-(dimethylamino)ethyl]-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid,
- 20 3R,1R-1-(2,4-difluorophenyl)-7-[3-[1-(dimethylamino)ethyl]-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-5-methyl-4-oxo-3-quinolinecarboxylic acid,
- 25 3R,1R-5-amino-1-cyclopropyl-7-[3-[1-(dimethylamino)ethyl]-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid,
- 30 3R,1R-1-cyclopropyl-7-[3-[1-(dimethylamino)ethyl]-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-5-methyl-4-oxo-3-quinolinecarboxylic acid, and
- 3R,1R-1-cyclopropyl-7-[3-[1-(dimethylamino)ethyl]-1-pyrrolidinyl]-8-ethoxy-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid.

Particularly valuable enantiomers of 7-[3-(1-aminoalkyl)-1-pyrrolidines and additional novel

intermediates used to prepare the 7-side chain for the final products are:

FINAL AMINES FOR COUPLING

- 5 (3R,1'R)-3-(1'-aminoethyl)pyrrolidine
(3R,1'S)-3-(1'-aminoethyl)pyrrolidine
(3S,1'R)-3-(1'-aminoethyl)pyrrolidine
(3S,1'S)-3-(1'-aminoethyl)pyrrolidine
(3R,1'R)-3-(1'-N-methylaminoethyl)pyrrolidine
10 (3R,1'S)-3-(1'-N-methylaminoethyl)pyrrolidine
(3S,1'R)-3-(1'-N-methylaminoethyl)pyrrolidine
(3S,1'S)-3-(1'-N-methylaminoethyl)pyrrolidine
(3R,1'R)-3-(1'-N-ethylaminoethyl)pyrrolidine
(3R,1'S)-3-(1'-N-ethylaminoethyl)pyrrolidine
15 (3S,1'R)-3-(1'-N-ethylaminoethyl)pyrrolidine
(3S,1'S)-3-(1'-N-ethylaminoethyl)pyrrolidine
(3R,1'R)-3-(1'-N,N-dimethylaminoethyl)pyrrolidine
(3R,1'S)-3-(1'-N,N-dimethylaminoethyl)pyrrolidine
(3S,1'R)-3-(1'-N,N-dimethylaminoethyl)pyrrolidine
20 (3S,1'S)-3-(1'-N,N-dimethylaminoethyl)pyrrolidine
(3R,1'R)-3-(1'-N-t-butyloxycarbonylaminoethyl)
pyrrolidine
(3R,1'S)-3-(1'-N-t-butyloxycarbonylaminoethyl)
pyrrolidine
25 (3S,1'R)-3-(1'-N-t-butyloxycarbonylaminoethyl)
pyrrolidine
(3S,1'S)-3-(1'-N-t-butyloxycarbonylaminoethyl)
pyrrolidine
(3R,1'R)-3-(1'-N-methyl-N-t-
30 butyloxycarbonylaminoethyl)pyrrolidine
(3R,1'S)-3-(1'-N-methyl-N-t-
butyloxycarbonylaminoethyl)pyrrolidine
(3S,1'R)-3-(1'-N-methyl-N-t-
butyloxycarbonylaminoethyl)pyrrolidine

-30-

(3S,1'S)-3-(1'-N-methyl-N-t-butylloxycarbonylaminoethyl)pyrrolidine

N1 BENZYL INTERMEDIATES

- 5 (3R,1'R)-3-(1'-aminoethyl)-1-(S- α -methylbenzyl)pyrrolidine
(3R,1'S)-3-(1'-aminoethyl)-1-(S- α -methylbenzyl)pyrrolidine
(3S,1'R)-3-(1'-aminoethyl)-1-(S- α -methylbenzyl)pyrrolidine
10 (3S,1'S)-3-(1'-aminoethyl)-1-(S- α -methylbenzyl)pyrrolidine
(3R,1'R)-3-(1'-N-methylaminoethyl)-1-(S- α -methylbenzyl)pyrrolidine
15 (3R,1'S)-3-(1'-N-methylaminoethyl)-1-(S- α -methylbenzyl)pyrrolidine
(3S,1'R)-3-(1'-N-methylaminoethyl)-1-(S- α -methylbenzyl)pyrrolidine
(3S,1'S)-3-(1'-N-methylaminoethyl)-1-(S- α -methylbenzyl)pyrrolidine
20 (3R,1'R)-3-(1'-N-ethylaminoethyl)-1-(S- α -methylbenzyl)pyrrolidine
(3R,1'S)-3-(1'-N-ethylaminoethyl)-1-(S- α -methylbenzyl)pyrrolidine
25 (3S,1'R)-3-(1'-N-ethylaminoethyl)-1-(S- α -methylbenzyl)pyrrolidine
(3S,1'S)-3-(1'-N-ethylaminoethyl)-1-(S- α -methylbenzyl)pyrrolidine
(3R,1'R)-3-(1'-N,N-dimethylaminoethyl)-1-(S- α -methylbenzyl)pyrrolidine
30 (3R,1'S)-3-(1'-N,N-dimethylaminoethyl)-1-(S- α -methylbenzyl)pyrrolidine
(3S,1'R)-3-(1'-N,N-dimethylaminoethyl)-1-(S- α -methylbenzyl)pyrrolidine

-31-

- (3S,1'S)-3-(1'-N,N-dimethylaminoethyl)-1-(S- α -methylbenzyl)pyrrolidine
- (3R,1'R)-3-(1'-N-t-butyloxycarbonylaminoethyl)-1-(S- α -methylbenzyl)pyrrolidine
- 5 (3R,1'S)-3-(1'-N-t-butyloxycarbonylaminoethyl)-1-(S- α -methylbenzyl)pyrrolidine
- (3S,1'R)-3-(1'-N-t-butyloxycarbonylaminoethyl)-1-(S- α -methylbenzyl)pyrrolidine
- 10 (3S,1'S)-3-(1'-N-t-butyloxycarbonylaminoethyl)-1-(S- α -methylbenzyl)pyrrolidine
- (3R,1'R)-3-(1'-N-methyl-N-t-butyloxycarbonylaminoethyl)-1-(S- α -methylbenzyl)pyrrolidine
- (3R,1'S)-3-(1'-N-methyl-N-t-butyloxycarbonylaminoethyl)-1-(S- α -methylbenzyl)pyrrolidine
- 15 (3S,1'R)-3-(1'-N-methyl-N-t-butyloxycarbonylaminoethyl)-1-(S- α -methylbenzyl)pyrrolidine
- 20 (3S,1'S)-3-(1'-N-methyl-N-t-butyloxycarbonylaminoethyl)-1-(S- α -methylbenzyl)pyrrolidine
- (3R,1'R)-3-(1'-aminoethyl)-1-(R- α -methylbenzyl)pyrrolidine
- 25 (3R,1'S)-3-(1'-aminoethyl)-1-(R- α -methylbenzyl)pyrrolidine
- (3S,1'R)-3-(1'-aminoethyl)-1-(R- α -methylbenzyl)pyrrolidine
- (3S,1'S)-3-(1'-aminoethyl)-1-(R- α -methylbenzyl)pyrrolidine
- 30 (3R,1'R)-3-(1'-N-methylaminoethyl)-1-(R- α -methylbenzyl)pyrrolidine
- (3R,1'S)-3-(1'-N-methylaminoethyl)-1-(R- α -methylbenzyl)pyrrolidine

- (3S,1'R)-3-(1'-N-methylaminoethyl)-1-(R- α -methylbenzyl)pyrrolidine
- (3S,1'S)-3-(1'-N-methylaminoethyl)-1-(R- α -methylbenzyl)pyrrolidine
- 5 (3R,1'R)-3-(1'-N-ethylaminoethyl)-1-(R- α -methylbenzyl)pyrrolidine
- (3R,1'S)-3-(1'-N-ethylaminoethyl)-1-(R- α -methylbenzyl)pyrrolidine
- 10 (3S,1'R)-3-(1'-N-ethylaminoethyl)-1-(R- α -methylbenzyl)pyrrolidine
- (3S,1'S)-3-(1'-N-ethylaminoethyl)-1-(R- α -methylbenzyl)pyrrolidine
- (3R,1'R)-3-(1'-N,N-dimethylaminoethyl)-1-(R- α -methylbenzyl)pyrrolidine
- 15 (3R,1'S)-3-(1'-N,N-dimethylaminoethyl)-1-(R- α -methylbenzyl)pyrrolidine
- (3S,1'R)-3-(1'-N,N-dimethylaminoethyl)-1-(R- α -methylbenzyl)pyrrolidine
- (3S,1'S)-3-(1'-N,N-dimethylaminoethyl)-1-(R- α -methylbenzyl)pyrrolidine
- 20 (3R,1'R)-3-(1'-N-t-butyloxycarbonylaminoethyl)-1-(R- α -methylbenzyl)pyrrolidine
- (3R,1'S)-3-(1'-N-t-butyloxycarbonylaminoethyl)-1-(R- α -methylbenzyl)pyrrolidine
- 25 (3S,1'R)-3-(1'-N-t-butyloxycarbonylaminoethyl)-1-(R- α -methylbenzyl)pyrrolidine
- (3S,1'S)-3-(1'-N-t-butyloxycarbonylaminoethyl)-1-(R- α -methylbenzyl)pyrrolidine
- (3R,1'R)-3-(1'-N-methyl-N-t-
- 30 butyloxycarbonylaminoethyl)-1-(R- α -methylbenzyl)pyrrolidine
- (3R,1'S)-3-(1'-N-methyl-N-t-butyloxycarbonylaminoethyl)-1-(R- α -methylbenzyl)pyrrolidine

-33-

(3S,1'R)-3-(1'-N-methyl-N-t-butylloxycarbonylaminoethyl)-1-(R- α -methylbenzyl)pyrrolidine

5 (3S,1'S)-3-(1'-N-methyl-N-t-butylloxycarbonylaminoethyl)-1-(R- α -methylbenzyl)pyrrolidine

PYRROLIDINONES

10 (3R,1'R)-3-(1'-aminoethyl)-1-(S- α -methylbenzyl)pyrrolidin-5-one

(3R,1'S)-3-(1'-aminoethyl)-1-(S- α -methylbenzyl)pyrrolidin-5-one

(3S,1'R)-3-(1'-aminoethyl)-1-(S- α -methylbenzyl)pyrrolidin-5-one

15 (3S,1'S)-3-(1'-aminoethyl)-1-(S- α -methylbenzyl)pyrrolidin-5-one

(3R,1'R)-3-(1'-N,N-dimethylaminoethyl)-1-(S- α -methylbenzyl)pyrrolidin-5-one

20 (3R,1'S)-3-(1'-N,N-dimethylaminoethyl)-1-(S- α -methylbenzyl)pyrrolidin-5-one

(3S,1'R)-3-(1'-N,N-dimethylaminoethyl)-1-(S- α -methylbenzyl)pyrrolidin-5-one

(3S,1'S)-3-(1'-N,N-dimethylaminoethyl)-1-(S- α -methylbenzyl)pyrrolidin-5-one

25 (3R,1'R)-3-(1'-N-acetylaminoethyl)-1-(S- α -methylbenzyl)pyrrolidin-5-one

(3R,1'S)-3-(1'-N-acetylaminoethyl)-1-(S- α -methylbenzyl)pyrrolidin-5-one

30 (3S,1'R)-3-(1'-N-acetylaminoethyl)-1-(S- α -methylbenzyl)pyrrolidin-5-one

(3S,1'S)-3-(1'-N-acetylaminoethyl)-1-(S- α -methylbenzyl)pyrrolidin-5-one

(3R,1'R)-3-(1'-N-t-butylloxycarbonylaminoethyl)-1-(S- α -methylbenzyl)pyrrolidin-5-one

-34-

- (3R,1'S)-3-(1'-N-t-butyloxycarbonylaminoethyl)-1-(S- α -methylbenzyl)pyrrolidin-5-one
- (3S,1'R)-3-(1'-N-t-butyloxycarbonylaminoethyl)-1-(S- α -methylbenzyl)pyrrolidin-5-one
- 5 (3S,1'S)-3-(1'-N-t-butyloxycarbonylaminoethyl)-1-(S- α -methylbenzyl)pyrrolidin-5-one
- (3R,1'R)-3-(1'-aminoethyl)-1-(R- α -methylbenzyl)pyrrolidin-5-one
- (3R,1'S)-3-(1'-aminoethyl)-1-(R- α -methylbenzyl)pyrrolidin-5-one
- 10 (3S,1'R)-3-(1'-aminoethyl)-1-(R- α -methylbenzyl)pyrrolidin-5-one
- (3S,1'S)-3-(1'-aminoethyl)-1-(R- α -methylbenzyl)pyrrolidin-5-one
- 15 (3R,1'R)-3-(1'-N,N-dimethylaminoethyl)-1-(R- α -methylbenzyl)pyrrolidin-5-one
- (3R,1'S)-3-(1'-N,N-dimethylaminoethyl)-1-(R- α -methylbenzyl)pyrrolidin-5-one
- (3S,1'R)-3-(1'-N,N-dimethylaminoethyl)-1-(R- α -methylbenzyl)pyrrolidin-5-one
- 20 (3S,1'S)-3-(1'-N,N-dimethylaminoethyl)-1-(R- α -methylbenzyl)pyrrolidin-5-one
- (3R,1'R)-3-(1'-N-acetylaminoethyl)-1-(R- α -methylbenzyl)pyrrolidin-5-one
- 25 (3R,1'S)-3-(1'-N-acetylaminoethyl)-1-(R- α -methylbenzyl)pyrrolidin-5-one
- (3S,1'R)-3-(1'-N-acetylaminoethyl)-1-(R- α -methylbenzyl)pyrrolidin-5-one
- (3S,1'S)-3-(1'-N-acetylaminoethyl)-1-(R- α -methylbenzyl)pyrrolidin-5-one
- 30 (3R,1'R)-3-(1'-N-t-butyloxycarbonylaminoethyl)-1-(R- α -methylbenzyl)pyrrolidin-5-one
- (3R,1'S)-3-(1'-N-t-butyloxycarbonylaminoethyl)-1-(R- α -methylbenzyl)pyrrolidin-5-one

-35-

(3S,1'R)-3-(1'-N-t-butyloxycarbonylaminoethyl)-1-(R- α -methylbenzyl)pyrrolidin-5-one

(3S,1'S)-3-(1'-N-t-butyloxycarbonylaminoethyl)-1-(R- α -methylbenzyl)pyrrolidin-5-one

5

OXIMES

3R-3-(1'-hydroxyaminoethyl)-1-(S- α -methylbenzyl)pyrrolidin-5-one

10 3S-3-(1'-hydroxyaminoethyl)-1-(S- α -methylbenzyl)pyrrolidin-5-one

3R-3-(1'-hydroxyaminoethyl)-1-(R- α -methylbenzyl)pyrrolidin-5-one

15 3S-3-(1'-hydroxyaminoethyl)-1-(R- α -methylbenzyl)pyrrolidin-5-one

KETONES

3-(acetyl)-1-(S- α -methylbenzyl)pyrrolidin-5-one

3-(acetyl)-1-(R- α -methylbenzyl)pyrrolidin-5-one

20 3R-3-(acetyl)-1-(S- α -methylbenzyl)pyrrolidin-5-one

3S-3-(acetyl)-1-(S- α -methylbenzyl)pyrrolidin-5-one

3R-3-(acetyl)-1-(R- α -methylbenzyl)pyrrolidin-5-one

3S-3-(acetyl)-1-(R- α -methylbenzyl)pyrrolidin-5-one

BETA KETO ESTERS

25 3-(2'-(ethoxycarbonyl)acetyl)-1-(S- α -methylbenzyl)pyrrolidin-5-one

3-(2'-(ethoxycarbonyl)acetyl)-1-(R- α -methylbenzyl)pyrrolidin-5-one

30 3R-3-(2'-(ethoxycarbonyl)acetyl)-1-(S- α -methylbenzyl)pyrrolidin-5-one

3S-3-(2'-(ethoxycarbonyl)acetyl)-1-(S- α -methylbenzyl)pyrrolidin-5-one

3R-3-(2'-(ethoxycarbonyl)acetyl)-1-(R- α -methylbenzyl)pyrrolidin-5-one

-36-

3S-3-(2'-(ethoxycarbonyl)acetyl)-1-(R- α -methylbenzyl)pyrrolidin-5-one

OTHER COMPOUNDS POSSIBLE

- 5 (3R,1'R)-3-(1'-N-t-butyloxycarbonyl-N-methylaminoethyl)-1-(S- α -methylbenzyl)pyrrolidin-5-one
(3R,1'S)-3-(1'-N-t-butyloxycarbonyl-N-methylaminoethyl)-1-(S- α -methylbenzyl)pyrrolidin-5-one
(3S,1'R)-3-(1'-N-t-butyloxycarbonyl-N-methylaminoethyl)-1-(S- α -methylbenzyl)pyrrolidin-5-one
10 (3S,1'S)-3-(1'-N-t-butyloxycarbonyl-N-methylaminoethyl)-1-(S- α -methylbenzyl)pyrrolidin-5-one
(3R,1'R)-3-(1'-N-t-butyloxycarbonyl-N-methylaminoethyl)-1-(R- α -methylbenzyl)pyrrolidin-5-one
15 (3R,1'S)-3-(1'-N-t-butyloxycarbonyl-N-methylaminoethyl)-1-(R- α -methylbenzyl)pyrrolidin-5-one
(3S,1'R)-3-(1'-N-t-butyloxycarbonyl-N-methylaminoethyl)-1-(R- α -methylbenzyl)pyrrolidin-5-one
(3S,1'S)-3-(1'-N-t-butyloxycarbonyl-N-methylaminoethyl)-1-(R- α -methylbenzyl)pyrrolidin-5-one
20 (3R,1'R)-3-(1'-N-trifluoroacetyl-N-methylaminoethyl)-1-(S- α -methylbenzyl)pyrrolidin-5-one
(3R,1'S)-3-(1'-N-trifluoroacetyl-N-methylaminoethyl)-1-(S- α -methylbenzyl)pyrrolidin-5-one
25 (3S,1'R)-3-(1'-N-trifluoroacetyl-N-methylaminoethyl)-1-(S- α -methylbenzyl)pyrrolidin-5-one
(3S,1'S)-3-(1'-N-trifluoroacetyl-N-methylaminoethyl)-1-(S- α -methylbenzyl)pyrrolidin-5-one
(3R,1'R)-3-(1'-N-trifluoroacetyl-N-methylaminoethyl)-1-(R- α -methylbenzyl)pyrrolidin-5-one
30 (3R,1'S)-3-(1'-N-trifluoroacetyl-N-methylaminoethyl)-1-(R- α -methylbenzyl)pyrrolidin-5-one
(3S,1'R)-3-(1'-N-trifluoroacetyl-N-methylaminoethyl)-1-(R- α -methylbenzyl)pyrrolidin-5-one

-37-


- (3S,1'S)-3-(1'-N-trifluoroacetyl-N-methylaminoethyl)-1-(R- α -methylbenzyl)pyrrolidin-5-one
- (3R,1'R)-3-(1'-N-trifluoroacetylaminomethyl)-1-(S- α -methylbenzyl)pyrrolidin-5-one
- 5 (3R,1'S)-3-(1'-N-trifluoroacetylaminomethyl)-1-(S- α -methylbenzyl)pyrrolidin-5-one
- (3S,1'R)-3-(1'-N-trifluoroacetylaminomethyl)-1-(S- α -methylbenzyl)pyrrolidin-5-one
- 10 (3S,1'S)-3-(1'-N-trifluoroacetylaminomethyl)-1-(S- α -methylbenzyl)pyrrolidin-5-one
- (3R,1'R)-3-(1'-N-trifluoroacetylaminomethyl)-1-(R- α -methylbenzyl)pyrrolidin-5-one
- (3R,1'S)-3-(1'-N-trifluoroacetylaminomethyl)-1-(R- α -methylbenzyl)pyrrolidin-5-one
- 15 (3S,1'R)-3-(1'-N-trifluoroacetylaminomethyl)-1-(R- α -methylbenzyl)pyrrolidin-5-one
- (3S,1'S)-3-(1'-N-trifluoroacetylaminomethyl)-1-(R- α -methylbenzyl)pyrrolidin-5-one

20 The final products and intermediates of the present invention may be prepared as detailed hereafter and as illustrated by the following schemes.


-38-

Scheme 1


Equation 1




Equation 2



Equation 3




Scheme 1 (cont.)

Equation 4


-40-

Scheme 1 (cont.)




-41-

Scheme 1 (cont.)




-42-

Scheme 1 (cont.)




-43-

Scheme 1 (cont.)



-44-


Scheme 1 (cont.)




-45-

Scheme 1 (cont.)


Equation 19



Equation 20



Equation 21



-46-

DETAILED DESCRIPTION

Starting from the previously prepared (J. Med. Chem., (1987), 30, 1711) 1-(S- α -methylbenzyl)-pyrrolidin-5-one-3-carboxylic acid (1) conversion to an activated intermediate (2) is preferably done by reaction with carbonyl diimidazole in THF at 30-50°C for 18-30 hours, Equation 1. Alternative solvents include diethylether, dioxane and the like, chlorocarbon solvents, toluene or other aromatic solvents at room temperature to 100°C for 1-72 hours. Alternative methods of carboxylic acid activation such as conversion to an acid chloride with thionyl chloride, phosphorus oxychloride, or the like or activation by conversion to a mixed anhydride with trifluoroacetic anhydride or the like are also suitable. The activated acid (2) is reacted in situ, preferably, or after isolation with an anion of diethylmalonate, preferably magnesium bis(ethylmalonate) (3) in THF at reflux temperature for 2-4 hours. The solvents employed above are also acceptable for this step at ambient temperatures to 150°C. The use of dilithio ethylmalonate, or the anion of diethylmalonate (cation = lithium, magnesium, sodium, calcium, or potassium) are also acceptable. In situ decarboxylation is accomplished next through the use of an aqueous workup or if desired an acidic workup to give 3-(2'-(ethoxycarbonyl)acetyl)-1-(S- α -methylbenzyl)pyrrolidin-5-one (4). Acids useful for affecting decarboxylation are HCl, H₂SO₄, H₃PO₄ and the like, Equation 1.

This β -keto ester (4) is reacted preferably with sodium chloride in DMSO containing 100-1000 mol% water at 120-220°C to affect decarboxylation, preferably 200-400 mol% of NaCl at 103-140°C for 18-24 hours,

-47-

giving 3-(acetyl)-1-(S- α -methylbenzyl)pyrrolidin-5-one (5), Equation 2.

5 The methyl ketone (5) was converted to 3-(1'-hydroxyiminoethyl)-1-(S- α -methylbenzyl)pyrrolidin-5-one (6 and 7) via reaction with hydroxylamine hydrochloride in a suitable solvent at ambient temperature to 100°C. Preferably this is performed in ethanol/water at 40°C to ambient temperature. Solvents such as pyridine, THF, and other alcohol
10 solvents are also useful for the preparation of the oxime. The oxime (6 and 7) is separated into its individual diastereomers (6) and (7) by column chromatography on silica gel (70-230 or 230-400 mesh) using ethyl acetate, ethyl acetate-saturated
15 hydrocarbon solvent, such as pentane, hexane, heptane, and isooctane. Final purification is through recrystallization of the purified diastereomers 3S-3-(1'-hydroxyiminoethyl)-1-(S- α -methylbenzyl)pyrrolidin-5-one (6) and 3R-3-(1'RS-hydroxyiminoethyl)-1-(S- α -methylbenzyl)pyrrolidin-5-one (7) from ethyl acetate
20 or a like solvent.

The individual oxime (7) is reduced to the primary amines, (3R,1RS)-3-(1'-aminoethyl)-1-(S- α -methylbenzyl)pyrrolidin-5-one (8 and 9) through the
25 use of catalytic hydrogenation with hydrogen gas (Equation 4) or a hydrogen source such as ammonium formate, cyclohexene, or cyclohexadiene. The preferred catalysts being platinum oxide, varying percentages of rhodium on an inert support such as
30 carbon, alumina, or Raney-nickel, or the like, in solvents such as methanol, ethanol, THF, ethyl acetate and the like at ambient temperatures to 40-60°C, preferably at room temperature. The reduction produced a set of diastereomers (8 and 9) which were
35 separated by column chromatography on silica gel

(70-230 or 230-400 mesh) using a chlorocarbon solvent containing varying concentrations of a tertiary amine and an alcohol, preferably chloroform-triethylamine-ethanol giving 3R,1'S-3-(1'-aminoethyl)-1-(S- α -methylbenzyl)pyrrolidin-5-one (8) and 3R,1'R-3-(1'-aminoethyl)-1-(S- α -methylbenzyl)pyrrolidin-5-one (9), (Equation 4).

Likewise the oxime (6) could be reduced to give 3S,1'RS-(1'-aminoethyl)-1-(S- α -methylbenzyl)-2pyrrolidin-5-one (10 and 11), Equation 4.

The individual diastereomeric pyrrolidone amines (8,9,10,11) were reduced to the pyrrolidines through the action of a hydride reducing agent in an inert solvent at an elevated temperature, usually lithium aluminum hydride in an ether solvent such as THF at 50-66°C or the like, Equation 5. The primary amines (12, 13, 14, 15) individually were each protected as the t-butylcarbamate by reaction of the amine with a t-butyloxycarbonyl transfer reagent such as di-t-butylcarbonate and the like, Equation 6, giving 16, 17, 18, 19.

The BOC-protected aminoethylpyrrolidine (16-19) were subjected to varying de- α -methylbenzylations via hydrogenolysis using varying percentages of palladium on a inert support such as carbon, alumina, silica, or the like, preferably 20% palladium on carbon in an inert solvent such as methanol, ethanol, THF, or ethyl acetate. This provides the individual diastereomeric 3-(1'-aminoethyl)pyrrolidines (20, 21, 22, 23), (Equation 7) in a protected form suitable for coupling with a quinolone or naphthyridone substrate.

The individual 3-(1'-N,N-dimethylaminoethyl)pyrrolidines (32, 33, 34, 35) could be prepared by reacting the amine (8, 9, 10, 11) with paraformaldehyde in formic acid at an elevated

-49-

temperature, preferably employing aqueous solutions of formaldehyde (20-80%, usually 35%) and aqueous formic acid (50-90%, usually 88%) beginning at 0-5°C and continuing at reflux temperature for 2-10 hours

5 (preferably five hours). This provides the individual diastereomeric N,N-dimethylamines (24, 25, 26, 27), Equation 8. The carbonyl function of 24-27 was removed by reducing the pyrrolidin-5-one with a hydride reducing agent in an inert solvent. The preferred
10 method was with lithium aluminum hydride in THF at reflux for 12-24 hours giving the pyrrolidines 28, 29, 30, 31, Equation 9. The 3-(1'-N,N-dimethylamino-ethyl)pyrrolidines (28-31) were de- α -methylbenzylated via hydrogenolysis using varying percentages of
15 palladium on a inert support such as carbon, alumina, silica, or the like, preferably 20% palladium on carbon in an inert solvent such as methanol, ethanol, THF, or ethyl acetate. This provides the individual diastereomeric 3-(1'-N,N-
20 dimethylaminoethyl)pyrrolidines, 32, 33, 34, 35, (Equation 10) in a form suitable for coupling with a quinolone or naphthyridone substrate.

The 3-(1'-N-ethylaminoethyl)pyrrolidines (44, 45, 46, 47) were prepared by reacting the amines (8, 9,
25 10, 11) with an acetyl transfer agent such as acetic anhydride or acetyl chloride or the like in the presence of an acid scavenger such as a tertiary amine including pyridine, lutidine, triethylamine and the like either with or without an inert solvent such as
30 an ether or chlorocarbon in a temperature range of room temperature to the reflux temperature of the reaction mixture for 6-72 hours, preferable in acetic anhydride-pyridine 4/1 at ambient temperature for 12-24 hours to give the 3-(N-acetyl-1'-
35 aminoethyl)pyrrolidin-5-ones, 36, 37, 38, 39,

-50-

Equation 11. The two amide functions of 36-39 were reduced by reacting the pyrrolidin-5-one with a hydride reducing agent in an inert solvent. The preferred method was with lithium aluminum hydride in THF at reflux for 12-24 hours giving the individual diastereomeric pyrrolidines, 40, 41, 42, 43,

Equation 12. The individual diastereomeric 3-(1'-N-ethylaminoethyl)-(1- α -methylbenzyl)pyrrolidines (40-43) were de- α -methylbenzylated via hydrogenolysis using varying percentages of palladium on an inert support such as carbon, alumina, silica, or the like, preferably 20% palladium on carbon in an inert solvent such as methanol, ethanol, THF, or ethyl acetate.

This provides the individual 3-(1'-N-ethylaminoethyl)pyrrolidines, 44, 45, 46, 47, (Equation 13) in a form suitable for coupling with a quinolone or naphthyridone substrate.

The 3-(N-t-butyloxycarbonyl-1'-N-methylaminoethyl)pyrrolidines (60, 61, 62, 63) were prepared by reacting the amines (8-11) with a t-butyloxycarbonyl transfer agent such as di-t-butylcarbonate or t-butyloxycarbonyl chloride or the like in the presence of an acid scavenger such as a tertiary amine including pyridine, lutidine, triethylamine and the like either with or without an inert solvent such as an ether or chlorocarbon in a temperature range of room temperature to the reflux temperature of the reaction mixture for 6-72 hours, preferable in dichloromethane and di-t-butylcarbonate at ambient temperature for 12-24 hours to give the 3-(N-t-butyloxycarbonyl-1'-aminoethyl)-1-(S- α -methylbenzyl)pyrrolidin-5-ones, 48, 49, 50, 51,

Equation 14. The two amides were removed by reacting the pyrrolidin-5-ones (48-51) with a hydride reducing agent in an inert solvent. The preferred method was

-51-

with lithium aluminum hydride in THF at reflux for 12-24 hours giving the individual diastereomeric pyrrolidines, 52, 53, 54, 55, Equation 15. The reduced pyrrolidines, 52-55, could be protected by reacting the 3-N-methyl-1'-aminomethyl moiety with a t-butyloxycarbonyl transfer agent such as di-t-butylcarbonate or t-butyloxycarbonyl chloride or the like in the presence of an acid scavenger such as a tertiary amine including pyridine, lutidine, triethylamine and the like either with or without an inert solvent such as an ether or chlorocarbon in a temperature range of room temperature to the reflux temperature of the reaction mixture for 6-72 hours, preferably in dichloromethane and di-t-butylldicarbonate at ambient temperature for 12-24 hours to give the 1-(α -methylbenzyl)-3-(N-t-butyloxycarbonyl-1'-N-methylaminoethyl)pyrrolidines, 56, 57, 58, 59, Equation 16. The 3-(N-t-butyloxycarbonyl-1'-N-methylaminoethyl)pyrrolidines, 56-59 were de- α -methylbenzylated via hydrogenolysis using varying percentages of palladium on an inert support such as carbon, alumina, silica, or the like, preferably 20% palladium on carbon in an inert solvent such as methanol, ethanol, THF, or ethyl acetate. This provides the 3-(1'-N-t-butoxycarbonyl-1'-N-methylaminoethyl)pyrrolidines, 60, 61, 62, 63 (Equation 17) in a form suitable for coupling with a quinolone or naphthyridone nucleus.

The 3-(1'-N-methylaminoethyl)pyrrolidines, 64-67, were prepared by the de- α -methylbenzylation, via hydrogenolysis using varying percentages of palladium on an inert support such as carbon, alumina, silica, or the like, preferably 20% palladium on carbon in an inert solvent such as methanol, ethanol, THF, or ethyl acetate, of the pyrrolidines, 52, 53, 54, 55,

-52-

Equation 18. This provides the individual diastereomers 64, 65, 66, 67, 3-(1'-N-methylaminoethyl)pyrrolidines (Equation 18) in a form suitable for coupling with a quinolone or naphthyridone substrate.


Alternatively, the 3-(1'-aminoethyl)pyrrolidin-5-one (8 and 9) were reacted with methyl trifluoroacetate in an inert solvent or alternatively with trifluoroacetic anhydride in the presence of an acid acceptor such as triethylamine or pyridine or the like at 0°C to ambient temperature to give the 3-(N-trifluoroacetyl-1'-aminoethyl)pyrrolidin-5-ones, 68, Equation 19. These compounds were reacted with a hydrogen abstractor such as sodium hydride or a similar agent in an ether solvent such as THF followed by addition of a methylating agent like methyl iodide to give the 3-(N-methyl-N-trifluoroacetyl-1'-aminoethyl)pyrrolidin-5-one, 69, Equation 20. The trifluoroacetyl group could be removed by hydrolysis using aqueous hydroxide, Equation 21. The resulting compounds 70 could be reduced as described above.

The pyrrolidines prepared could be coupled to the appropriate quinolone or naphthyridone substrate by published procedures including; Domagala, et al., J. Medicinal Chemistry, 31, 503 (1988), Sanchez, et al., J. Medicinal Chemistry, 31, 983, (1988), Itawa, et al., European Patent Application 8702813.8 1987, and British Patent 2,011,395A.

A representative group of quinolones is shown in Figure 1.

-53-

FIGURE 1



-54-

The enantiomeric quinolones and naphthyridones of the invention display potent antibacterial activity against gram negative and especially gram positive organisms both in vitro as well as in vivo. Their overall therapeutic advantages are also shown by including phototoxicity and cytotoxicity data as compared to compounds described in European Patent Publication 207,420.

The in vitro antibacterial activity, is obtained by the microtitration dilution method as described in Heifetz, et al., Antimicrob. Agents & Chemother., 6, 124 (1974), which is incorporated herein by reference.

The in vivo activity is obtained when the compounds are tested according to the procedure of Miller, et al (Proc. Soc. Exp. Biol. Med. 57, 261, 1944). The median protective dose (PD₅₀) was determined in mice given lethal systemic infections. Single doses of compound were given at time of challenge.

The phototoxicity data is obtained using depilated mice. The compound was administered orally each day for four successive days, followed each day by 3 hours of UVA radiation. The mice were examined for any positive signs (redness, erythema) relative to control animals. The no effect dose and the 50% effect dose were determined.

The cytotoxicity data is obtained using hamster V-79 cells. The cells were suspended in tissue culture medium and grown overnight. Cells were treated with drug for 3 hours, washed free of drug and then replated, and the colonies counted after 5 days. The concentration of drug that reduced colonies by 50% relative to control was recorded.

By use of the above methods, the following minimum inhibiting concentration values (MICs in

-55-

5 $\mu\text{g/mL}$), PD_{50} 's in mg/kg , no effect phototoxicity dose in mg/kg and the cytotoxicity IC_{50} in $\mu\text{g/mL}$ were obtained for representative enantiomers of the invention and compounds of the prior art as shown in the table.

 The in vivo data as PD_{50} s are reported below the line of MICs for the same compound.


-56-

Example Number	Ent. cloacae MR2646	Esch. coli Vogel	Klebs. pneumoniae MGH-2	Prot. rettgeri M 1771	Pseud. aeruginosa UI-18	Staph. aureus H 228	Staph. aureus UC-76	Strep. faecalis MGH-2	Strep. pneumoniae SV-1	Strep. pyogenes C-203	Photo NED mg/kg	Cytotox µg/mL
2	0.2 PO SC	0.2 100 4	0.4	0.8	1.6	0.8	0.1	0.4	0.2 >100 12	0.1		160
1	0.2 PO SC	0.2 35 2	0.4	0.8	1.6	0.4	0.05	0.2	0.1 >100 3	0.1		160
3	0.05 PO SC	0.05 47 0.9	0.1	0.2	0.4	0.05	0.003	0.025	0.003 11 0.7	0.003		42
4	0.2 PO SC	0.1 72 2	0.4	0.8	1.6	0.2	0.05	0.1	0.025 105 2	0.1		140
Enantiomer Mixture (Mixture B)	0.1 PO SC	0.05 29 2	0.2	0.4	1.6	0.1	0.013	0.05	0.006 12 1	0.006		60
5	0.05 PO SC	0.05 4 1	0.1	0.2	0.8	0.2	0.025	0.1	0.05 15 7	0.05	>100	84

SUBSTITUTE SHEET

-57-

Example Number	Ent. cloacae MA2646	Esch. coli Vogel	Klebs. pneumoniae MGH-2	Prot. rettgeri M 1771	Pseud. aeruginosa UI-18	Staph. aureus H 228	Staph. aureus UC-76	Strep. faecalis MGH-2	Strep. pneumoniae SV-1	Strep. pyogenes C-203	Photo NED mg/kg	Cytotox μ g/mL
6	0.05 PO SC	0.05 8 1	0.2	0.4	1.6 96 25	0.2 0.025	0.025	0.1	0.05 28 10	0.05	>100	77
7	0.025 PO SC	0.025 2 0.4	0.05	0.1	0.4 15 4	0.025	0.03	0.025	0.006 3 1	0.013 3 1	30	33
8	0.05 PO SC	0.05 6 1	0.1	0.4	0.8 35 12	0.05	0.06	0.05	0.006 14 2	0.013	55	100
	0.05 PO SC	0.025 2 0.8	0.1	0.2	0.8 16 6	0.05	0.006	0.05	0.013 5 2	0.013 4 1	55	48




Enantiomeric Mixture
(Mixture B)

SUBSTITUTE SHEET

-58-

Example Number	Ent. cloacae MA2646	Esch. coli Vogel	Kiebs. pneumoniae MGH-2	Prot. rettgeri M 1771	Pseud. aeruginosa UI-18	Staph. aureus H 228	Staph. aureus UC-76	Strep. faecalis MGH-2	Strep. pneumoniae SV-1	Strep. pyogenes C-203	Photo NED mg/kg	Cytotox µg/mL
Reference Example 5	0.4	0.05	0.2	0.4	1.6	0.1	0.013	0.05	0.013	0.05		150
EFO 207420 (Mixture C)	PO SC	9 2										
24	0.4	0.2	0.4	0.8	3.1	0.8	0.2	0.8	0.4	0.4		
23	0.1	0.1	0.2	0.8	1.6	0.2	0.05	0.2	0.1	0.1		
21	0.1	0.1	0.2	0.4	1.6	0.05	0.0013	0.05	0.013	0.025		130
	PO SC	1.0 0.5								2 2		
22	0.1	0.1	0.2	0.4	1.6	0.1	0.05	0.025	0.05	0.05		88
	PO SC	4,6 1.2								8 5		
Enantiomer Mixture (Mixture B)	0.05	0.05	0.1	0.8	1.6	0.1	0.025	0.1	0.05	0.1		140
	PO SC	4 1								11 6		



-59-

Example Number	Ent. cloacae NA2646	Esch. coli Vogel	Klebs. pneumoniae MGH-2	Prot. retigeri M 1771	Pseud. aeruginosa UI-18	Staph. aureus H 228	Staph. aureus UC-76	Strep. faecalis MGH-2	Strep. pneumoniae SV-1	Strep. pyogenes C-203	Photo NED mg/kg	Cytotox µg/mL
42	0.025 PO SC	0.025 3 0.4	0.05	0.1	0.8	0.006	0.003	0.013	0.006	0.006 0.55 0.25	<30	17
41	0.05 PO SC	0.05 3 2	0.1	0.2	0.8	0.006	0.003	0.013	0.006	0.006 2 0.7	30	33
81	0.8	0.4	0.8	3.1	6.3	0.8	0.4	0.8	0.2	0.4		
80	0.2	0.2	0.4	1.6	3.1	0.2	0.1	0.2	0.1	0.4		
79	0.1 PO SC	0.1 2 1	0.2	0.8	1.6	0.1	0.025	0.05	0.025	0.05 2 2		
78	0.4 PO SC	0.1	0.2	1.6	1.6	0.05	0.025	0.05	0.025	0.05 6 4		
20	0.8	0.8	1.6	3.1	6.3	0.2	0.05	0.4	0.2	0.2		
19	0.4	0.4	0.8	1.6	6.3	0.1	0.05	0.1	0.013	0.025		

SUBSTITUTE SHEET

-60-

Example Number	Ent. cloacae MR2646	Esch. coli Vogel	Klebs. pneumoniae MGH-2	Prot. rettgeri M 1771	Pseud. aeruginosa UI-18	Staph. -aureus H 228	Staph. aureus UC-76	Strep. faecalis MGH-2	Strep. pneumoniae SV-1	Strep. pyogenes C-203	Photo NED mg/kg	Cytotox µg/mL
18	0.1	0.1	0.2	0.4	3.1	0.013	0.003	0.025	0.006	0.006	>100	110
	PO	5								0.5		
	SC	2								0.2		
17	0.2	0.2	0.4	0.8	3.1	0.013	0.003	0.013	0.003	0.003	>100	130
	PO	14								2		
	SC	4								0.6		
36	0.05	0.05	0.1	0.2	0.8	0.013	0.013	0.025	0.013	0.003	>100	33
	PO	4								1		
	SC	1								0.1		
38	0.2	0.2	0.4	0.8	3.1	0.05	0.013	0.05	0.025	0.025	--	130
	PO									6		
	SC									1		
44	0.05	0.025	0.05	0.05	0.4	0.006	≤0.003	0.006	≤0.003	≤0.003		
45	0.05	0.05	0.1	0.2	0.8	0.25	≤0.03	0.025	0.013	0.013		
46	0.2	0.2	0.4	0.4	1.6	0.025	0.013	0.1	0.013	0.013		
47	0.1	0.1	0.1	0.2	0.8	0.025	0.003	0.025	0.003	0.003		

SUBSTITUTE SHEET

-61-

Example Number	Ent. cloacae MA2646	Esch. coli Vogel	Klebs. pneumoniae NGH-2	Prot. retigeri M 1771	Pseud. aeruginosa UI-18	Staph. aureus H 228	Staph. aureus UC-76	Strep. faecalis MGH-2	Strep. pneumoniae SV-1	Strep. pyogenes C-203	Photo NED mg/kg	Cytotox µg/mL
48	0.1	0.1	0.2	0.4	1.6	0.1	0.025	0.1	0.05	0.05		
	PO									9		
	SC									3		
49	0.2	0.1	0.2	0.2	1.6	0.013	≤0.003	0.025	0.006	0.006		
43	0.2	0.1	0.2	0.4	0.8	0.05	0.006	0.025	0.006	0.006	>100	280
	PO	3.5							3	1		
	SC	1							3	1		
50	0.8	0.4	0.8	1.6	3.1	0.05	0.013	0.2	0.1	0.1		
	PO								2			
	SC								2			
51	0.8	0.8	1.6	3.1	>3.1	0.2	0.05	0.4	0.2	0.2		
52	0.4	0.4	0.4	1.6	3.1	0.05	0.013	0.05	0.05	0.05		
53	0.025	0.025	0.05	0.1	0.8	≤0.003	≤0.003	0.013	≤0.003	≤0.003		
	PO	1.6								0.3		
	SC	0.8								0.3		
54	0.4	0.4	0.8	1.6	3.1	0.025	0.013	0.1	0.013	0.013		
55	0.1	0.1	0.2	0.8	1.6	0.05	0.025	0.05	0.013	0.013	--	
56	0.2	0.1	0.2	0.4	1.6	0.013	0.006	0.025	0.006	0.006		

SUBSTITUTE SHEET

-62-

Example Number	Ent. cloacae MA2646	Esch. coli Vogel	Klebs. pneumoniae MGH-2	Prot. rettingi M 1771	Pseud. aeruginosa UI-18	Staph. aureus H 228	Staph. aureus UC-76	Strep. faecalis MGH-2	Strep. pneumoniae SV-1	Strep. pyogenes C-203	Photo NED mg/kg	Cytotox µg/mL
57	0.4	0.4	0.4	0.8	3.1	0.025	0.013	0.05	0.025	0.025		220
58	0.013	0.013	0.013	0.025	0.4	0.003	0.003	0.003	0.003	0.003		
59	0.05	0.05	0.1	0.1	0.8	0.006	0.003	0.006	0.003	0.003		
60	0.2	0.2	0.2	0.4	1.6	0.013	0.006	0.025	0.006	0.006		
61	0.1	0.1	0.2	0.4	1.6	0.006	≤0.003	0.025	≤0.003	≤0.003		
34	0.4	0.4	0.8	1.6	3.1	0.8	0.4	1.6	0.8	1.6		
35	0.2	0.2	0.8	0.8	3.1	0.1	0.05	0.2	0.2	0.2		
63	0.4	0.4	0.4	0.8	3.1	0.1	0.05	0.2	0.2	0.2		
64	0.8	0.4	0.8	1.6	3.1	0.1	0.025	0.2	0.025	0.05		310
	PO	5								4		
	SC	2								2		
65	0.1	0.1	0.2	0.4	0.8	0.013	0.006	0.025	0.003	0.003		10
	PO									5		
	SC									0.6		
67	0.4	0.4	0.8	1.6	3.1	0.05	0.013	0.1	0.013	0.025		
	PO									29		
	SC									3		

SUBSTITUTE SHEET

-63-

Example Number	Ent. cloacae MA2646	Esch. coli Vogel	Klebs. pneumoniae MGH-2	Prot. rettgeri M 1771	Pseud. aeruginosa UI-18	Staph. aureus H 228	Staph. aureus UC-76	Strep. faecalis MGH-2	Strep. pneumoniae SV-1	Strep. pyogenes C-203	Photo NED mg/kg	Cytotox µg/mL
69	0.1	0.1	0.2	0.4	1.6	0.05	0.006	0.025	0.013	0.025		
70	0.4	0.4	0.8	3.1	12.5	0.4	0.2	0.8	0.2	0.4		
72	0.2	0.1	0.2	0.8	1.6	0.025	0.025	0.1	0.025	0.05	<30	120
	PO	1			17				2	2		
	SC	1			11				2	2		
73	0.2	0.1	0.2	0.8	1.6	0.1	0.05	0.1	0.05	0.05	<30	
	PO	5								4		
	SC	4								4		

SUBSTITUTE SHEET

-64-

The compounds of the invention are capable of forming both pharmaceutically acceptable acid addition and/or base salts. Base salts are formed with metals or amines, such as alkali and alkaline earth metals or organic amines. Examples of metals used as cations are sodium, potassium, magnesium, calcium, and the like. Also included are heavy metal salts such as for example silver, zinc, cobalt, and cerium. Such heavy metal salts are effective in the treatment of burns especially when applied to the affected surface of a burn victim either directly or in combination with a physiologically acceptable carrier such as a water dispersible, hydrophilic carrier. Examples of suitable amines are N,N' dibenzylethylenediamine, chlorprocaine, choline, diethanolamine, ethylenediamine, N-methylglucamine, and procaine.

Pharmaceutically acceptable acid addition salts are formed with organic and inorganic acids.

Examples of suitable acids for salt formation are hydrochloric, sulfuric, phosphoric, acetic, citric, oxalic, malonic, salicylic, malic, gluconic, fumaric, succinic, ascorbic, maleic, methanesulfonic, and the like. The salts are prepared by contacting the free base form with a sufficient amount of the desired acid to produce either a mono or di, etc. salt in the conventional manner. The free base forms may be regenerated by treating the salt form with a base. For example, dilute solutions of aqueous base may be utilized. Dilute aqueous sodium hydroxide, potassium carbonate, ammonia, and sodium bicarbonate solutions are suitable for this purpose. The free base forms differ from their respective salt forms somewhat in certain physical properties such as solubility in polar solvents, but the salts are otherwise equivalent to their respective free base forms for purposes of the

-65-

invention. Use of excess base where R_2 is hydrogen gives the corresponding basic salt.

The compounds of the invention can exist in unsolvated as well as solvated forms, including hydrated forms. In general, the solvated forms, including hydrated forms and the like are equivalent to the unsolvated forms for purposes of the invention.

The compounds of the invention can be prepared and administered in a wide variety of oral, parenteral and topical dosage forms. It will be obvious to those skilled in the art that the following dosage forms may comprise as the active component, either a compound of formula I or a corresponding pharmaceutically acceptable salt of a compound of formula I.

For preparing pharmaceutical compositions from the compounds described by this invention, inert, pharmaceutically acceptable carriers can be either solid or liquid. Solid form preparations include powders, tablets, dispersible granules, capsules, cachets, suppositories, and ointments. A solid carrier can be one or more substances which may also act as diluents, flavoring agents, solubilizers, lubricants, suspending agents, binders, or tablet-disintegrating agents; it can also be an encapsulating material. In powders, the carrier is a finely divided solid which is in admixture with the finely divided active compound. In the tablet the active compound is mixed with carrier having the necessary binding properties in suitable proportions and compacted in the shape and size desired. The powders and tablets preferably contain from 5 or 10 to about 70% of the active ingredient. Suitable solid carriers are magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methyl cellulose, sodium carboxymethyl cellulose, a low melting wax, cocoa butter, and the like. The term

-66-

"preparation" is intended to include the formulation of the active compound with encapsulating material as carrier providing a capsule in which the active component (with or without other carriers) is surrounded by carrier, which is thus in association with it. Similarly, cachets are included. Tablets, powders, cachets, and capsules can be used as solid dosage forms suitable for oral administration.

Liquid form preparations include solutions suspensions and emulsions. An example may be water or water-propylene glycol solutions for parenteral injection. Such solutions are prepared so as to be acceptable to biological systems (isotonicity, Ph, etc.). Liquid preparations can also be formulated in solution in aqueous polyethylene glycol solution. Aqueous solutions suitable for oral use can be prepared by dissolving the active component in water and adding suitable colorants, flavors, stabilizing, and thickening agents as desired. Aqueous suspension suitable for oral use can be made by dispersing the finely divided active component in water with viscous material, i.e., natural or synthetic gums, resins, methyl cellulose, sodium carboxymethyl cellulose, and other well-known suspending agents.

Ointment preparations contain heavy metal salts of a compound of formula I with a physiologically acceptable carrier. The carrier is desirably a conventional water-dispersible hydrophilic or oil-in-water carrier, particularly a conventional semi-soft or cream-like water-dispersible or water soluble, oil-in-water emulsion which may be applied to an affected burn surface or infected surface with a minimum of discomfort. Suitable compositions may be prepared by merely incorporating or homogeneously admixing finely

-67-

divided compounds with the hydrophilic carrier or base or ointment.

5 Preferably, the pharmaceutical preparation is in unit dosage form. In such form, the preparation is subdivided into unit doses containing appropriate quantities of the active component. The unit dosage form can be a packaged preparation, the package containing discrete quantities of preparation, for example, packeted tablets, capsules, powders in vials or 10 ampoules, and ointments in tubes or jars. The unit dosage form can also be a capsule, cachet, tablet, gel or cream itself or it can be the appropriate number of any of these packaged forms.

15 The quantity of active compound in a unit dose of preparation may be varied or adjusted from 1 mg to 100 mg according to the particular application and the potency of the active ingredient.

20 In therapeutic use as agents for treating bacterial infections, the compounds utilized in the pharmaceutical method of this invention are administered at the initial dosage of about 3 mg to about 40 mg per kilogram daily. A daily dose range of about 6 mg to about 14 mg per kilogram is preferred. The dosages, however, may be varied depending upon the requirements of the patient, 25 the severity of the condition being treated, and the compound being employed. Determination of the proper dosage for a particular situation is within the skill of the art. Generally, treatment is initiated with smaller dosages which are less than the optimum dose of the 30 compound. Thereafter, the dosage is increased by small increments until the optimum effect under the circumstances is reached. For convenience, the total daily dosage may be divided and administered in portions during the day if desired.

-68-

The following nonlimiting examples illustrate the inventors' preferred methods for preparing the compounds of the invention.

PREPARATION OF INTERMEDIATES

5

EXAMPLE A

(3R,1'S)-3-(1'-N-acetylaminoethyl)-1-(S- α -methylbenzyl)pyrrolidin-5-one, 36

(3R,1'S)-3-(1'-Aminoethyl)-1-(S- α -methylbenzyl)pyrrolidin-5-one, 8, (10.0 g, 0.043 mol) was dissolved in pyridine (50 mL) and acetic anhydride (250 mL) and stirred for 18 hours, then evaporated to an oil. This oil was purified by column chromatography using methylene chloride methanol (20/1) to give the title compound as a very viscous oil, yield = 9.2 g.

15 Calculated for $C_{16}H_{22}N_2O_2$. 0.3 $C_2H_6O_1$. 0.2 H_2O :

C, 68.33; H, 8.36; N, 9.60

Found: C, 68.37; H, 8.09; N, 9.57.

$[\alpha]_D = -165^\circ$ (C = 0.4%, $CHCl_3$).

20 ^1H -NMR ($CDCl_3$) δ 7.4-7.2 (m, 5H), 5.49 (q, 1H, J=9.1 Hz), 5.1-5.05 (broad m, 1H) 4.0-3.85 (m, 1H), 3.39 (dd, 1H, J=8.2, 11.2 Hz), 2.78 (dd, 1H, J=5.8, 10.3 Hz), 2.6-2.36 (m, 2H), 2.25-2.15 (m, 1H), 1.88 (s, 3H), 1.52 (d, 3H, J=7.2 Hz), 0.97 (d, 3H, J=6.7 Hz).

25

EXAMPLE A-1

(3R,1'R)-3-(1'-N-acetylaminoethyl)-1-(S- α -methylbenzyl)-pyrrolidin-5-one, 37

The procedure described above was employed to give 8.3 g of the title compound.

30

Calculated for $C_{16}H_{22}N_2O_2$:

C, 70.04; H, 8.08; N, 10.21

Found: C, 70.08; H, 8.10; N, 10.23.

-69-

$[\alpha]_D = -120^\circ$ (C = 1.1%, CHCl_3).

$^1\text{H-NMR}$ (CDCl_3) δ 7.4-7.2 (m, 5H), 5.85-5.75 (broad m, 1H), 5.47 (q, 1H, $J=7.1$ Hz), 4.05-3.90 (m, 1H), 3.40-3.30 (m, 1H), 2.80-2.70 (m, 1H), 2.55-2.20 (m, 3H), 1.84 (s, 3H), 1.52 (d, 3H, $J=7.0$ Hz), 0.99 (d, 3H, $J=6.7$ Hz).

EXAMPLE A-2

(3S,1'S)-3-(1'-N-acetylaminoethyl)-1-(S- α -methylbenzyl)-pyrrolidin-5-one, 38

The procedure described above was employed to give 9.5 g of the title compound.

Calculated for $\text{C}_{16}\text{H}_{22}\text{N}_2\text{O}_2$:

C, 70.04; H, 8.08; N, 10.21

Found: C, 70.09; H, 8.01; N, 9.84.

$^1\text{H-NMR}$ (CDCl_3) δ 7.4-7.2 (m, 5H), 6.25-6.1 (broad d, 1H), 5.46 (q, 1H, $J=7.1$ Hz), 4.15-4.05 (m, 1H), 3.20-2.95 (m, 2H), 2.55-2.20 (m, 3H), 1.98 (s, 3H), 1.49 (d, 3H, $J=7.1$ Hz), 1.09 (d, 3H, $J=6.7$ Hz).

EXAMPLE A-3

(3S,1'R)-3-(1'-N-acetylaminoethyl)-1-(S- α -methylbenzyl)-pyrrolidin-5-one, 39

The procedure described above was employed to give 7.4 g of the title compound.

Calculated for $\text{C}_{16}\text{H}_{22}\text{N}_2\text{O}_2 \cdot 0.27 \text{ H}_2\text{O}$:

C, 68.82; H, 8.14; N, 10.03

Found: C, 68.87; H, 8.27; N, 9.65.

$^1\text{H-NMR}$ (CDCl_3) δ 7.4-7.2 (m, 5H), 5.85-5.75 (broad d, 1H), 5.46 (q, 1H, $J=7.1$ Hz), 4.05-3.95 (m, 1H), 3.25-3.15 (m, 1H), 3.10-2.95 (m, 1H), 2.55-2.40 (m, 1H), 2.30-2.15 (m, 2H), 1.93 (s, 3H), 1.49 (d, 3H, $J=7.0$ Hz), 1.11 (d, 3H, $J=6.6$ Hz).

-70-

EXAMPLE B

(3R,1'S)-3-(1'-N-ethylaminoethyl)-1-(S- α -methylbenzyl)pyrrolidine, 40

5 (3R,1'S)-3-(1'-N-acetylaminoethyl)-1-(S- α -methylbenzyl)pyrrolidin-5-one (9.2 g, 0.03 mol) was dissolved in THF (150 mL) and lithium aluminum hydride (2.6 g) was added portionwise. The resulting slurry was heated at reflux for 18 hours then cooled and cautiously quenched with water (2.6 mL), 15% NaOH solution (3 mL),
10 and water (6 mL). The resulting suspension was filtered and evaporated to an oil. This oil was distilled at 0.1 mm Hg at 107-112°C to give 7.1 g of the title compound.

15 $^1\text{H-NMR}$ (CDCl_3) δ 7.35 (m, 5H), 3.17 (q, 1H, $J=6.7$ Hz), 2.85-2.60 (m, 3H), 2.60-2.45 (m, 2H), 2.20-1.85 (m, 4H), 1.50-1.30 (m, 1H overlapping with doublet), 1.36 (d, 3H, $J=6.5$ Hz), 1.08-1.00 (m, 6H).

EXAMPLE B-1

20 (3R,1'R)-3-(1'-N-ethylaminoethyl)-1-(S- α -methylbenzyl)-pyrrolidine, 41

Following the procedure of Example B, the (3R,1'R)-3-(1'-N-acetylaminoethyl)-1-(S- α -methylbenzyl)-pyrrolidin-5-one (8.0 g, 0.029 mol) was converted to a
25 crude oil. This oil was distilled at 0.1 mm Hg at 110°C to give 6.1 g of the title compound.

Calculated for $\text{C}_{16}\text{H}_{26}\text{N}_2 \cdot 0.1 \text{ H}_2\text{O}$:

C, 77.43; H, 10.64, N, 11.29

Found: C, 77.50; H, 10.53; N, 11.56.

30 $^1\text{H-NMR}$ (CDCl_3) δ 7.35-7.15 (m, 5H), 3.15 (q, 1H, $J=6.6$ Hz), 2.80-2.65 (m, 2H), 2.60-2.40 (m, 3H), 2.40-2.30 (m, 1H), 2.20-1.90 (m, 4H), 1.70-1.50 (m, 1H), 1.36 (d, 3H, $J=6.6$ Hz), 1.10 (t, 3H, $J=7.2$ Hz), 0.95 (d, 3H, $J=6.3$ Hz).

-71-

EXAMPLE B-2

(3S,1'S)-3-(1'-N-ethylaminoethyl)-1-(S- α -methylbenzyl)-pyrrolidine, 42

The procedure described above was employed to give
5 6.88 g of the title compound.

Calculated for $C_{16}H_{26}N_2$:

C, 77.99; H, 10.64, N, 11.37

Found: C, 77.68; H, 10.58; N, 11.19.

^1H -NMR ($CDCl_3$) δ 7.35-7.15 (m, 5H), 3.15 (q, 1H,
10 J=6.6 Hz), 2.80-2.65 (m, 2H), 2.60-2.35 (m, 4H),
2.20-2.10 (m, 2H), 2.05-1.80 (m, 1H), 1.70-1.60
(m, 1H), 1.37 (d, 3H, J=6.6 Hz), 1.10 (t, 3H,
J=7.1 Hz), 0.98 (d, 3H, J=6.2 Hz).

EXAMPLE B-3

15 (3S,1'R)-3-(1'-N-ethylaminoethyl)-1-(S- α -methylbenzyl)-pyrrolidine, 43

The procedure described above was employed to give
5.21 g of the title compound.

Calculated for $C_{16}H_{22}N_2$:

20 C, 77.99; H, 10.64, N, 11.37

Found: C, 78.22; H, 10.63; N, 11.11.

MS (EI) 245(P+), 201, 186, 174, 155, 141, 121,
105 (base), 96, 72

^1H -NMR ($CDCl_3$) δ 7.40-7.20 (m, 5H), 3.19 (q, 1H,
25 J=6.5 Hz), 2.90-2.75 (m, 1H), 2.75-2.65 (m, 1H),
2.60-2.45 (m, 4H), 2.25-2.10 (m, 2H), 1.95-2.70
(m, 1H), 1.55-1.35 (m, 1H, overlapped with doublet),
1.37 (d, 3H, J=6.5 Hz), 1.15-1.00 (m, 6H).

EXAMPLE C

30 (3R,1'R)-3-(1'-N-ethylaminoethyl)pyrrolidine, 45

(3R,1'R)-3-(1'-N-ethylaminoethyl)-1-(S- α -methylbenzyl)pyrrolidine (5.4 g, 0.022 mol) was dissolved in methanol (100 mL) and 20% palladium on

-72-

carbon (1.0 g) was added. The resulting slurry was shaken under 50 psig of hydrogen for 21 hours then depressurized. The resulting suspension was filtered and the filtrate distilled to remove the methanol. The remaining oil was distilled at 10-12 mm Hg at 85-89°C to give 2.4 g of the title compound.

$^1\text{H-NMR}$ (CDCl_3) δ 3.10-2.85 (m, 3H), 2.80-2.70 (m, 1H), 2.65-2.50 (m, 2H), 2.10-1.85 (m, 2H), 1.50-1.35 (m, 2H), 1.11 (t, 3H, $J=7.0$ Hz), 1.04 (d, 3H, $J=6.2$ Hz).

EXAMPLE C-1

(3R,1'S)-3-(1'-N-ethylaminoethyl)pyrrolidine, 44

The procedure described above was followed to give 3.2 g of the title compound, bp 85-92° at 10-12 mm Hg.

Calculated for $\text{C}_8\text{H}_{18}\text{N}_2$:

C, 67.55; H, 12.76; N, 19.70

Found: C, 67.58; H, 12.98; N, 19.60.

$^1\text{H-NMR}$ (CDCl_3) δ 3.09 (dd, 1H, $J=7.7, 10.6$ Hz), 3.00-2.85 (m, 2H), 2.80-2.45 (m, 4H), 2.05-1.80 (m, 2H), 1.50-1.30 (m, 1H), 1.15-1.00 (m, 6H).

EXAMPLE C-2

(3S,1'R)-3-(1'-N-ethylaminoethyl)pyrrolidine, 47

The procedure described above was followed to give 2.38 g of the title compound, bp 87-92° at 10-12 mm Hg.

Calculated for $\text{C}_8\text{H}_{18}\text{N}_2 \cdot 0.065 \text{ H}_2\text{O}$:

C, 67.00; H, 12.74; N, 19.35

Found: C, 67.09; H, 13.16; N, 19.35.

$^1\text{H-NMR}$ (CDCl_3) δ 3.08 (dd, 1H, $J=7.7, 10.5$), 2.95-2.85 (m, 2H), 2.75-2.45 (m, 5H), 2.05-1.90 (m, 1H), 1.90-1.80 (m, 1H), 1.50-1.30 (m, 1H), 1.15-1.00 (m, 6H).

-73-

EXAMPLE C-3

(3S,1'S)-3-(1'-N-ethylaminoethyl)pyrrolidine, 46

The procedure described above was followed to give 3.28 g of the title compound, bp 88-92° at 10-12 mm Hg.

5 Calculated for $C_8H_{18}N_2$:

C, 67.55; H, 12.75; N, 19.70

Found: C, 67.35; H, 13.14; N, 19.57.

^1H -NMR ($CDCl_3$) δ 3.10-2.85 (m, 3H), 2.80-2.55 (m, 1H),
2.50-2.40 (m, 3H), 2.05-1.80 (m, 2H), 1.50-1.30
10 (m, 1H), 1.10 (t, 3H, $J=7.3$ Hz), 1.03 (d, 3H,
 $J=6.1$ Hz).

EXAMPLE D

1-(S- α -methylbenzyl)-3-(1'-N-methyl-N-trifluoroacetyl-
aminoethyl)pyrrolidin-5-one, 69

15 A methanol solution (10 mL) of 1-(S- α -methyl-
benzyl)-3-(1'-aminoethyl)pyrrolidin-5-one (8 + 9, 13 mmol)
was treated with methyl trifluoroacetate (1.92 g,
15 mmol) with stirring for 18 hours, then was evaporated
to an oil. This crude oil was dissolved in DMF and
20 added to a suspension of NaH (0.2 g, 5 mmol, 60 wt %) in
DMF (10 mL). This mixture was heated to 60°C for one
hour then cooled to ambient temperature. To this was
added methyl iodide (0.3 mL, 5 mmol) and the reaction
was stirred for 18 hours. The solvent was removed under
25 vacuum (bath = 50°C) and the residue partitioned between
methylene chloride and water. The organic layer was
dried, filtered, and evaporated to give 1.5 g of the
title compound, which was used without purification.

-74-

EXAMPLE E

1-(S- α -methylbenzyl)-3-(RS-1'-N-methylaminoethyl)-pyrrolidin-5-one, 70

Compound 69 (1.5 g, 4.4 mmol) was dissolved in 1.0 N NaOH solution (10 mL) and ethanol (15 mL) and stirred at 50°C for one hour. The solution was evaporated under vacuum to remove the ethanol and the residue was partitioned between water and methylene chloride. The methylene chloride layer was separated, the water layer was reextracted, and the combined organic layers were washed with water, dried, filtered and evaporated to give the title compound (0.95 g).

EXAMPLE F

3-(2'-(ethoxycarbonyl)acetyl)-1-(S- α -methylbenzyl)-pyrrolidin-5-one, 4

The acid 1 (20.0 g, 85.7 mmol) was suspended in dry THF (350 mL) and the reaction was warmed to 40°C. 1,1'-carbonyldiimidazole (16.0 g, 98.6 mmol) was added to the reaction in portions over 15 minutes. The reaction was warmed to 45°C and stirred for 24 hours. To the reaction was added the magnesium salt, 3, (30.7 g, 107 mmol). The reaction was warmed to reflux over 0.50 hour, refluxed 3.5 hours, then allowed to cool. The reaction was concentrated in vacuo. The residue taken up in CH₂Cl₂ (600 mL) was washed with H₂O (2X150 mL) followed by dilute NaHCO₃ (saturated solution diluted 10 fold, 2X200 mL). The aqueous phases were washed with CH₂Cl₂ (2X100 mL). The organic layers were combined and washed with saturated NaCl (3X150 mL). The combined brine layers were washed with CH₂Cl₂ (100 mL). All CH₂Cl₂ layers were combined, washed again with saturated NaCl (1X150 mL), dried with MgSO₄ and concentrated to give the desired product as a brown oil (29.8 g). The crude product was chromatographed (silica

-75-

- gel/EtOAc) giving pure diastereomers; (higher Rf diastereomer)-4 (Rf = 0.45, 10.5 g, 37.6%), a mixture of isomers-4 (9.68 g, 30.1%) and (lower Rf diastereomer)-4 (Rf = 0.30, 1.61 g, 5.6%) as viscous oils.
- 5 (Higher Rf diastereomer); $^1\text{H-NMR}$ (CDCl_3) δ 1.14-1.32 (m, 3H), 1.54 (d, $J=7.1$ Hz, 3H), 2.57-2.78 (m, 2H), 3.05-3.24 (m, 1H), 3.30-3.46 (m, 1H), 3.48 (s, less than 2H), 3.59 (dd, $J=7.2, 6.4$ Hz, 1H), 4.11-4.30 (m, 2H), 5.02 (s, less than 1H), 5.49 (q, $J=7.1$ Hz, 1H), 7.22-7.43 (m, 5H), 12.19 (s, less than 1H), enol tautomer present; Anal. [$\text{C}_{17}\text{H}_{21}\text{NO}_4$ 0.27 EtOAc] (Calc., found):
- C, (66.38, 66.37); H, (7.13, 7.02); N, (4.28, 4.28).
- 15 (Lower Rf diastereomer); $^1\text{H-NMR}$ (CDCl_3) δ 1.16-1.35 (m, 3H), 1.54 (d, $J=7.1$ Hz, 3H), 2.58-2.78 (m, 2H), 2.97-3.27 (m) + 3.32-3.64, (m) + 4.94(s)-5H total, 4.07-4.27 (m, 2H), 5.51 (q, $J=7.1$ Hz, 1H), 7.19-7.46 (m, 5H), 12.04 (s, less than 1H), enol tautomer present; Anal. [$\text{C}_{17}\text{H}_{21}\text{NO}_4$, 0.34 EtOAc] (Calc., found):
- C, (66.16, 66.08); H, (7.17, 6.80); N, (4.21, 4.20).

25 The isomers purified above were recombined and used in the next step.

EXAMPLE G

3-acetyl-1-(S- α -methylbenzyl)pyrrolidin-5-one, 5

The combined fractions of the above ketoester, 4, (19.9 g, 65.8 mmol) were dissolved in DMSO (84.0 mL).

30 To the reaction was added NaCl (8.30 g, 142 mmol) and H_2O (4.38 mL, 243 mmol). The reaction was warmed to 130-135°C for 20 hours, cooled to room temperature and partitioned between H_2O (400 mL) and CH_2Cl_2 (80 mL). The resulting layers were separated. The aqueous layer was

-76-

washed with CH_2Cl_2 (6X75 mL). The organic layers were combined, extracted with H_2O (3X80 mL), dried with MgSO_4 and concentrated in vacuo to give crude 6 (15.9 g) as a dark oil. The crude product was chromatographed [silica gel/THF:hexane (1:1)] giving pure diastereomers.

Higher Rf diastereomer ($R_f = 0.22$, 5.53 g, 36.3%), a mixture of isomers- (3.14, 20.6%) and lower Rf diastereomer ($R_f = 0.11$, 6.10 g, 33.9%) as viscous oils.

Higher Rf diastereomer; $^1\text{H-NMR}$ (CDCl_3) δ 1.51 (d, $J=7.3$ Hz, 3H), 2.16 (s, 3H), 2.63 (d, $J=8.4$ Hz, 2H), 2.97-3.30 (m, 2H), 3.40-3.63 (m, 1H), 5.46 (q, $J=7.3$ Hz, 1H), 7.18-7.43 (m, 5H); Anal. [$\text{C}_{14}\text{H}_{17}\text{NO}_2$]:

(Calc., found):

C, (72.70, 72.67); H, (7.41, 7.73);

N, (6.06, 5.81).

Lower Rf diastereomer; $^1\text{H-NMR}$ (CDCl_3) δ 1.53 (d, $J=7.2$ Hz, 3H), 2.09 (s, 3H), 2.65 (d, $J=8.0$ Hz, 2H), 3.08-3.38 (m, 2H), 3.47 (t, $J=8.0$ Hz, 1H), 5.48 (q, $J=7.2$ Hz, 1H), 7.20-7.43 (m, 5H); Anal. [$\text{C}_{14}\text{H}_{17}\text{NO}_2$ -0.20 C_6H_{14}]:

(Calc., found):

C, (73.46, 73.34); H, (8.03, 7.85);

N, (5.64, 5.28).

The isomers purified above were combined and used in the next step.

EXAMPLE H

3S and 3R-(hydroxyimino)-1-(S- α -methylbenzyl)pyrrolidin-5-one, 6 and 7

To a solution of the ketone, 5 (12.9 g, 56.0 mmol) in pyridine (223 mL), was added hydroxylamine hydrochloride (4.27 g, 61.6 mmol). The reaction was warmed to 45°C . After stirring for 24 hours, the pyridine was removed in vacuo, and the residue was dissolved in CHCl_3 (230 mL). The CHCl_3 layer was

-77-

extracted with 0.5 N HCl (11x75.0 mL), dried with MgSO₄ and concentrated to a solid (14.2 g). The crude product was chromatographed [silica gel/EtOAc] giving pure diastereomers; 3S-3-(hydroxyimino)-1-(S- α -methylbenzyl)pyrrolidin-5-one, 6, (R_f = 0.40, mp 109-110°C, 5.36 g, 38.9%). Mixture of 6 and 7 (3.21 g, 23.3%) and 3R-3-(hydroxyimino)-1-(S- α -methylbenzyl)pyrrolidin-5-one, 7, (R_f = 0.31, mp 125-127°C, 3.15 g, 22.8%) as solids.

6; ¹H-NMR (CDCl₃) δ 1.50 (d, J=7.0 Hz, 3H), 1.84 (s, 3H), 2.56-2.68 (m, 2H), 2.93-3.22 (m, 2H), 3.34 (dd, J=9.6, 7.0 Hz, 1H), 5.51 (q, J=7.0 Hz, 1H), 7.22-7.43 (m, 5H), 8.65 (s, 1H); Anal. [C₁₄H₁₈N₂O₂]: (Calc., found):

C, (68.27, 68.11); H, (7.37, 7.33);
N, (11.37, 11.26).

7; ¹H-NMR (CDCl₃) δ 1.53 (d, J=7.2 Hz, 3H), 1.70 (s, 3H), 2.49-2.70 (m, 2H), 2.92 (dd, J=9.8, 6.4 Hz, 1H), 3.03-3.20 (m, 1H), 3.48 (dd, J=9.7, 8.3 Hz, 1H), 5.53 (q, J=7.2 Hz, 1H), 7.19-7.40 (m, 5H), 8.12 (s, 1H); Anal. [C₁₄H₁₈N₂O₂] (Calc., found):

C, (68.27, 68.11); H, (7.37, 7.65);
N, (11.37, 11.19).

EXAMPLE I

(3S,1'S)-3-(1'-aminoethyl)-1-(S- α -methylbenzyl)-pyrrolidin-5-one, 10

(3S,1'R)-3-(1'-aminoethyl)-1-(S- α -methylbenzyl)-pyrrolidin-5-one, 11

The oxime, 6, (11.5 g, 46.7 mmol) was dissolved in MeOH saturated with NH₃ (100 mL) and placed in a Parr shaker with Raney nickel (4.00 g). The reaction was placed under 51.0 psi of hydrogen and shaken for 20 hours. The reaction was filtered and the filtrate

-78-

was concentrated to an oil (11.4 g). The crude product was chromatographed [silica gel/CHCl₃:EtOH:TEA (20:1:1)] to give pure diastereomers; (3S,1'R)-3-(1'-aminoethyl)-1-(S- α -methylbenzyl)pyrrolidin-5-one, 11, (R_f = 0.33, 3.02 g, 27.6%), a mixture of isomers-10 and 11 (1.73 g, 15.8%) and (3S,1'S)-3-(1'-aminoethyl)-1-(S- α -methylbenzyl)pyrrolidin-5-one, 10, (R_f = 0.24, 5.70 g, 52.1%) as viscous oils.

11; ¹H-NMR (CDCl₃) δ 1.06 (d, J=6.4 Hz, 3H), 1.12 (br. s., 2H - disappears with D₂O wash), 1.51 (d, J=7.2 Hz, 3H), 1.90-2.30 (m, 2H), 2.46 (dd, J=16.2, 8.7 Hz, 1H), 2.72-2.92 (m, 1H), 3.12 (d, J=7.7 Hz, 2H), 5.48 (q, J=7.2 Hz, 1H), 7.17-7.43 (m, 5H); IR (LF) 3359, 3030, 1683, 1428, 701 cm⁻¹; Anal. [C₁₄H₂₀N₂O, 0.10 H₂O] (Calc., found):

C, (71.82, 71.84); H, (8.70, 8.64);

N, (11.96, 12.16).

HPLC = 99.5%.

10; ¹H-NMR (CDCl₃/200 MHz) δ 0.99 (d, J=6.4 Hz, 3H), 1.18 (br. s., 2H - disappears with D₂O wash), 1.49 (d, J=7.0 Hz, 3H), 2.00-2.37 (m, 2H), 2.52 (dd, J=16.4, 9.0 Hz, 1H), 2.75-3.13 (m, 3H), 5.47 (q, J=7.0 Hz, 1H), 7.13-7.42 (m, 5H); IR (LF) 3366, 2934, 1680, 1427, 701 cm⁻¹; Anal. [C₁₄H₂₀N₂O, 0.09 H₂O]:

(Calc., found):

C, (71.88, 71.87); H, (8.69, 8.85);

N, (11.97, 11.94).

HPLC = 97.2%.

-79-

EXAMPLE J

(3R,1'S)-3-(1'-aminoethyl)-1-(S- α -methylbenzyl)
pyrrolidin-5-one, 8

(3R,1'R)-3-(1'-aminoethyl)-1-(S- α -methylbenzyl)
pyrrolidin-5-one, 9

5

In a manner similar to the reduction of 6 (Example I), the oxime 7 was reduced and purified to give pure diastereomers; (3R,1'S)-3-(1'-aminoethyl)-1-(S- α -methylbenzyl)pyrrolidin-5-one, 8, (R_f = 0.33, 3.96 g, 33.8%), a mixture of 8 and 9 (1.97 g, 16.7%) and (3R,1'R)-3-(1'-aminoethyl)-1-(S- α -methylbenzyl)pyrrolidin-5-one, 9, (R_f = 0.24, 5.14 g, 43.8%) as viscous oils.

(3R,1'S)-3-(1'-aminoethyl)-1-(S- α -methylbenzyl)pyrrolidin-5-one, 9; ¹H-NMR (CDCl₃) δ 1.03 (d, J=6.1 Hz, 3H), 1.21 (br. s., 2H - disappears with D₂O wash), 1.52 (d, J=7.0 Hz, 3H), 2.00-2.30 (m, 2H), 2.38-2.60 (m, 1H), 2.62-2.90 (m, 2H), 3.44 (dd, J=9.7, 7.7 Hz, 1H), 5.52 (q, J=7.0 Hz, 1H), 7.17-7.50 (m, 5H); Anal. [C₁₄H₂₀N₂O, 0.68 H₂O]:

20

(Calc., found):

C, (68.75, 68.77); H, (8.80, 8.68);

N, (11.45, 11.30); [α]_D = -116° (c=1.0, CH₃OH);

HPLC =99.1%.

(3R,1'R)-3-(1'-aminoethyl)-1-(S- α -methylbenzyl)pyrrolidin-5-one, 8; ¹H NMR (CDCl₃) δ 0.91 (d, J=6.3 Hz, 3H), 1.39 (br. s., 2H - disappears with D₂O wash), 1.51 (d, J=7.3 Hz, 3H), 2.02-2.37 (m, 2H), 2.43-2.80 (m, 3H), 3.25-3.43 (m, 1H), 5.51 (q, J=7.3 Hz, 1H), 7.17-7.43 (m, 5H); Anal. [C₁₄H₂₀N₂O, 0.71 H₂O]:

30

(Calc., found):

C, (68.65, 68.29); H, (8.81, 8.38);

N, (11.44, 11.23); [α]_D = -128° (c=1.0, CH₃OH);

HPLC = 99.4%.

-80-

EXAMPLE K

(3S,1'R)-3-(1'-aminoethyl)-1-(S- α -methylbenzyl)
pyrrolidine, 15

To dry THF (150 mL) cooled to 0°C was added 95%
5 LiAlH_4 (2.34 g, 58.6 mmol) portionwise. The ice bath
was removed and a solution of 11 (6.81 g, 29.3 mmol) in
dry THF (100 mL) was added dropwise. The reaction was
warmed to reflux. After 24 hours the reaction was
cooled to room temperature and quenched by adding H_2O
10 (2.34 mL), then 15% NaOH (2.34 mL), followed by H_2O
(7.20 mL). The reaction was filtered through celite and
the pad was washed with THF. The filtrate was
concentrated and the residue partitioned between CH_2Cl_2
(50.0 mL) and H_2O (15.0 mL). The resulting phases were
15 separated and the aqueous phase was washed with CH_2Cl_2
(3X10.0 mL). The CH_2Cl_2 layers were combined, dried
with MgSO_4 and concentrated in vacuo to crude product
(6.49 g). This material was distilled to give product
as an oil (bp = 89-96°C at 0.15 mm, 5.56 g, 86.9%).

20 15; $^1\text{H-NMR}$ (CDCl_3) δ 1.04 (d, $J=6.2$ Hz, 3H), 1.31-
1.73 (m, 6H - contains 1.38 (d, $J=6.6$ Hz)), 1.77-2.11
(m, 2H), 2.13-2.27 (m, 1H), 2.38-2.57 (m, 2H), 2.65-2.81
(m, 1H), 2.81-2.93 (m, 1H), 3.19 (q, $J=6.6$ Hz, 1H),
7.16-7.43 (m, 5H); Anal. [$\text{C}_{14}\text{H}_{22}\text{N}_2$]:
25 (Calc., found):
C, (77.01, 76.70); H, (10.16, 10.21);
N, (12.83, 12.46).

EXAMPLE K-1

(3S,1'S)-3-(1'-aminoethyl)-1-(S- α -methylbenzyl)
30 pyrrolidine, 14

The reduction of 10 was carried out in the same
manner as above to give 14 (bp 91-100°C at 0.25 mm,
5.57 g, 79.9%).

-81-

$^1\text{H-NMR}$ (CDCl_3) δ 1.00 (d, $J=6.3$ Hz, 3H), 1.24-1.47 (m, 5H - contains 1.37 (d, $J=6.6$ Hz)), 1.49-1.67 (m, 1H), 1.80-2.16 (m, 3H), 2.38-2.59 (m, 2H), 2.65-2.86 (m, 2H), 3.16 (q, $J=6.6$ Hz, 1H), 7.13-7.38 (m, 5H);

5 Anal. [$\text{C}_{14}\text{H}_{22}\text{N}_2$]:

(Calc., found):

C, (77.01, 76.66); H, (10.16, 10.08);

N, (12.83, 12.50).

EXAMPLE K-2

10 (3R,1'S)-3-(1'-aminoethyl)-1-(S- α -methylbenzyl)
pyrrolidine, 12

Compound 8 (3.44 g, 14.8 mmol) was reduced as in K and gave 12 (bp = 92-101°C at 0.10 mm, 2.53 g 78.0%);

Anal. [$\text{C}_{14}\text{H}_{22}\text{N}_2$]:

15 (Calc., found):

C, (77.01, 76.59); H, (10.16, 9.96);

N, (12.83, 11.98).

EXAMPLE K-3

20 (3R,1'R)-3-(1'-aminoethyl)-1-(S- α -methylbenzyl)
pyrrolidine, 13

Compound 9 (4.51 g, 19.4 mmol) was reduced as in K and gave 13 (bp 83-94°C at 0.05 mm, 2.93 g, 68.9%);

Anal. [$\text{C}_{14}\text{H}_{22}\text{N}_2$]: (Calc., found):

C, (77.01, 76.21); H, (10.16, 10.28);

25 N, (12.83, 12.20).

General preparation of the 3-(1'-N-t-butyloxycarbonyl-
aminoethyl)-1-(S- α -methylbenzyl)pyrrolidines (16-19)

The pyrrolidines (12-15) were added to a cold solution of di-t-butyloxycarbonate (1.10-1.20 eq), 1 N NaOH (1.10-1.20 eq) and t-BuOH (35-50 mL). The ice bath
30 was removed and the reactions stirred at room temperature. After stirring 24 hours, the product was

-82-

isolated by diluting the reaction with H₂O (100 mL) and extracting the aqueous solution with ether (5X25 mL). The ether layers were combined, dried with MgSO₄ and concentrated in vacuo to give crude product. The crude products were purified by chromatography [silica gel/CH₂Cl₂:EtOH(90:10)/] to give pure products.

EXAMPLE L

(3S,1'R)-3-(1'-N-t-butyloxycarbonylaminoethyl)-1-(S- α -methylbenzyl)pyrrolidine, 19

This compound was obtained from 15 using the general procedure described (Rf = 0.24, 4.87 g, 62.5%); ¹H-NMR (CDCl₃) δ 1.06 (d, J=6.6 Hz, 3H), 1.30-1.68 (m, 13H - contains 1.38 (d, J=6.7 Hz) and 1.46 (s)), 1.83-2.23 (m, 2H), 2.25-2.60 (m, 3H), 2.68-2.90 (m, 1H), 3.19 (q, J=6.5 Hz, 1H), 3.40-3.63 (m, 1H), 5.26-5.47 (m, 1H), 7.17-7.43 (m, 5H); Anal. [C₁₉H₃₀N₂O, 0.13 CH₂Cl₂]: (Calc., found): C, (69.73, 69.68); H, (9.26, 9.17); N, (8.50, 8.50).

EXAMPLE L-1

(3S,1'S)-3-(1'-N-t-butyloxycarbonylaminoethyl)-1-(S- α -methylbenzyl)pyrrolidine, 18

This compound was obtained from 14 using the general procedure described (Rf = 0.33, 5.18 g, 67.4%); ¹H-NMR (CDCl₃) δ 1.11 (d, J=6.2 Hz, 3H), 1.30-2.00 (m, 14H - contains 1.37 (d, J=6.3 Hz)), 2.03-2.38 (m, 3H), 2.43-2.63 (m, 1H), 2.65-2.85 (m, 1H), 3.14 (q, J=6.4 Hz, 1H), 3.37-3.63 (m, 1H), 5.20 (br. s., 1H), 7.17-7.43 (m, 5H); Anal. [C₁₉H₃₀N₂O₂, 0.17 CH₂Cl₂]: (Calc., found): C, (69.17, 69.15); H, (9.19, 8.98); N, (8.41, 8.22).

-83-

EXAMPLE L-2

(3R,1'S)-3-(1'-N-t-butyloxycarbonylaminoethyl)-1-(S- α -methylbenzyl)pyrrolidine, 16

5 This compound was obtained from 12 using the
general procedure described (R_f = 0.24, 1.64 g, 44%);
 $^1\text{H-NMR}$ (CDCl_3) δ 1.16 (d, J =7.3 Hz, 3H), 1.32-1.66
(m, 13H), 1.85-2.27 (m, 2H), 2.30-2.87 (m, 4H), 3.10-
3.33 (m, 1H), 3.40-3.67 (m, 1H), 5.65 (br. s., 1H),
7.17-7.43 (m, 5H); Anal. [$\text{C}_{19}\text{H}_{30}\text{N}_2\text{O}_2$, 0.19 CH_2Cl_2]:
10 (Calc., found):
C, (68.89, 68.96); H, (9.15, 8.86);
N, (8.37, 8.13).

EXAMPLE L-3

15 (3R,1'R)-3-(1'-N-t-butyloxycarbonylaminoethyl)-1-(S- α -methylbenzyl)pyrrolidine, 17

This procedure was obtained from 13 using the
general procedure described (R_f = 0.33, 1.76 g, 45.4%);
 $^1\text{H-NMR}$ (CDCl_3) δ 1.07 (d, J =7.3 Hz, 3H), 1.32-1.55
(m, 12H), 1.55-1.77 (m, 1H), 1.77-2.03 (m, 1H), 2.03-
20 2.87 (m, 5H), 3.07-3.30 (m, 1H), 3.43-3.70 (m, 1H), 5.13
(br. s., 1H), 7.17-7.43 (m, 5H); Anal. [$\text{C}_{19}\text{H}_{30}\text{N}_2\text{O}_2$, 0.08
 CH_2Cl_2]:
(Calc., found):
C, (70.46, 70.39); H, (9.35, 9.10);
25 N, (8.61, 8.70).

General Procedure for the Preparation of 3-(1'-N-t-butyloxycarbonylaminoethyl)pyrrolidines, 20-23

30 The compound (16-19) was dissolved in MeOH (100 mL)
and 20% Pd/C (0.30-1.00 g) in a Parr shaker. The
reaction was placed under H_2 (50.0 psi). After shaking
18-26 hours, additional catalyst was required (0.30-
1.60 g). The reaction was shaken for another 2-6 hours,
then filtered. The filtrate was concentrated in vacuo

-84-

and the residue was taken up in H₂O. The aqueous solution was extracted with diethyl ether, made basic with 50% NaOH, extracted with CH₂Cl₂ or CHCl₃. The combined organic layers were dried with MgSO₄ and concentrated to a waxy solid. These compounds were used as is or were purified by trituration with ether or ether/pentane and filtration of the purified solid.

EXAMPLE M

(3S,1'R)-3-(1'-N-t-butyloxycarbonylaminoethyl)-pyrrolidine, 23

Compound 23 was obtained from 19 using the method described above; (0.93 g, 62.8%); ¹H-NMR (CDCl₃) δ 1.15 (d, J=6.5 Hz, 3H), 1.30-1.57 (m, 10H), 1.72-2.15 (m, 2H), 2.60 (br. s., disappears with D₂O wash), 2.70-2.86 (m, 1H), 2.87-3.17 (m, 3H), 3.43-3.70 (m, 1H), 4.50-4.73 (m, 1H - disappears with D₂O wash); Anal. [C₁₁H₂₂N₂O₂, 0.08 CH₂Cl₂]:

(Calc., found):

C, (60.19, 60.25); H, (10.10, 9.77);

N, (12.67, 12.30).

EXAMPLE M-1

(3S,1'S)-3-(1'-N-t-butyloxycarbonylaminoethyl)-pyrrolidine, 22

Compound 22 was obtained from 18 using the method described above; (0.72 g, 89.8%); ¹H-NMR (CDCl₃) δ 1.11 (d, J=6.5 Hz, 3H), 1.30-1.63 (m, 10H), 1.73-2.15 (m, 2H), 2.43-2.67 (m, 1H), 2.77-3.12 (m, 3H), 3.45-3.70 (m, 1H). Anal. [C₁₁H₂₂N₂O₂]:

(Calc., found):

C, (61.65, 60.82); H, (10.35, 10.10);

N, (13.07, 12.03).

Used without further purification in the next step.

-85-

EXAMPLE M-2

(3R,1'S)-3-(1'-N-t-butyloxycarbonylaminoethyl)-pyrrolidine, 20

Compound 20 was obtained from 16 using the method described above; mp 71.5-74.5°C; ¹H-NMR (CDCl₃) δ 1.15 (d, J=6.5 Hz, 3H), 1.30-1.60 (m, 10H - contains 1.44 (s)), 1.70-2.13 (m, 2H - contains broad peak which disappears with D₂O wash), 2.66-3.10 (m, 4H), 3.42-3.70 (m, 1H), 4.62 (br. s., 1H - disappears with D₂O wash); Anal. [C₁₁H₂₂N₂O₂, 0.25 H₂O]: (Calc., found):

C, (60.38, 60.37); H, (10.36, 10.09);
N, (12.80, 12.62).

EXAMPLE M-3

(3R,1'R)-3-(1'-N-t-butyloxycarbonylaminoethyl)-pyrrolidine, 21

Compound 21 was obtained from 17 using the method described above; mp 85.5-88.5°C; ¹H-NMR (CDCl₃) δ 1.12 (d, J=6.5 Hz, 3H), 1.21-1.67 (m, 10H - contains 1.44 (s)), 1.73-2.17 (m, 2H - contains br. s. which disappears with D₂O wash), 2.50-2.68 (m, 1H), 2.80-3.17 (m, 3H), 3.43-3.75 (m, 1H), 4.50 (br. s., 1H - disappears with D₂O wash); Anal. [C₁₁H₂₂N₂O₂, 0.25 H₂O]: (Calc., found):

C, (60.38, 60.36); H, (10.36, 10.16);
N, (12.80, 12.63).

General Procedure for the Preparation of the 3-(1'-N,N-dimethylaminoethyl)-1-S-α-methylbenzyl)pyrrolidinones 24-27

To the chiral amines (8-11), cooled in an ice/water bath was added 88% formic acid (2.5 eq) and 35% formaldehyde. The ice bath was removed and the reaction was warmed slowly over 25-60 minutes. Gas evolution

-86-

occurred. The reaction was then warmed to reflux for five hours, cooled to room temperature, and made basic with 1 N NaOH. The reaction was extracted with diethyl ether. The combined ether layers were washed with saturated NaCl, dried with MgSO₄, filtered and concentrated in vacuo to provide the desired products.

EXAMPLE N

(3S,1'R)-3-(1'-N,N-dimethylaminoethyl)-1-(S- α -methylbenzyl)pyrrolidin-5-one, 27

The compound 27 was obtained from 11 as described above; bp 0.20-0.25 mm, mp 140-157°C; ¹H-NMR (CDCl₃) δ 0.88 (d, J=6.5 Hz, 3H), 1.52 (d, J=7.1 Hz, 3H), 2.03-2.32 (m, 8H - contains 2.14 (s)), 2.35-3.55 (m, 2H), 3.01-3.30 (m, 2H), 5.48 (q, J=7.1 Hz, 1H), 7.19-7.40 (m, 5H); Anal. [C₁₆H₂₄N₂O]:

(Calc., found):

C, (73.81, 73.48); H, (9.29, 9.47);

N, (10.76, 10.55).

EXAMPLE N-1

(3S,1'S)-3-(1'-N,N-dimethylaminoethyl)-1-(S- α -methylbenzyl)pyrrolidin-5-one, 26

The compound 26 was obtained from 10 as described above. The crude product was recrystallized from diethyl ether to give (1.31 g, 30%). The filtrate was concentrated to give an additional material which was used without further purification (2.52 g, 57.6%); ¹H-NMR (CDCl₃) δ 0.83 (d, J=6.4 Hz, 3H), 1.51 (d, J=7.1 Hz, 3H), 2.08-2.59 (m, 10H - contains 2.18 (s)), 2.87-3.07 (m, 2H), 5.50 (q, J=7.1 Hz, 1H), 7.19-7.40 (m, 5H); Anal. [C₁₆H₂₄N₂O]:

(Calc., found):

C, (73.81, 73.68); H, (9.29, 9.46);

N, (10.76, 10.71).

-87-

EXAMPLE N-2

(3R,1'S)-3-(1'-N,N-dimethylaminoethyl)-1-(S- α -methylbenzyl)pyrrolidin-5-one, 24

5 The compound 24 was obtained from 8 as described above; (12.54 g, 92.3%); $^1\text{H-NMR}$ (CDCl_3) δ 0.84 (d, $J=6.0$ Hz, 3H), 1.52 (d, $J=7.1$ Hz, 3H), 1.97-2.20 (m, 7H - contains 2.11 (s)), 2.20-2.58 (m, 3H), 2.88 (dd, $J=10.1$, 6.8 Hz, 1H), 3.38 (dd, $J=10.1$, 7.3 Hz, 1H), 5.51 (q, $J=7.1$ Hz, 1H), 7.18-7.43 (m, 5H); Anal. 10 $[\text{C}_{16}\text{H}_{24}\text{N}_2\text{O}$, 0.15 H_2O]: (Calc., found): C, (73.05, 73.37); H, (9.31, 9.38); N, (10.65, 10.25).

EXAMPLE N-3

15 (3R,1'R)-3-(1'-N,N-dimethylaminoethyl)-1-(S- α -methylbenzyl)pyrrolidin-5-one, 25

The desired product 25 was obtained from 9 as described above; (11.27 g, 83.8%); $^1\text{H-NMR}$ (CDCl_3) δ 0.73 (d, $J=5.9$ Hz, 3H), 1.52 (d, $J=7.1$ Hz, 3H), 2.15 (s, 6H), 20 2.22-2.63 (m, 5H), 3.22-3.38 (m, 1H), 5.52 (q, $J=7.1$ Hz, 1H), 7.18-7.43 (m, 5H); Anal. $[\text{C}_{16}\text{H}_{24}\text{N}_2\text{O}$, 0.17 H_2O]: (Calc., found): C, (72.95, 73.00); H, (9.31, 9.69); N, (10.63, 10.39).

25 General Procedure for the Preparation of the 3-(1'-N,N-dimethylaminoethyl)-1-(S- α -methylbenzyl)-pyrrolidines 28-31

To cold, dry THF (100-200 mL) was added 95% LiAlH_4 (2 eq). The ice bath was removed and a solution of the 30 chiral amides (24-27) in THF (50 mL) was added dropwise. The reaction was refluxed 17-18 hours then cooled to room temperature. The reaction was quenched by adding first 1 mL of H_2O /gram of LiAlH_4 used followed by 1 mL

-88-

of 15% NaOH/gram of LiAlH_4 used and finally 3 mL of H_2O /gram of LiAlH_4 used. The suspension was filtered through celite and the filter pad was washed with THF. The filtrate was concentrated and the residue was partitioned between CH_2Cl_2 and saturated NaCl solution. The resulting layers were isolated. The aqueous layer was washed with CH_2Cl_2 . The CH_2Cl_2 layers were combined, dried with MgSO_4 and concentrated in vacuo. The crude material was distilled to give the pure product.

10

EXAMPLE O

(3S,1'R)-3-(1'-N,N-dimethylaminoethyl)-1-(S- α -methylbenzyl)pyrrolidine, 31

Compound 31 (4.65 g, 80%) was obtained from 27 as described; bp 0.10-0.15 mm Hg, 95-105°C; $^1\text{H-NMR}$ (CDCl_3) δ 0.86 (d, $J=6.2$ Hz, 3H), 1.23-1.46 (m, 4H - contains 1.39 (d, $J=6.6$ Hz)), 1.74-1.95 (m, 1H), 2.08-2.46 (m, 10H), 2.46-2.61 (m, 1H), 3.00-3.24 (m, 2H - contains 3.18 (q, $J=6.6$ Hz)), 7.11-7.38 (m, 5H); Anal. [$\text{C}_{16}\text{H}_{26}\text{N}_2$]: (Calc., found):

C, (77.99, 77.70); H, (10.64, 10.98);
N, (11.37, 11.32).

20

EXAMPLE O-1

(3S,1'S)-3-(1'-N,N-dimethylaminoethyl)-1-(S- α -methylbenzyl)pyrrolidine, 30

Compound 30 (3.97 g, 79%) was obtained from 26 as described; bp 0.15 mm Hg, 96-102°C; $^1\text{H-NMR}$ (CDCl_3) δ 0.83 (d, $J=6.4$ Hz, 3H), 1.38 (d, $J=6.6$ Hz, 3H), 1.54-1.78 (m, 1H), 1.78-2.04 (m, 2H), 2.07-2.41 (m, 9H - contains 2.19 (s)), 2.41-2.62 (m, 1H), 2.90 (dd, $J=8.5$, 7.7 Hz, 1H), 3.17 (q, $J=6.6$ Hz, 1H), 7.12-7.36 (m, 5H); Anal. [$\text{C}_{16}\text{H}_{26}\text{N}_2$]: (Calc., found):

C, (77.99, 77.52); H, (10.64, 11.02);
N, (11.37, 11.06).

25

30

-89-

EXAMPLE O-2

(3R,1'S)-3-(1'-N,N-dimethylaminoethyl)-1-(S- α -methylbenzyl)pyrrolidine, 28

Compound 28 (9.06 g, 82%) was obtained from 24 as described; bp 0.10 mm Hg, 98-109°C; $^1\text{H-NMR}$ (CDCl_3 , 250 MHz) 0.85 (d, $J=6.4$ Hz, 3H), 1.24-1.45 (m, 4H - contains 1.36 (d, $J=6.6$ Hz), 1.77-2.00 (m, 1H), 2.00-2.48 (m, 10H - contains 2.14 (s)), 2.61-2.83 (m, 2H), 3.19 (q, $J=6.6$ Hz, 1H), 7.12-7.37 (m, 5H); Anal. [$\text{C}_{16}\text{H}_{26}\text{N}_2$]: (Calc., found):

C, (77.99, 77.96); H, (10.64, 10.72);
N, (11.34, 11.36).

EXAMPLE O-3

(3R,1'R)-3-(1'-N,N-dimethylaminoethyl)-1-(S- α -methylbenzyl)pyrrolidine, 29

Compound 29 (7.99 g, 80%) was obtained from 25 as described; bp 0.10 mm Hg, 103-109°C; $^1\text{H-NMR}$ (CDCl_3) δ 0.75 (d, $J=6.4$ Hz, 3H), 1.37 (d, $J=6.6$ Hz, 3H), 1.58-1.77 (m, 1H), 1.81-2.46 (m, 11H - contains 2.17 (s)), 2.51-2.66 (m, 1H), 2.85-3.00 (m, 1H), 3.15 (q, $J=6.6$ Hz, 1H), 7.15-7.38 (m, 5H).
Anal. [$\text{C}_{16}\text{H}_{26}\text{N}_2$]: (Calc., found):

C, (77.99, 77.95); H, (10.64, 10.75);
N, (11.36, 11.23).

General Procedure for the Preparation of
3-(1'-N,N-dimethylaminoethyl)pyrrolidines 32-35

The chiral amines (28-31) were dissolved in MeOH (100 mL) and placed in a Parr shaker. To this solution was added 20% Pd/C (1.00-1.50 g). The reaction was placed under H_2 gas (50 psi) and shaken for 3-4 hours.

-90-

The reaction was filtered and the filtrate was concentrated in vacuo. The residue was distilled to give pure product.

EXAMPLE P

5 (3S,1'R)-3-(1'-N,N-dimethylaminoethyl)pyrrolidine, 35

Compound 35 (1.76 g, 56%) was obtained from 31 as described; bp 10.0 mm Hg, 89-104°C; ¹H-NMR (CDCl₃) δ 0.91 (d, J=6.4 Hz, 3H), 1.19-1.40 (m, 1H), 1.75-2.12 (m, 3H), 2.20 (s, 6H), 2.25-2.47 (m, 1H), 2.69 (dd, J=10.9, 8.1 Hz, 1H), 2.82-3.02 (m, 2H), 3.10 (dd, J=10.9, 7.6 Hz, 1H); ¹³C-NMR (CDCl₃, 250 MHz) 9.5, 30.8, 40.2, 44.2, 47.0, 51.7, 63.2; Anal. [C₈H₁₈N₂, 0.10 H₂O]: (Calc., found):

15 C, (66.71, 66.95); H, (12.74, 12.64);
N, (19.45, 19.09).

EXAMPLE P-1

(3S,1'S)-3-(1'-N,N-dimethylaminoethyl)pyrrolidine, 34

Compound 34 (1.19 g, 71%) was obtained from 30 as described; bp 10.0 mm Hg, 83-110°C; ¹H-NMR (CDCl₃) δ 0.87 (d, J=6.4Hz, 3H), 1.47-1.67 (m, 1H), 1.82-2.13 (m, 2H), 2.22 (s, 6H), 2.28-2.53 (m, 2H), 2.82-2.98 (m, 2H).

EXAMPLE P-2

(3R,1'S)-3-(1'-N,N-dimethylaminoethyl)pyrrolidine, 32

Compound 32 (3.53 g, 68%) was obtained from 28 as described; bp 14.0 mm Hg, 81-84°C; ¹H-NMR (CDCl₃), δ 0.90 (d, J=6.1 Hz, 3H), 1.17-1.41 (m, 1H), 1.73-2.13 (m, 2H), 2.20 (s, 6H), 2.25-2.47 (m, 1H), 2.68 (dd, J=11.0, 7.9 Hz, 1H), 2.81-3.00 (m, 2H), 3.08 (dd, J=11 Hz, 7.3 Hz, 1H); ¹³C NMR (CDCl₃, 63 MHz), 9.3, 30.7, 40.1,

-91-

44.1, 46.9, 51.6, 63.1; Anal. [$C_8H_{18}N_2$, $0.12H_2O$] (Calc. found):

C (66.54, 66.41); H (12.73, 12.79);
N (19.40, 19.79).

5

EXAMPLE P-3

(3R,1'R)-3-(1'-N,N-dimethylaminoethyl)pyrrolidine, 33

Compound 33 (3.04 g, 68%) was obtained from 29 as described; bp 15.0-17.0 mm Hg, 83-86°C; ^1H -NMR ($CDCl_3$ + D_2O) δ 0.87 (d, $J=6.3$ Hz, 3H), 1.44-1.68 (m, 1H), 1.97-2.52 (m, 10H - contains 2.22 (s)), 2.78-3.11 (m, 3H - contains 3.01 (dd, $J=10.5$, 7.5 Hz)). Anal. [$C_8H_{18}N_2$, $0.09 H_2O$] (Calc., found):

C (66.79, 66.78); H (12.74, 13.00);
N (19.47, 19.74).

15

General Procedure for the Preparation of the
3-(1'-N-tert-butoxycarbonylaminoethyl)-1-(S- α -
methylbenzyl)pyrrolidin-5-ones, 48-50

A solution of di-tert-butylcarbonate (1.1 eq) in dichloromethane was added portionwise to a stirred solution of the corresponding primary amine (8-11) and triethylamine (1.1 eq) in dichloromethane (250 mL). The resulting solution was stirred at room temperature for 20 hours, and then concentrated under reduced pressure to give a light yellow oil. These crude products were purified by column chromatography (silica gel, heptane-isopropanol 4:1).

25

EXAMPLE Q

(3R,1'R)-3-(1'-N-tert-butoxycarbonylaminoethyl)-1-(S- α -
methylbenzyl)pyrrolidin-5-one, 49

30

From 6.68 g (28.7 mmol) of amine 9, 7.64 g (35 mmol) of di-tert-butylcarbonate, and 3.54 g

-92-

(35 mmol) of triethylamine, there was obtained 49 (5.43 g, 57%) as a white, wax-like glass.

$[\alpha]_D = -116^\circ$ ($c=0.99$, chloroform).

$^1\text{H-NMR}$ (CDCl_3) δ 0.96 (d, 3H, $J=6.7$ Hz),

5 1.38 (s, 9H), 1.52 (d, 3H, $J=7.2$ Hz), 2.23-2.55
 (m, 3H), 2.66 (dd, 1H, $J=9.8, 7.0$ Hz), 3.32 (dd,
 1H, $J=9.8, 8.1$ Hz), 3.50-3.70 (m, 1H), 4.35-4.45
 (m, 1H), 5.50 (q, 1H, $J=7.1$ Hz), 7.23-7.37 (m, 5H).

Anal. Calcd. for $\text{C}_{19}\text{H}_{28}\text{N}_2\text{O}_3$:

10 C, 68.65; H, 8.49; N, 8.43

Found: C, 68.55; H, 8.53; N, 8.13.

EXAMPLE Q-1

(3R, 1'S)-3-(1'-N-tert-butoxycarbonylaminoethyl)-1-(S- α -methylbenzyl)pyrrolidin-5-one, 48

15 From 5.95 g (25.6 mmol) of amine 8, 6.77 g
 (31.0 mmol) of di-tert-butylcarbonate, and 3.14 g
 (31.0 mmol) of triethylamine, there was obtained 48
 (7.46 g, 88%) as a white, wax-like glass.

$[\alpha]_D = -127^\circ$ ($c=1.04$, chloroform).

20 $^1\text{H-NMR}$ (d_6 -DMSO) δ 0.90 (d, 3H, $J=6.5$ Hz),

 1.34 (s, 9H), 1.44 (d, 3H, $J=7.1$ Hz), 2.04-2.20
 (m, 1H), 2.21-2.41 (m, 2H), 2.69 (dd, 1H, $J=9.6,$
 6.5 Hz), 3.28-3.42 (m, 2H), 5.25 (q, 1H, $J=7.1$ Hz),
 6.78 and 6.85 (2xd, 1H, $J=8.6$ and 7.9 Hz), 7.24-
25 7.37 (m, 5H).

Anal. Calcd. for $\text{C}_{19}\text{H}_{28}\text{N}_2\text{O}_3$:

C, 68.65; H, 8.49; N, 8.43.

Found: C, 68.45; H, 8.59; N, 8.38.

-93-

EXAMPLE Q-2

(3S,1'R)-3-(1'-N-tert-butoxycarbonylaminoethyl)-1-(S- α -methylbenzyl)pyrrolidin-5-one, 51

From 10.19 g (44 mmol) of amine 11, 11.57 g
5 (53 mmol) of di-tert-butylcarbonate, and 5.36 g
(53 mmol) of triethylamine, there was obtained 51
(13.16 g, 90%) as a white solid; mp 120-121°C (from
dichloromethane-heptane).

$[\alpha]_D = -32^\circ$ (c=0.96, chloroform).

10 $^1\text{H-NMR}$ (CDCl_3) δ 1.10 (d, 3H, J=6.6 Hz), 1.41
(s, 9H), 1.50 (d, 3H, J=7.2 Hz), 2.14-2.29 (m, 2H),
2.45 (dd, 1H, J=19.5, 12.2 Hz), 2.99-3.06 (m, 1H),
3.12-3.19 (m, 1H), 3.57-3.68 (m, 1H), 4.81 (br. d,
1H, J=9.1 Hz), 5.45 (q, 1H, J=7.1 Hz), 7.19-7.35
15 (m, 5H).

Anal. Calcd. for $\text{C}_{19}\text{H}_{28}\text{N}_2\text{O}_3$:

C, 68.65; H, 8.49; N, 8.43.

Found: C, 68.66; H, 8.64; N, 8.38.

EXAMPLE Q-3

20 (3S,1'S)-3-(1'-N-tert-butoxycarbonylaminoethyl)-1-(S- α -methyl-benzyl)pyrrolidin-5-one, 50

From 10.02 g (43 mmol) of amine 10, 11.35 g
(52 mmol) of di-tert-butylcarbonate, and 5.26 g
(52 mmol) of triethylamine, there was obtained 50
25 (13.00 g, 91%) as a white solid; mp 148-149°C (from
dichloromethane-hexane).

$[\alpha]_D = -110^\circ$ (c=1.03, chloroform).

$^1\text{H-NMR}$ (CDCl_3) δ 1.08 (d, 3H, J=6.7 Hz), 1.43
(s, 9H), 1.50 (d, 3H, J=7.1 Hz), 2.20-2.56 (m, 3H),
30 2.97-3.13 (m, 2H), 3.70-3.83 (m, 1H), 4.76 (br. d,
1H, J=9.1 Hz), 5.48 (q, 1H, J=7.1 Hz), 7.23-7.36
(m, 5H).

-94-

Anal. Calcd. for $C_{19}H_{28}N_2O_3$:

C, 68.64; H, 8.49; N, 8.43.

Found: C, 68.50; H, 8.61; N, 8.57.

General Procedure for the Preparation of the

5 3-(1'-N-methylaminoethyl)-1-(S- α -methylbenzyl)-
pyrrolidines, 52-55

A solution of 3-(1'-N-tert-butoxycarbonylamino
ethyl)-1-(S- α -methylbenzyl)pyrrolidin-5-one (48-51) in
dry THF (25 mL) was added dropwise to a stirred
10 suspension of lithium aluminum hydride (2 equivalents)
in dry THF (10 mL). The suspension was heated at reflux
for six hours, allowed to cool to room temperature, and
quenched by the dropwise addition of saturated aqueous
ammonium sulfate solution (2 mL) and water (2 mL). The
15 resulting slurry was stirred at room temperature for a
few minutes and then filtered through a pad of Celite.
The solids were rinsed with dichloromethane, and the
combined filtrate and washings were dried and
concentrated to afford the corresponding 3-(1'-N-
20 methylaminoethyl)-1-(S- α -methylbenzyl)pyrrolidine.

EXAMPLE R

(3R,1'R)-3-(1'-N-methylaminoethyl)-1-(S- α -methylbenzyl)
pyrrolidine, 53

From 11.80 g (36 mmol) of 49 and 2.69 g (71 mmol)
25 of $LiAlH_4$, the above procedure provided 53 (7.85 g, 94%)
as a yellow oil.

$[\alpha]_D = -75^\circ$ (c=1.90, chloroform).

^1H -NMR ($CDCl_3$) δ 0.94 (d, 3H, J=6.3 Hz),

1.12-1.40 (m, 1H), 1.36 (d, 3H, J=6.4 Hz), 1.50-
30 1.63 (m, 1H), 1.88-2.07 (m, 1H), 2.09-2.20 (m, 2H),
2.25-2.45 (m, 2H), 2.39 (s, 3H), 2.49-2.62 (m, 1H),
2.72-2.81 (m, 1H), 3.15 (q, 1H, J=6.5 Hz), 7.21-
7.33 (m, 5H).

-95-

Anal. Calcd. for $C_{15}H_{24}N_2 \cdot 0.25H_2O$:

C, 76.06; H, 10.43; N, 11.83.

Found: C, 76.20; H, 10.16; N, 11.57.

EXAMPLE R-1

5 (3R,1'S)-3-(1'-N-methylaminoethyl)-1-(S- α -methylbenzyl)pyrrolidine, 52

From 5.30 g (16 mmol) of 48 and 1.21 g (32 mmol) of $LiAlH_4$ the above procedure provided 52 (3.54 g, 95%) as a clear liquid.

10 ^1H -NMR ($CDCl_3$) δ 1.01 (d, 3H, $J=6.2$ Hz), 1.36 (d, 3H, $J=6.5$ Hz), 1.40-1.55 (m, 1H), 1.83-2.02 (m, 1H), 2.04-2.20 (m, 2H), 2.27-2.44 (m, 2H), 2.35 (s, 3H), 2.63-2.69 (m, 1H), 2.74-2.85 (m, 1H), 3.16 (q, 1H, $J=6.6$ Hz), 7.20-7.34 (m, 5H).

15 Anal. Calcd. for $C_{15}H_{24}N_2 \cdot 0.04 CH_2Cl_2$:

C, 76.62; H, 10.29; N, 11.88

Found: C, 76.55; H, 10.69; N, 11.57.

EXAMPLE R-2

20 (3S,1'R)-3-(1'-N-methylaminoethyl)-1-(S- α -methylbenzyl)pyrrolidine, 55

From 14.95 g (45 mmol) of 51 and 3.42 g (90 mmol) of $LiAlH_4$, the above procedure provided 55 (9.12 g, 87%) as a light yellow oil.

$[\alpha]_D = -49^\circ$ ($c=0.89$, chloroform).

25 ^1H -NMR ($CDCl_3$) δ 1.02 (d, 3H, $J=6.2$ Hz), 1.38 (d, 3H, $J=6.6$ Hz), 1.43-1.54 (m, 1H), 1.78-1.92 (m, 1H), 2.09-2.29 (m, 2H), 2.35-2.40 (m, 1H), 2.38 (s, 3H), 2.46 (t, 2H, $J=6.9$ Hz), 2.83-2.93 (m, 1H), 3.19 (q, 1H, $J=6.6$ Hz), 7.20-7.34 (m, 5H).

30 Anal. Calcd. for $C_{15}H_{24}N_2 \cdot 0.25 H_2O$:

C, 76.06; H, 10.43; N, 11.83

Found: C, 76.10; H, 10.54; N, 12.04.

-96-

EXAMPLE R-3

(3S,1'S)-3-(1'-N-methylaminoethyl)-1-(S- α -methylbenzyl)pyrrolidine, 54

5 From 12.74 g (38 mmol) of 50 and 2.66 g (70 mmol) of LiAlH_4 , the above procedure provided 54 (7.30 g, 82%) as a faint yellow oil.

$[\alpha]_D = -38^\circ$ (c=1.00, chloroform).

$^1\text{H-NMR}$ (CDCl_3) δ 0.98 (d, 3H, $J=6.2$ Hz), 1.37 (d, 3H, $J=6.6$ Hz), 1.47-1.70 (m, 2H), 1.81-1.95 (m, 1H), 2.08-2.23 (m, 2H), 2.30-2.58 (m, 3H), 2.39 (s, 3H), 2.65-2.78 (m, 1H), 3.16 (q, 1H, $J=6.6$ Hz), 7.21-7.37 (m, 5H).

Anal. Calcd. for $\text{C}_{15}\text{H}_{24}\text{N}_2 \cdot 0.50 \text{ H}_2\text{O}$:

C, 74.64; H, 10.44; N, 11.61

15 Found: C, 74.82; H, 10.29; N, 11.48.

General Procedure for the Preparation of the 3-(1'-N-tert-butoxycarbonyl-N-methylaminoethyl)-1-(S- α -methylbenzyl)pyrrolidines, 56-59

20 A solution of di-tert-butylcarbonate (1.1-1.3 eq) in dichloromethane (5 mL) was added portionwise to a chilled solution of 3-(1'-N-methylaminoethyl)-1-(S- α -methylbenzyl)pyrrolidines (52-55) and triethylamine (1.1-1.3 eq) in dichloromethane (15 mL). The resulting solution was stirred at room temperature overnight, and 25 then concentrated to afford the product as a viscous yellow oil. The crude product was purified by column chromatography (silica gel, hexanes/2-propanol 4:1).

EXAMPLE S

30 (3R,1'R)-3-(1'-N-tert-butoxycarbonyl-N-methylaminoethyl)-1-(S- α -methylbenzyl)pyrrolidine, 57

From 3.33 g (14 mmol) of amine 53, 3.71 g (17 mmol) of di-tert-butylcarbonate, and 1.72 g (17 mmol) of triethylamine, the above procedure provided 57 (4.17 g,

-97-

88%) as a yellow oil which solidified upon cooling to 0°C.

$[\alpha]_D = -25^\circ$ (c=0.25, chloroform).

$^1\text{H-NMR}$ (CDCl_3) δ 0.92 and 0.95 (2xd

5 superimposed, 3H), 1.36 d, 3H, $J=6.5$ Hz), 1.40-1.60 (m, 1H), 1.46 (s, 9H), 1.75-1.93 (m, 2H), 2.08-2.35 (m, 2H), 2.55-2.71 (m, 4H), 2.90-3.09 (m, 1H), 3.11-3.24 (m, 1H), 3.75-3.90 and 3.98-4.12 (m, 1H), 7.18-7.37 (m, 5H).

10 Anal. Calcd. for $\text{C}_{20}\text{H}_{32}\text{N}_2\text{O}_2 \cdot 0.03 \text{CH}_2\text{Cl}_2 \cdot 0.72 \text{C}_4\text{H}_8\text{O}_2$:
C, 69.06; H, 9.57; N, 7.03
Found: C, 69.04; H, 9.59; N, 7.05.

EXAMPLE S-1

15 (3R,1'S)-3-(1'-N-tert-butoxycarbonyl-N-methylaminoethyl)-1-(S- α -methylbenzyl)pyrrolidine, 56

From 3.45 g (15 mmol) of amine 52, 3.93 g (18 mmol) of di-tert-butylcarbonate, and 1.82 g (18 mmol) of triethylamine, the above procedure provided 56 (3.92 g, 80%) as an oil.

20 $[\alpha]_D = -71^\circ$ (c=0.65, chloroform).

$^1\text{H-NMR}$ (CDCl_3) δ 1.05 (d, 3H, $J=6.7$ Hz),

1.30-1.45 (m, 12H), 1.85-2.09 (m, 2H), 2.10-2.28 (m, 1H), 2.30-2.50 (m, 2H), 2.54 and 2.64 (2xs, 3H), 2.65-2.85 and 2.89-3.06 (2xm, 1H), 3.16 (q, 1H, $J=6.6$ Hz), 3.75-3.91 and 3.98-4.13 (2xm, 1H), 7.15-7.35 (m, 5H).

Anal. Calcd. for $\text{C}_{20}\text{H}_{32}\text{N}_2\text{O}_2 \cdot 0.1 \text{H}_2\text{O}$:

C, 71.86; H, 9.71; N, 8.38

Found: C, 72.23; H, 10.11; N, 8.21.

-98-

EXAMPLE S-2

(3S,1'R)-3-(1'-N-tert-butoxycarbonyl-N-methylaminoethyl)-1-(S- α -methylbenzyl)pyrrolidine, 59

From 9.00 g (38.7 mmol) of amine 55, 10.15 g (46.5 mmol) of di-tert-butylcarbonate, and 4.71 g (46.5 mmol) of triethylamine, the above procedure provided 59 (10.86 g, 84%) as an oil.

$[\alpha]_D = -28^\circ$ (c=0.99, chloroform).

$^1\text{H-NMR}$ (d_6 -DMSO, 75°C) δ 1.03 (d, 3H, J=6.7 Hz), 1.28 (d, 3H, J=6.7 Hz), 1.33-1.42 (m, 10H), 1.78-1.88 (m, 1H), 2.14-2.28 (m, 2H), 2.40 (dd, 1H, J=16.2, 7.3 Hz), 2.50 (t, 1H, J=7.8 Hz), 2.54-2.64 (m, 4H), 3.24 (q, 1H, J=6.6 Hz), 3.75-3.93 (m, 1H), 7.20-7.31 (m, 5H).

Anal. Calcd. for $\text{C}_{20}\text{H}_{32}\text{N}_2\text{O}_2 \cdot 0.1 \text{ H}_2\text{O}$:

C, 71.86; H, 9.71; N, 8.38

Found: C, 71.80; H, 9.89; N, 8.44

EXAMPLE S-3

(3S,1'S)-3-(1'-N-tert-butoxycarbonyl-N-methylaminoethyl)-1-(S- α -methylbenzyl)pyrrolidine, 58

From 7.13 g (31 mmol) of amine 54, 8.08 g (37 mmol) of di-tert-butylcarbonate, and 3.74 g (37 mmol) of triethylamine, the above procedure provided 58 (9.15 g, 90%) as an oil.

$[\alpha]_D = -26^\circ$ (c=1.00, chloroform).

$^1\text{H-NMR}$ (CDCl_3) δ 1.03 and 1.20 (2xd, 3H, J=6.7 and 6.1 Hz), 1.38 (d, 3H, J=6.4 Hz), 1.39-1.50 (m, 1H), 1.45 (s, 9H), 1.63-1.80 (m, 1H), 1.90-2.01 (m, 1H), 2.15-2.37 (m, 2H), 2.42-2.55 (m, 1H), 2.65 and 2.70 (2xs, 3H), 2.84-2.99 (m, 1H), 3.10-3.21 (m, 1H), 3.72-4.11 (m, 1H), 7.16-7.34 (m, 5H).

-99-

Anal. Calcd. for $C_{20}H_{32}N_2O_2 \cdot 0.30 H_2O$:

C, 71.09; H, 9.72; N, 8.29

Found: C, 71.11; H, 9.88; N, 8.45.

General Procedure for the Preparation of the

5 3-(1'-N-tert-butoxycarbonyl-N-methylaminoethyl)-
pyrrolidines, 60-63

A suspension of compound 56-59 (3 mmol) and 20%
palladium-on-charcoal catalyst (0.1 g) in methanol
(10 mL) was placed in a Parr shaker and hydrogenated
10 (50 psi) until no more uptake of hydrogen was observed
and thin-layer-chromatography (dichloromethane-methanol
10:1) indicated complete conversion. The suspension was
filtered through a pad of Celite and the filtrate
concentrated to give the product.

15

EXAMPLE T

(3R, 1'S)-3-(1'-N-tert-butoxycarbonyl-N-methylamino-
ethyl)pyrrolidine, 60

From 3.35 g (10 mmol) of 56, there was obtained 60
(2.20 g, 96%) as a pale yellow oil.

20 $[\alpha]_D = -2^\circ$ ($c=1.38$, chloroform).

^1H -NMR (250 MHz, $CDCl_3$): 1.13 (d, 3H, $J=6.7$ Hz),
1.30-1.48 (m, 1H), 1.46 (s, 9H), 1.83-1.98 (m, 1H),
2.06-2.27 (m, 1H), 2.55-2.80 (m, 4H), 2.83-3.25
(m, 4H), 3.73-3.92 and 3.97-4.12 (2Xm, 1H).

25 Anal. Calcd. for $C_{12}H_{24}N_2O_2 \cdot 0.45 H_2O$:

C, 60.96; H, 10.61; N, 11.85

Found: C, 61.27; H, 10.58; N, 11.43.

-100-

EXAMPLE T-1

(3R,1'R)-3-(1'-N-tert-butoxycarbonyl-N-methylamino-ethyl)pyrrolidine, 61

From 3.19 g (9.6 mmol) of 57, there was obtained 61
5 (2.16 g, 99%) as a faint yellow oil which solidified
upon cooling to 0°C.

$[\alpha]_D = +15^\circ$ (c=0.38, chloroform).

$^1\text{H-NMR}$ (CDCl_3) δ 1.09 (d, 3H, J=6.7 Hz),

1.40-1.48 (m, 1H), 1.46 (s, 9H), 1.70-1.84 (m, 1H),
10 2.12-2.27 (m, 1H), 2.47-2.62 (m, 1H), 2.70 and 2.73
(2Xs, 3H), 2.90-3.03 (m, 2H), 3.10 (dd, 1H, J=10.8,
7.7 Hz), 3.78-3.90 and 3.98-4.10 (2xm, 2H).

Anal. Calcd. for $\text{C}_{12}\text{H}_{24}\text{N}_2\text{O}_2$:

C, 63.12; H, 10.59; N, 12.27

15 Found: C, 63.06; H, 10.59; N, 12.26.

EXAMPLE T-2

(3S,1'R)-3-(1'-N-tert-butoxycarbonyl-N-methylamino-ethyl)pyrrolidine, 63

From 10.12 g (30 mmol) of 59, there was obtained 63
20 (4.47 g, 64%) as a clear, colorless liquid; bp 100-
105°C, 1 mm Hg.

$[\alpha]_D = -1^\circ$ (c=0.95, chloroform).

$^1\text{H-NMR}$ (CDCl_3) δ 1.12 (d, 3H, J=6.7 Hz),

1.28-1.52 (m, 10H), 1.80-1.98 (m, 1H), 2.05-2.23
25 (m, 1H), 2.51-2.79 (m, 4H), 2.80-3.08 (m, 3H),
3.73-3.87 and 3.96-4.08 (2xm, 1H).

Anal. Calcd. for $\text{C}_{12}\text{H}_{24}\text{N}_2\text{O}_2 \cdot 0.30 \text{ H}_2\text{O}$:

C, 61.66; H, 10.61; N, 11.98

Found: C, 61.62; H, 10.56; N, 12.10.

-101-

EXAMPLE T-3

(3S,1'S)-3-(1'-N-tert-butoxycarbonyl-N-methylaminoethyl)pyrrolidine, 62

From 8.16 g (25 mmol) of 58, there was obtained 62 (4.26 g, 76%) as a colorless oily liquid after vacuum distillation (bp 100-102°C, ca. 1 mm Hg). This product crystallized into a white, wax-like solid upon cooling to 0°C.

$[\alpha]_D = -12^\circ$ (c=0.49, chloroform).

$^1\text{H-NMR}$ (CDCl_3) δ 1.08 (d, 3H, $J=6.7$ Hz), 1.40-1.54 (m, 10H), 1.71-1.82 (m, 1H), 2.06-2.20 (m, 1H), 2.47-2.58 (m, 2H), 2.69 and 2.73 (2xs, 3H), 2.86-3.08 (m, 3H), 3.77-3.86 and 3.98-4.15 (2xm, 1H).

Anal. Calcd. for $\text{C}_{12}\text{H}_{24}\text{N}_2\text{O}_2 \cdot 0.17 \text{H}_2\text{O}$:

C, 62.29; H, 10.60; N, 12.11

Found: C, 62.30; H, 10.74; N, 11.93.

PREPARATION OF FINAL PRODUCTS

General Method for Coupling Pyrrolidines to the Appropriate Quinolone Nucleus and Removal of the BOC Group

To the substrate (1.40-3.30 mmol) in CH_3CN (10-30 mL) was added triethylamine (1.10-1.40 eq) and the diastereomerically pure pyrrolidine (1.10-1.20 eq). The reaction was stirred at room temperature (0-96 hours) then warmed to reflux (6.5-48 hours). The reaction was cooled to room temperature, stirred (0-18 hours) and filtered. The filter pad was washed with CH_3CN and/or ether, then air dried to give pure products as solids.

The amines were deprotected by one of three methods.

Method A: The protected quinolone (2.00-3.00 mmol) was dissolved in TFA (15.0 mL). After stirring one hour

-102-

at 25°C, the reaction was concentrated in vacuo. The residue was dissolved in a minimum amount of H₂O. Fifty percent NaOH was added to make the pH of the solution equal to 12. The homogenous solution was filtered and the filtrate was acidified with 3 N HCl until the pH of the solution was equal to 8.3. The filtrate was filtered and the pad washed with a small amount of H₂O and/or 0.50 N HCl. After drying, the solid was dissolved in concentrated HCl (14.0-40.0 mL). The acidic solution was centrifuged (little or no solid present) and the supernatant was concentrated to dryness.

Method B: The protected quinolone (1.80-3.50 mmol) was suspended in absolute EtOH (10.0-20.0 mL) and 1 N HCl (5.00-10.0 mL). The reaction was warmed to reflux and became homogeneous after a short period of time. After refluxing 2-5 hours, the reaction was allowed to cool to room temperature. After 3-18 hours, any solid formed was obtained by filtration. The pad was washed sequentially with H₂O and/or EtOH or IPA then ether. After drying, pure product was obtained. Additional pure material could be obtained from the filtrate. If, after stirring at room temperature, no solid had formed, the reaction was concentrated in vacuo. The residue was triturated with IPA and the solid which formed was filtered, washed with isopropanol and then ether to provide the desired product.

Method C: Hydrogen chloride gas was bubbled during 3-5 minutes through a solution of the N-Boc protected compound (2.5 mmol) in dichloromethane (40 mL). A small amount of methanol was added to the reaction mixture to dissolve the material that precipitated out, and the resulting solution was stirred at room temperature for 15-20 hours. The solvent was evaporated and the residue was dissolved in hot methanol and crystallized by the

-103-

addition of ether. The solid was filtered, washed with ether, and dried to provide the desired product.

EXAMPLE 1

5 3S,1R-1-cyclopropyl-6-fluoro-7-[3-(1-N-t-butyloxy-carbonylaminoethyl)-1-pyrrolidinyl]-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid

The desired product (1.40 g, 92%) was obtained starting from pyrrolidine 23 and quinolone B; mp 244.5-245°C; ¹H-NMR (DMSO-d₆) δ 1.03-1.35 (m, 7H), 1.40 (s, 9H), 1.58-1.87 (m, 1H), 1.96-2.18 (m, 1H), 2.20-2.45 (m, 1H), 3.37-3.83 (m, 6H), 6.96 (d, J=9.0 Hz, 1H), 7.02 (d, J=7.9 Hz, 1H), 7.79 (d, J=14 Hz, 1H), 8.57 (s, 1H); Anal. [C₂₄H₃₀FN₃O₅]: (Calcd., found):

15 C, (62.73, 62.52); H, (6.58, 6.49); N, (9.14, 9.11); F, (4.13, 4.08).

3S,1R-1-cyclopropyl-6-fluoro-7-[3-(1-aminoethyl)-1-pyrrolidinyl]-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid

20 The protecting group was removed using method A, to provide the desired product (0.94 g, 82.0%); mp >300°C; ¹H-NMR (NaOD + D₂O) δ 0.70-1.49 (m, 9H), 1.73-2.05 (m, 2H), 2.49-2.70 (m, 1H), 2.73-3.00 (m, 1H), 3.03-3.49 (m, 4H), 6.36 (d, J=7.3 Hz, 1H), 7.46 (d, J=15 Hz, 1H), 8.31 (s, 1H); Anal. [C₁₉H₂₂FN₃O₃, 1.43 HCl, 0.71 H₂O]: (Calcd., found):

25 C, (53.78, 53.78); H, (5.90, 5.83); N, (9.90, 9.81); F, (4.88, 4.66); Cl, (11.95, 11.96); [α]_D = +48° (c=0.97, 1N NaOH).

30

-104-

EXAMPLE 2

3S,1S-1-cyclopropyl-6-fluoro-7-[3-(1-N-t-butyloxy-carbonylaminoethyl)-1-pyrrolidinyl]-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid

5 The desired product (1.09 g, 85%) was obtained starting from pyrrolidine 22 and quinolone B; mp 217-219°C; $^1\text{H-NMR}$ (CDCl_3) δ 1.08-1.67 (m, 16H), 1.73-2.05 (m, 1H), 2.07-2.50 (m, 2H), 3.27-3.97 (m, 6H), 4.37-4.60 (m, 1H), 6.86 (d, $J=7.4$ Hz, 1H), 7.91 (d, $J=14$ Hz, 1H), 8.68 (s, 1H); Anal. [$\text{C}_{24}\text{H}_{30}\text{FN}_3\text{O}_5$, 0.28 H_2O]:

(Calcd., found):

C, (62.05, 62.06); H, (6.63, 6.51);

N, (9.04, 8.92); F, (4.09, 4.19).

15 3S,1S-1-cyclopropyl-6-fluoro-7-[3-(1-aminoethyl)-1-pyrrolidinyl]-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid

20 The protecting group was removed using method A to provide the desired product (0.71 g, 78.1%), mp $>300^\circ\text{C}$; $^1\text{H-NMR}$ ($\text{NaOD} + \text{D}_2\text{O}$) δ 0.62-1.51 (m, 9H), 1.59-1.88 (m, 1H), 1.90-2.18 (m, 1H), 2.32-2.78 (m, 2H), 2.88-3.46 (m, 4H), 6.27 (d, $J=7.3$ Hz, 1H), 7.37 (d, $J=6.7$ Hz, 1H), 8.28 (s, 1H); Anal. [$\text{C}_{19}\text{H}_{22}\text{FN}_3\text{O}_3$, 1.64 HCl , 1.12 H_2O]:

(Calcd., found):

25 C, (51.94, 51.94); H, (5.94, 5.75);

N, (9.56, 9.33); F, (4.32, 4.30);

Cl, (13.23, 13.25); $[\alpha]_D = -62.7^\circ$

($c=0.73$, 1N NaOH).

-105-

EXAMPLE 3

3R,1S-1-cyclopropyl-6-fluoro-7-[3-(1-N-t-butyloxy-carbonylaminoethyl)-1-pyrrolidinyl]-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid

5 The desired product (1.15 g, 84%) was obtained starting from pyrrolidine 20 and quinolone B; mp 240-241.5°C; ¹H-NMR (CDCl₃) δ 1.10-1.66 (m, 16H - contains 1.26 (d, J=6.5 Hz) and 1.47 (s)), 1.66-1.93 (m, 1H), 2.08-2.48 (m, 2H), 3.38-3.90 (m, 6H), 4.40-4.60 (m, 1H),
10 6.86 (d, J=7.3 Hz, 1H), 7.90 (d, J=14 Hz, 1H), 8.67 (s, 1H); Anal. [C₂₄H₃₀FN₃O₅, 0.09 H₂O]:
(Calcd., found):

C, (62.51, 62.18); H, (6.60, 6.18);

N, (9.11, 9.14); F, (4.12, 4.81).

15 3R,1S-1-cyclopropyl-6-fluoro-7-[3-(1-aminoethyl)-1-pyrrolidinyl]-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid

 The protecting group was removed using method B to provide the desired product (0.69 g 74.8%), mp >300°C;
20 ¹H-NMR (DMSO-d₆ + heat) δ 1.08-1.23 (m, 2H), 1.23-1.53 (m, 5H), 1.67-1.97 (m, 1H), 2.03-2.26 (m, 1H), 2.35-2.63 (m, 1H), 3.17-3.83 (m, 1H), 3.40-3.57 (m, 1H), 3.57-3.92 (m, 4H), 7.10 (d, J=7.4 Hz, 1H), 7.82 (d, J=15 Hz, 1H), 8.30 (br. s., 2H), 8.59 (s, 1H); Anal. [C₁₉H₂₂FN₃O₃ 1.00
25 HCl]:

(Calcd., found):

C, (57.65, 57.53); H, (5.60, 5.86);

N, (10.61, 10.51); F, (4.80, 5.00);

Cl, (8.96, 8.83); [α]_D = -58.8°

30 (c = 0.99, 1 N NaOH).

-106-

EXAMPLE 4

3R,1R-1-cyclopropyl-6-fluoro-7-[3-(1-N-t-butyloxy-carbonylaminoethyl)-1-pyrrolidinyl]-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid

5 The desired product (0.97 g, 73%) was obtained starting from pyrrolidine 21 and quinolone B; mp 209.5-211.5°C dec.; ¹H-NMR (CDCl₃) δ 1.10 (m, 16H - contains 1.24 (d, J=6.7 Hz) and 1.46 (s)), 1.72-2.05 (m, 1H), 2.08-2.48 (m, 2H), 3.30-3.97 (m, 6H), 4.40-4.60 (m, 1H), 10 6.86 (d, J=7.5 Hz, 1H), 7.90 (d, J=14 Hz, 1H), 8.67 (s, 1H); Anal. [C₂₄H₃₀FN₃O₅, 1.79 H₂O]: (Calcd., found):

C, (58.62, 59.01); H, (6.88, 6.87);
N, (8.54, 8.48); F, (3.86, 4.15).

15 3R,1R-1-cyclopropyl-6-fluoro-7-[3-(1-aminoethyl)-1-pyrrolidinyl]-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid

20 The protecting group was removed using method B to provide the desired product (0.80 g, 89.6%), mp >300°C; ¹H-NMR (DMSO + heat) δ 1.07-1.50 (m, 7H), 1.72-2.00 (m, 1H), 2.12-2.37 (m, 1H), 2.37-2.65 (m, 1H), 3.18-3.51 (m, 2H), 3.53-3.87 (m, 4H), 7.09 (d, J=7.9 Hz, 1H), 7.82 (d, J=14 Hz, 1H), 8.18 (br. s., 1H), 8.59 (s, 1H); Anal. [C₁₉H₂₂FN₃O₃, 1.00 HCl, 2.56 H₂O]:
25 (Calcd., found):

C, (51.63, 51.26); H, (6.41, 6.56);
N, (9.51, 9.44); Cl, (8.02, 8.19);
F, (4.30, 4.80); [α]_D = -60.3°
(c=0.95 1N NaOH).

-107-

EXAMPLE 5

3S,1R-1-cyclopropyl-6-fluoro-7-[3-(1-N-t-butyloxy-carbonylaminoethyl)-1-pyrrolidinyl]-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid

5 The desired product (0.63 g, 88%) was obtained starting from pyrrolidine 23 and quinolone A, mp 220-220.5°C; ¹H-NMR (DMSO-d₆ + heat) δ 0.97-1.27 (m, 7H), 1.39 (s, 9H), 1.53-1.83 (m, 1H), 1.95-2.17 (m, 1H), 2.17-2.43 (m, 1H), 3.40-3.83 (m, 4H), 3.83-4.13 (m, 2H),
10 6.98 (d, J=9.0 Hz, 1H), 7.95 (d, J=13 Hz, 1H), 8.56 (s, 1H), 15.45 (s); Anal. [C₂₃H₂₉FN₄O₅]:
(Calcd., found):

C, (59.99, 59.75); H, (6.35, 6.37);
N, (12.17, 12.21); F, (4.12, 4.29).

15 3S,1R-1-cyclopropyl-6-fluoro-7-[3-(1-aminoethyl)-1-pyrrolidinyl]-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid

 The protecting group was removed using method B to provide the desired product (1.02 g, 74.1%), mp >300°C;
20 ¹H-NMR (DMSO-d₆ + heat) δ 0.93-1.17 (m, 2H), 1.17-1.47 (m, 5H), 1.63-1.95 (m, 1H), 2.00-2.37 (m, 1H), 2.33-2.63 (m, 1H), 3.20-3.47 (m, 1H), 3.50-3.87 (m, 3H), 3.90-4.25 (m, 2H), 8.00 (d, J=13 Hz, 1H), 8.30 (br. s., 1H), 8.58 (s, 1H); Anal. [C₁₈H₂₁FN₄O₃, 1.00 HCl]:
25 (Calcd., found):

C, (54.48, 54.47); H, (5.59, 5.44);
N, (14.18, 13.88); Cl, (8.93, 8.72);
F, (4.79, 5.09); [α]_D = +3.6°
(c=1.00 1N NaOH).

-108-

EXAMPLE 6

3S,1S-1-cyclopropyl-6-fluoro-7-[3-(1-N-t-butyloxy-carbonylaminoethyl)-1-pyrrolidinyl]-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid

5 The desired product (0.78 g, 53%) was obtained starting from pyrrolidine 22 and quinolone A; mp 208-208.5°C dec; $^1\text{H-NMR}$ (DMSO- d_6 + heat) δ 1.00-1.32 (m, 7H), 1.37 (s, 9H), 1.63-1.91 (m, 1H), 1.93-2.15 (m, 1H), 2.18-2.43 (m, 1H), 3.38-3.80 (m, 4H), 3.80-4.12 (m, 2H), 6.95 (d, J=8.9 Hz, 1H), 7.93 (d, J=13 Hz, 1H), 8.55 (s, 1H), 15.4 (s); Anal. [$\text{C}_{23}\text{H}_{29}\text{FN}_4\text{O}_5$, 1.09 H_2O , 0.06 CH_3CN]:

(Calcd., found):

15 C, (57.54, 57.57); H, (6.56, 6.52); N, (11.78, 11.68); F, (3.94, 4.26).

3S,1S-1-cyclopropyl-6-fluoro-7-[3-(1-aminoethyl)-1-pyrrolidinyl]-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid

20 The protecting group was removed using method B to provide the desired product (0.65 g, 69.1%), mp $>300^\circ\text{C}$; $^1\text{H-NMR}$ (DMSO- d_6 + heat) δ 1.00-1.50 (m, 7H), 1.65-2.00 (m, 1H), 2.10-2.35 (m, 1H), 2.37-2.67 (m, 1H), 3.17-3.87 (m, 4H), 3.90-4.20 (m, 2H), 8.00 (d, J=13 Hz, 1H), 8.23 (br. s.), 8.58 (s, 1H); Anal. [$\text{C}_{18}\text{H}_{21}\text{FN}_4\text{O}_3$, 1.00 HCl]:

25 (Calcd., found):

 C, (54.48, 54.42); H, (5.59, 5.41); N, (14.18, 13.86); Cl, (8.93, 9.10); F, (4.79, 4.88); $[\alpha]_D = +13.1^\circ$ (c=1.00, 1N NaOH).

-109-

EXAMPLE 7

3R,1S-1-cyclopropyl-6-fluoro-7-[3-(1-N-t-butyloxy-carbonylaminoethyl)-1-pyrrolidinyl]-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid

- 5 The desired product (0.76 g, 92%) was obtained starting from pyrrolidine 20 and quinolone A; mp 216.5-217.0°C; $^1\text{H-NMR}$ (DMSO-d_6) δ 1.00-1.27 (m, 7H), 1.39 (s, 9H), 1.56-1.83 (m, 1H), 1.95-2.17 (m, 1H), 2.18-2.43 (m, 1H), 3.40-3.83 (m, 4H), 3.83-4.10 (m, 2H), 6.98 (d, J=8.6 Hz, 1H), 7.94 (d, J=13 Hz, 1H), 8.56 (s, 1H), 15.4 (s); Anal. [$\text{C}_{23}\text{H}_{29}\text{N}_4\text{O}_5$]: (Calcd., found):
- C, (59.99, 59.75); H, (6.30, 6.20);
- N, (12.17, 12.03); F, (4.12, 3.85).

- 15 3R,1S-1-cyclopropyl-6-fluoro-7-[3-(1-aminoethyl)-1-pyrrolidinyl]-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid

- The protecting group was removed using method B to provide the desired product (0.64 g, 88.7%), mp >300°C; $^1\text{H-NMR}$ (DMSO-d_6 + heat) δ 0.97-1.18 (m, 2H), 1.18-1.50 (m, 5H), 1.65-1.95 (m, 1H), 2.02-2.27 (m, 1H), 2.33-2.63 (m, 1H), 3.20-3.40 (m, 1H), 3.47-3.87 (m, 3H), 3.88-4.25 (m, 2H), 8.00 (d, J=13 Hz, 1H), 8.26 (br. s.), 8.58 (s, 1H); Anal. [$\text{C}_{18}\text{H}_{21}\text{FN}_4\text{O}_3$, 1.00 HCl, 0.22 H_2O]:
- 20 (Calcd., found):
- C, (53.94, 53.95); H, (5.64, 5.51);
- N, (13.98, 13.95); Cl, (8.44, 8.66);
- F, (4.73, 4.62); $[\alpha]_D = -4.8^\circ$
- 25 (c = 1.03, 1 N NaOH).

-110-

EXAMPLE 8

3R,1R-1-cyclopropyl-6-fluoro-7-[3-(1-N-t-butyloxy-carboxylaminoethyl)-1-pyrrolidinyl]-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid

5 The desired product (0.56 g, 81%) was obtained starting from pyrrolidine 21 and quinolone A; mp 210.0-210.5°C; ¹H-NMR (DMSO) δ 1.00-1.28 (m, 7H), 1.38 (s, 9H), 1.63-1.90 (m, 1H), 1.93-2.15 (m, 1H), 2.17-2.45 (m, 1H), 3.33-3.83 (m, 4H), 3.83-4.10 (m, 2H), 6.95 (d, J=8.6 Hz, 1H), 7.95 (d, J=13 Hz, 1H), 8.56 (s, 1H), 15.4 (s); Anal. [C₂₃H₂₉FN₄O₅, 0.78 H₂O, 0.10 CH₃N]: (Calcd., found):

C, (58.22, 58.12); H, (6.50, 6.39);

N, (12.00, 11.68); F, (3.97, 4.21).

15 3R,1R-1-cyclopropyl-6-fluoro-7-[3-(1-aminoethyl)-1-pyrrolidinyl]-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid

20 The protecting group was removed using method B to provide the desired compound (0.67 g, 77.1%), mp >300°C; ¹H-NMR (DMSO-d₆ + heat) δ 1.00-1.47 (m, 7H), 1.68-2.00 (m, 1H), 2.11-2.35 (m, 1H), 2.35-2.67 (m, 1H), 3.17-3.87 (m, 4H), 3.90-4.17 (m, 2H), 8.00 (d, J=13 Hz, 1H), 8.30 (br. s.), 8.58 (s, 1H); Anal. [C₁₈H₂₁FN₄O₃, 1.00 HCl]: (Calcd., found):

25 C, (54.48, 54.31); H, (5.59, 5.68);

N, (14.18, 14.08); Cl, (8.93, 8.58);

F, (4.79, 4.44); [α]_D = -13.9°

(c=1.09%, 1N NaOH); HPLC = 99.7%.

EXAMPLE 9

30 3R,1R-1-cyclopropyl-6-fluoro-7-[3-(1-N-ethylaminoethyl)-1-pyrrolidinyl]-8-trifluoromethyl-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid

-111-

The quinolone (D, 0.90 g, 2.7 mmol), pyrrolidine (45) (0.43 g, 3.0 mmol), and triethylamine (0.42 mL) were dissolved in acetonitrile (25 mL) and heated to reflux for 20 hours. The reaction was cooled to 5°C and the solid collected by filtration. This solid was washed with cold acetonitrile and dried under vacuum at 50°C for 60 hours. This yielded 0.83 g of the title compound.

Calcd. for $C_{22}H_{25}F_4N_3O_3 \cdot 0.5 H_2O$:

10 C, 56.89; H, 5.64; N, 9.05

Found: C, 56.98; H, 5.69; N, 9.12.

^1H -NMR (CD_3OD) δ 8.63 (s, 1H), 7.76 (d, 1H, $J=14.5$ Hz), 4.00-3.55 (broad m, 6H), 3.20-2.90 (m, 2H), 2.65-2.50 (m, 1H), 2.25-2.10 (m, 1H), 1.90-1.80 (m, 1H), 1.40-1.10 (m, 8H), 1.00-1.85 (m, 1H), 0.80-0.70 (m, 1H).

EXAMPLE 10

3R,1S-1-cyclopropyl-6-fluoro-7-[3-(1-N-ethylaminoethyl)-1-pyrrolidinyl]-8-trifluoromethyl-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid

The quinolone (D, 0.90 g, 2.7 mmol), pyrrolidine (44) (0.43 g, 3.0 mmol), and triethylamine (0.42 mL) were dissolved in acetonitrile (25 mL) and heated to reflux for 20 hours. The reaction was cooled to 5°C and the solid collected by filtration. This solid was washed with cold acetonitrile and dried under vacuum at 50°C for 60 hours. This yielded 0.27 g of the title compound. The reaction filtrate was evaporated to a solid and triturated with water. The solid collected was dried at 50°C for 24 hours to give an additional 0.62 g of the title compound.

Calcd. for $C_{22}H_{25}F_4N_3O_3 \cdot 1.14 H_2O$

C, 55.51; H, 5.78; N, 8.83

Found: C, 55.13; H, 5.37; N, 8.47.

-112-

¹H-NMR (CD₃OD) δ 8.58 (s, 1H), 7.74 (d, 1H, J=14.7 Hz),
3.95-3.45 (m, 5H), 3.30-3.15 (m, 2H), 3.10-2.95
(m, 1H), 2.50-2.30 (m, 1H), 2.20-2.05 (m, 1H),
1.80-1.60 (m, 1H), 1.45-1.30 (m, 6H), 1.25-1.05
(m, 2H), 0.95-0.80 (m, 1H), 0.75-0.60 (m, 1H).

EXAMPLE 11

3S,1R-1-cyclopropyl-6-fluoro-7-[3-(1-N-ethylaminoethyl)-
1-pyrrolidinyl]-8-trifluoromethyl-1,4-dihydro-4-oxo-3-
quinolinecarboxylic acid

The quinolone (D, 0.90 g, 2.7 mmol), pyrrolidine
(47) (0.43 g, 3.0 mmol), and triethylamine (0.42 mL)
were dissolved in acetonitrile (25 mL) and heated to
reflux for 20 hours. The reaction was cooled to 5°C and
the solid collected by filtration. This solid was
washed with cold acetonitrile and dried under vacuum at
50°C for 60 hours. This yielded 0.33 g of the title
compound. The reaction filtrate was evaporated to a
solid and triturated with water. The solid collected was
dried at 50°C for 24 hours to give an additional 0.73 g
of the title compound.

Calcd. for C₂₂H₂₅F₄N₃O₃, 0.95 H₂O:

C, 55.92; H, 5.74; N, 8.89

Found: C, 55.91; H, 5.70; N, 9.06.

¹H-NMR (CD₃OD) δ 8.55 (s, 1H), 7.73 (d, 1H, J=14 Hz),
3.95-3.45 (m, 5H), 3.30-3.10 (m, 2H), 3.05-2.90
(m, 1H), 2.50-2.30 (m, 1H), 2.20-2.05 (m, 1H),
1.80-1.60 (m, 1H), 1.50-1.30 (broad featureless
peak, 6H), 1.30-1.05 (m, 2H), 0.95-0.80 (m, 1H),
0.75-0.60 (m, 1H).

-113-

EXAMPLE 12

3S,1S-1-cyclopropyl-6-fluoro-7-[3-(1-N-ethylaminoethyl)-1-pyrrolidinyl]-8-trifluoromethyl-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid

5 The quinolone (D, 0.90 g, 2.7 mmol), pyrrolidine (46) (0.43 g, 3.0 mmol), and triethylamine (0.42 mL) were dissolved in acetonitrile (25 mL) and heated to reflux for 20 hours. The reaction was cooled to 5°C and the solid collected by filtration. This solid was
10 washed with cold acetonitrile and dried under vacuum at 50°C for 60 hours. This yielded 0.92 g of the title compound.

Calcd. for $C_{22}H_{25}F_4N_3O_3$, 1.34 H_2O :

C, 55.10; H, 5.82; N, 8.76

15 Found: C, 54.84; H, 5.55; N, 9.16.

^1H -NMR (CD_3OD) δ 8.67 (s, 1H), 7.79 (d, 1H, 14.5 Hz),
4.00-3.55 (m, 6H), 3.20-3.10 (m, 1H), 3.10-2.90
(m, 1H), 2.65-2.50 (m, 1H), 2.30-2.15 (m, 1H),
1.90-1.70 (m, 1H), 1.40-1.10 (m, 8H), 1.00-0.90
20 (m, 1H), 0.85-0.70 (m, 1H).

EXAMPLE 13

3R,1R-1-cyclopropyl-6-fluoro-7-[3-(1-N-ethylaminoethyl)-1-pyrrolidinyl]-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid

25 The quinolone (B, 0.50 g, 1.9 mmol), pyrrolidine (45) (0.30 g, 2.1 mmol), and triethylamine (0.30 mL) were dissolved in acetonitrile (7 mL) and heated to reflux for 20 hours. The reaction became very viscous upon heating and an additional 5 mL of acetonitrile was
30 added. The reaction was cooled to 5°C and the solid collected by filtration. This solid was washed with cold acetonitrile and dried under vacuum at 50°C for 18 hours. This yielded 0.70 g of the title compound.
Calcd. for $C_{21}H_{26}FN_3O_3$, 0.33 HF:

-114-

C, 64.01; H, 6.73; N, 10.66; F, 6.41

Found: C, 63.73; H, 6.70; N, 10.55; F, 6.17.

¹H-NMR (TFA) δ 9.18 (s, 1H), 8.13 (d, 1H, J=13.5 Hz),
7.33 (d, 1H, J=6.7 Hz), 7.20-6.90 (broad m, 1H),
4.30-4.15 (m, 1H), 4.10-3.30 (m, 7H), 3.00-2.80
(m, 1H), 2.70-2.55 (m, 1H), 2.20-2.05 (m, 1H),
1.75-1.60 (m, 5H), 1.53 (t, 3H, J=7.1 Hz), 1.50-
1.30 (m, 2H).

EXAMPLE 14

10 3R,1S-1-cyclopropyl-6-fluoro-7-[3-(1-N-ethylaminoethyl)-
1-pyrrolidinyl]-1,4-dihydro-4-oxo-3-quinolinecarboxylic
acid

15 The quinolone (B, 0.50 g, 1.9 mmol), pyrrolidine
(44) (0.30 g, 2.1 mmol), and triethylamine (0.30 mL)
were dissolved in acetonitrile (7 mL) and heated to
reflux for 20 hours. The reaction became very viscous
upon heating and an additional 5 mL of acetonitrile was
added. The reaction was cooled to 5°C and the solid
collected by filtration. This solid was washed with
20 cold acetonitrile and dried under vacuum at 50°C for
18 hours. This yielded 0.63 g of the title compound.
Calcd. for C₂₁H₂₆FN₃O₃, 0.6 HF:

C, 63.14; H, 6.71; N, 10.52; F, 7.61

Found: C, 62.80; H, 6.66; N, 10.73; F, 7.63.

25 ¹H-NMR (CD₃OD) δ 8.45 (s, 1H), 7.51 (d, 1H, J=14.4 Hz),
3.85-3.75 (m, 1H), 3.70-3.40 (m, 4H), 3.25-2.85
(m, 3H), 3.55-3.45 (m, 1H), 2.25-2.10 (m, 1H),
1.95-1.80 (m, 1H), 1.40-1.25 (m, 8H), 1.20-1.10
(m, 2H).

-115-

EXAMPLE 15

3S,1R-1-cyclopropyl-6-fluoro-7-[3-(1-N-ethylaminoethyl)-1-pyrrolidinyl]-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid

5 The quinolone (B, 0.50 g, 1.9 mmol), pyrrolidine (47) (0.30 g, 2.1 mmol), and triethylamine (0.30 mL) were dissolved in acetonitrile (7 mL) and heated to reflux for 20 hours. The reaction became very viscous upon heating and an additional 5 mL of acetonitrile was
10 added. The reaction was cooled to 5°C and the solid collected by filtration. This solid was washed with cold acetonitrile and dried under vacuum at 50°C for 18 hours. This yielded 0.63 g of the title compound. Calcd. for C₂₁H₂₆FN₃O₃, 0.75 HF:

15 C, 62.67; H, 6.70; N, 10.44; F, 8.26
Found: C, 62.74; H, 6.72; N, 10.71; F, 8.20.
¹H-NMR (TFA) δ 9.18 (s, 1H), 8.13 (d, 1H, J=13.5 Hz),
7.34 (d, 1H, 7.1 Hz), 7.10-6.90 (broad m, 1H),
4.45-4.30 (m, 1H), 4.05-3.60 (m, 5H), 3.60-3.50
20 (m, 1H), 3.50-3.30 (m, 1H), 3.00-2.75 (m, 1H),
2.55-2.40 (m, 1H), 2.20-1.95 (m, 1H), 1.70-1.55
(m, 5H), 1.51 (t, 3H, J=7.2 Hz), 1.45-1.30 (m, 2H).

EXAMPLE 16

25 3S,1S-1-cyclopropyl-6-fluoro-7-[3-(1-N-ethylaminoethyl)-1-pyrrolidinyl]-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid

30 The quinolone (B, 0.50 g, 1.9 mmol), pyrrolidine (46) (0.30 g, 2.1 mmol), and triethylamine (0.30 mL) were dissolved in acetonitrile (7 mL) and heated to reflux for 20 hours. The reaction became very viscous upon heating and an additional 5 mL of acetonitrile was added. The reaction was cooled to 5°C and the solid collected by filtration. This solid was washed with

-116-

cold acetonitrile and dried under vacuum at 50°C for 18 hours. This yielded 0.69 g of the title compound.

Calcd. for $C_{21}H_{26}FN_3O_3$, 0.6 HF:

C, 63.14; H, 6.71; N, 10.52; F, 7.61

5 Found: C, 63.07; H, 6.73; N, 10.72; F, 7.85.

EXAMPLE 17

3R,1R-1-cyclopropyl-6-fluoro-7-[3-(1-N-ethylaminoethyl)-
1-pyrrolidinyl]-8-methoxy-1,4-dihydro-4-oxo-3-
quinolinecarboxylic acid

10 The 1-cyclopropyl-6,8-difluoro-8-methoxy-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid (E) borondifluoride complex (1.20 g, 3.5 mmol), and pyrrolidine (45) (1.00 g, 7.0 mmol) were dissolved in
15 acetonitrile (20 mL) and stirred for four hours, then allowed to stand for 96 hours. The reaction mixture was evaporated to an oil and dissolved in 95% ethanol (25 mL) containing 5 mL of triethylamine and heated to reflux for four hours then allowed to stand for
20 24 hours. The mixture was diluted with 300 mL of ethanol and evaporated and redissolved in water (50 mL) and reevaporated to an oil. This oil was purified by flash chromatography using silica gel eluting with methylene chloride (1900 mL), 2.6% NH_3 in methanol (95 mL), water (5 mL). The appropriate fractions were
25 combined and evaporated to give the title compound (0.96 g).

Calcd. for $C_{22}H_{28}FN_3O_4$. 0.84 CH_2Cl_2

C, 56.12; H, 6.12; N, 8.60;

Found: C, 56.80; H, 6.29; N, 8.86.

30 ^1H -NMR (CD_3OD) δ 8.67 (s, 1H), 7.59 (d, 1H, $J=14$ Hz), 4.10-3.95 (m, 1H), 3.90-3.75 (m, 1H), 3.70-3.55 (m, 2H), 3.42 (s, 3H), 3.42-3.25 (m, 2H, underlies singlet and CD_3OD peak), 3.20-3.05 (m, 1H), 3.15-2.95 (m, 1H), 2.65-2.45 (m, 1H), 2.25-2.10 (m, 1H),

-117-

1.90-1.70 (m, 1H), 1.40-1.30 (m, 6H), 1.30-0.95
(m, 3H), 0.90-0.70 (m, 1H).

EXAMPLE 18

5 3R,1S-1-cyclopropyl-6-fluoro-7-[3-(1-N-ethylaminoethyl)-
1-pyrrolidinyl]-8-methoxy-1,4-dihydro-4-oxo-3-quinoline-
carboxylic acid

Using pyrrolidine 44, the procedure described above
was employed to prepare 0.78 g of the title compound.

Calcd. for $C_{22}H_{28}FN_3O_4$. 1.22 CH_2Cl_2 :

10 C, 53.52; H, 5.89; N, 8.06;

Found: C, 53.50; H, 6.04; N, 8.27.

^1H -NMR (CD_3OD) δ 8.70 (s, 1H), 7.55 (d, 1H, $J=13.9$ Hz),
4.15-4.05 (m, 1H), 3.90-3.70 (m, 2H), 3.80-3.55
(m, 1H), 3.55-3.40 (m and s, 4H, singlet at 3.50),
15 3.40-3.35 (m, 1H, overlapped with CD_3OD peak),
3.35-3.20 (m, 1H), 3.20-3.05 (m, 1H), 2.55-2.40
(m, 1H), 2.25-2.10 (m, 1H), 1.90-1.70 (m, 1H),
1.45-1.30 (m, 6H), 1.30-1.20 (m, 1H), 1.20-1.00
(m, 2H), 0.95-0.80 (m, 1H).

20

EXAMPLE 19

3S,1R-1-cyclopropyl-6-fluoro-7-[3-(1-N-ethylaminoethyl)-
1-pyrrolidinyl]-8-methoxy-1,4-dihydro-4-oxo-3-
quinolinecarboxylic acid

25 Using pyrrolidine 47, the procedure described above
was employed to prepare 1.14 g of the title compound.

Calcd. for $C_{22}H_{28}FN_3O_4$. 0.21 CH_2Cl_2 :

C, 6.28; H, 6.58; N, 9.58.

Found: C, 61.24; H, 6.70; N, 9.71.

^1H -NMR (CD_3OD) δ 8.57 (s, 1H), 7.59 (d, 1H, $J=13.9$ Hz),
30 4.04-3.90 (m, 1H), 3.85-3.65 (m, 2H), 3.60-3.45
(m, 1H), 3.25 (s, 3H), 3.20-3.05 (m, 3H), 3.05-2.95
(m, 1H), 2.40-2.10 (m, 2H), 1.80-1.60 (m, 1H),

-118-

1.45-1.30 (m, 6H), 1.25-1.10 (m, 2H), 1.10-0.95
(m, 1H), 0.80-0.65 (m, 1H).

EXAMPLE 20

5 3S,1S-1-cyclopropyl-6-fluoro-7-[3-(1-N-ethylaminoethyl)-
1-pyrrolidinyl]-8-methoxy-1,4-dihydro-4-oxo-3-quinoline-
carboxylic acid

Using pyrrolidine 46, the procedure described above
was employed to prepare 0.93 g of the title compound.

Calcd. for $C_{22}H_{28}FN_3O_4$. 0.18 CH_2Cl_2 :

10 C, 61.56; H, 6.61; N, 9.71.

Found: C, 61.55; H, 6.69; N, 9.79.

MS (EI) 417 (M+), 372, 357, 313, 287, 72 (base).

^1H -NMR (CD_3OD) δ 8.60 (s, 1H), 7.58 (d, 1H, $J=13.7$ Hz),
4.10-3.95 (m, 1H), 3.85-3.70 (m, 1H), 3.70-3.50
15 (m, 2H), 3.31 (s, 3H), 3.30-3.20 (m, 2H), 3.20-3.10
(m, 1H), 3.05-2.90 (m, 1H), 2.65-2.45 (m, 1H),
2.20-2.05 (m, 1H), 1.85-1.65 (m, 1H), 1.36 (t, 3H,
 $J=7.1$ Hz), 1.30 (t, 3H, $J=6.7$ Hz), 1.25-1.05
(m, 2H), 1.05-0.95 (m, 1H), 0.85-0.70 (m, 1H).

20

EXAMPLE 21

3R,1S-1-cyclopropyl-6-fluoro-7-[3-(1-N-tert-
butoxycarbonyl-N-methylaminoethyl)-1-pyrrolidinyl]-1,4-
dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid

25 From 0.85 g (3 mmol) of 7-chloro-1,8-
naphthyridine A, 0.70 g (3.1 mmol) of pyrrolidine 60,
and 0.46 g (4.5 mmol) of triethylamine, there was
obtained 0.84 g (59%) of the title compound after column
chromatography (silica gel, dichloromethane/methanol
20:1); mp 233-234°C.

30 $[\alpha]_D = -48^\circ$ (c=0.56, chloroform).

^1H -NMR (250 MHz, $CDCl_3$) δ 0.99-1.10 (m, 2H), 1.18-1.26
(m, 5H), 1.43 and 1.46 (2xs, 9H), 1.68-1.87
(m, 1H), 2.07-2.23 (m, 1H), 2.38-2.60 (m, 1H), 2.78

-119-

(br. s, 3H), 3.40-3.68 (m, 2H), 3.72-4.34 (m, 4H),
7.89 (d, 1H, J=12.5 Hz), 8.61 (s, 1H), 15.12-15.25
(m, 1H).

Anal. Calcd. for $C_{24}H_{31}FN_4O_5$:

5 C, 60.75; H, 6.58; N, 11.81.

Found: C, 60.67; H, 6.87; N, 11.50.

3R,1S-1-cyclopropyl-6-fluoro-7-[3-(1-N-methylamino-ethyl)-1-pyrrolidinyl]-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid

10 From 0.75 g (1.6 mmol) of the above protected derivative, the title compound (0.44 g) was obtained using Method C as an off-white solid; mp >280°C.

^1H -NMR (TFA) δ 1.20-1.35 (m, 2H),

1.47-1.60 (m, 2H), 1.65 (dist. d, 3H, J=5.8 Hz),
15 1.90-2.20 (m, 1H), 2.35-2.55 (m, 1H), 2.85-3.10
(m, 1H), 3.04 (s, 3H), 3.60-3.79 (m, 1H), 3.82-4.20
(m, 3H), 4.26-4.48 (m, 1H), 4.51-4.78 (m, 1H),
7.20-7.55 (m, 1H), 8.11 (d, 1H, J=11.6 Hz), 9.16
(s, 1H).

20 Anal. Calcd. for $C_{19}H_{23}FN_4O_3 \cdot 1.0 HCl \cdot 0.2 H_2O$:

C, 55.06; H, 5.93; N, 13.52; Cl, 8.55

Found: C, 54.74; H, 5.79; N, 12.89; Cl, 9.24.

EXAMPLE 22

25 3R,1R-1-cyclopropyl-6-fluoro-7-[3-(1-N-tert-butoxycarbonyl-N-methylaminoethyl)-1-pyrrolidinyl]-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid

From 0.73 g (2.6 mmol) of 7-chloro-1,8-naphthyridine A, 0.60 g (2.6 mmol) of pyrrolidine 61, and 0.38 g (3.8 mmol) of triethylamine, there was
30 obtained 1.03 g (84%) of the title compound after column chromatography (silica gel, dichloro-methane/methanol 10:1); mp 212-213°C.
[α]_D = -13° (c 1.00, EtOH).

-120-

¹H-NMR (CDCl₃) δ 0.90-1.10 (m, 2H), 1.12-1.30 (m, 5H), 1.49 (s, 9H), 1.70-1.92 (m, 1H), 1.94-2.15 (m, 1H), 2.30-2.55 (m, 1H), 2.78 and 2.81 (2xs, 3H), 3.35-3.55 (m, 1H), 3.55-3.67 (m, 1H), 3.67-3.88 (m, 1H), 3.88-4.15 and 4.17-4.30 (m, 3H), 7.90 (d, 1H, J=12.6 Hz), 8.62 (s, 1H), 14.55-14.62 (m, 1H).

Anal. Calcd. for C₂₄H₃₁FN₄O₅·0.40 H₂O:

C, 59.84; H, 6.65; N, 11.63

Found: C, 59.96; H, 6.48; N, 11.54.

3R,1R-1-cyclopropyl-6-fluoro-7-[3-(1-N-methylamino-ethyl)-1-pyrrolidinyl]-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid

Using Method B on the above protected derivative (1.00 g, 2.1 mmol), there was obtained the title compound (0.85 g) as an off-white solid; mp >280°C.

¹H-NMR (TFA) δ 1.20-1.40 (m, 2H), 1.45-1.75 (m, 5H), 1.97-2.30 (m, 1H), 2.50-2.70 (m, 1H), 2.80-3.18 (m, 1H), 3.05 (s, 3H), 3.53-4.23 (m, 4H), 4.30-4.60 (m, 2H), 7.20-7.50 (m, 1H), 8.12 (d, 1H, J=11.6 Hz), 9.18 (s, 1H).

Anal. Calcd. for C₁₉H₂₃FN₄O₃ · 1.0 HCl · 0.75 H₂O:

C, 53.77; H, 6.06; N, 13.20; Cl, 8.35;

F, 4.48

Found: C, 53.70; H, 5.82; N, 13.09; Cl, 8.68;

F, 4.48.

EXAMPLE 23

3S,1R-1-cyclopropyl-6-fluoro-7-[3-(1-N-tert-butoxycarbonyl-N-methylaminoethyl)-1-pyrrolidinyl]-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid

From 0.76 g (2.7 mmol) of 7-chloro-1,8-naphthyridine A, 0.75 g (3.3 mmol) of pyrrolidine 63, and 0.41 g (4.1 mmol) of triethylamine, there was

-121-

obtained 0.77 g (60%) of the title compound.

Concentration of the filtrate and washings provided additional product (0.40 g, 31%); mp 232-233°C.

$[\alpha]_D = 43^\circ$ (c=0.50, chloroform).

5 $^1\text{H-NMR}$ (CDCl_3) δ 0.99-1.08 (m, 2H), 1.19-1.27
(m, 5H), 1.42 and 1.46 (2xs, 9H), 1.65-1.80
(m, 1H), 2.07-2.20 (m, 1H), 2.36-2.50 (m, 1H), 2.77
and 2.80 (2xs, 3H), 3.75-4.13 (m, 4H), 7.92 (d, 1H,
10 $J=12.4$ Hz), 8.64 (s, 1H), 15.20 and 15.24 (2xs,
1H).

Anal. Calcd. for $\text{C}_{24}\text{H}_{31}\text{FN}_4\text{O}_5 \cdot 2/3 \text{H}_2\text{O}$:

C, 59.26; H, 6.70; N, 11.51

Found: C, 59.24; H, 6.41; N, 11.44.

15 3S,1R-1-cyclopropyl-6-fluoro-7-[3-(1-N-
methylaminoethyl)-1-pyrrolidinyl]-1,4-dihydro-4-oxo-1,8-
naphthyridine-3-carboxylic acid

Using Method C on 1.20 g (2.5 mmol) of the above
protected derivative, there was obtained the title
compound (1.07 g); mp >280°C.

20 $^1\text{H-NMR}$ (250 MHz, d_6 -DMSO + TFA): 0.97-1.30 (m, 7H),
1.70-1.86 (m, 1H), 2.05-2.19 (m, 1H), 2.40-2.70
(m, 1H), 2.67 and 2.76 (2xs, 3H), 3.24-3.39
(m, 1H), 3.43-3.78 (m, 3H), 3.90-4.01 (1H), 4.04-
4.20 (m, 1H), 8.11 (d, 1H, $J=13.0$ Hz), 8.72
25 (s, 1H).

Anal. Calcd. for $\text{C}_{19}\text{H}_{23}\text{FN}_4\text{O}_3 \cdot 1.0 \text{HCl} \cdot 0.6 \text{H}_2\text{O}$:

C, 54.12; H, 6.02; N, 13.29; F, 4.51

Found: C, 53.94; H, 6.39; N, 12.90; F, 4.19.

-122-

EXAMPLE 24

3S,1S-1-cyclopropyl-6-fluoro-7-[3-(1-N-tert-butoxycarbonyl-N-methylaminoethyl)-1-pyrrolidinyl]-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid

5 From 0.71 g (2.5 mmol) of 7-chloro-1,8-naphthyridine A, 0.70 g (3.1 mmol) of pyrrolidine 62, and 0.40 g (4.0 mmol) of triethylamine, there was obtained 0.98 g (83%) of the title compound; mp 218.0-219.5°C.

10 $[\alpha]_D = 28^\circ$ (c=1.04, chloroform).

$^1\text{H-NMR}$ (CDCl_3) δ 1.02-1.07 (m, 2H), 1.18-1.26 (m, 5H), 1.48 (s, 9H), 1.75-1.93 (m, 1H), 1.97-2.15 (m, 1H), 2.36-2.56 (m, 1H), 2.77 and 2.81 (2Xs, 3H), 3.41-3.56 (m, 1H), 3.58-3.67 (m, 1H), 3.70-15 3.84 (m, 1H), 3.93-4.34 (m, 3H), 7.95 (d, 1H, J=12.5 Hz), 8.66 (s, 1H), 15.15-15.23 (m, 1H).

Anal. Calcd. for $\text{C}_{24}\text{H}_{31}\text{FN}_4\text{O}_5 \cdot 0.2 \text{ H}_2\text{O}$:

C, 60.29; H, 6.62; N, 11.72

Found: C, 59.91; H, 6.74; N, 11.67.

20 3S,1S-1-cyclopropyl-6-fluoro-7-[3-(1-N-methylaminoethyl)-1-pyrrolidinyl]-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid

Using Method B on 1.20 g (2.5 mmol) of the above protected derivative there was obtained the title 25 compound (0.75 g). Concentration of the mother liquor provided additional product (0.28 g); mp >280°C.

$[\alpha]_D = 20^\circ$ (c=1.08, 1 N NaOH).

$^1\text{H-NMR}$ (CDCl_3) δ 1.01-1.10 (m, 2H), 1.15-1.25 (m, 2H), 1.29 (d, 3H, J=6.4 Hz), 1.78-30 1.99 (m, 1H), 2.22-2.37 (m, 1H), 2.50-2.70 (m, 1H), 2.58 (s, 3H), 3.30-3.60 (m, 2H), 3.62-3.80 (m, 2H), 3.92-4.10 (m, 2H), 7.92 (d, 1H, J=12.7 Hz), 8.53 (s, 1H), 8.98-9.16 (m, 1H), 9.17-9.30 (m, 1H), 15.37 (br. s, 1H).

-123-

Anal. Calcd. for $C_{19}H_{23}FN_4O_3 \cdot 1.0 \text{ HCl} \cdot 0.5 \text{ H}_2\text{O}$:

C, 54.35; H, 6.00; N, 13.34; Cl, 8.44

Found: C, 54.47; H, 5.97; N, 13.28, Cl, 8.48.

EXAMPLE 25

5 3R,1S-1-cyclopropyl-6-fluoro-7-[3-(1-N-tert-butoxycarbonyl-N-methylaminoethyl)-1-pyrrolidinyl]-8-chloro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid

From 0.90 g (3.0 mmol) of quinolone C, 0.70 g (3.1 mmol) of pyrrolidine 60, and 0.61 g (6.0 mmol) of triethylamine, there was obtained 1.22 g (80%) of the title compound after recrystallization from dichloromethane/heptane.

$[\alpha]_D = -180^\circ$ (c=1.05, chloroform).

10 $^1\text{H-NMR}$ (CDCl_3) δ 0.84-0.95 (m, 1H), 0.96-1.09 (m, 1H), 1.23 (dist. d, 3H, $J=5.0$ Hz), 1.30-1.58 (m, 2H), 1.45 (s, 9H), 1.62-1.81 (m, 1H), 2.06-2.21 (m, 1H), 2.37-2.57 (m, 1H), 2.76 and 2.78 (2xs, 3H), 3.35-3.85 (m, 3H), 3.93-4.17 (m, 2H), 4.22-4.39 (m, 1H), 7.81 and 7.83 (2xd, 1H, $J=13.4$ Hz), 8.83 (s, 1H), 14.67 and 14.71 (2xbr. s, 1H).

Anal. Calcd. for $C_{25}H_{31}ClFN_3O_5$:

C, 59.11; H, 6.15; N, 8.27; Cl, 6.98

Found: C, 59.03; H, 6.21; N, 8.22; Cl, 7.17.

25 3R,1S-1-cyclopropyl-6-fluoro-7-[3-(1-N-methylaminoethyl)-1-pyrrolidinyl]-8-chloro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid

Using 1.15 g (2.3 mmol) of the above quinolone, hydrolysis of the tert-butoxycarbonyl group according to general Method C provided the title compound (0.10 g) as the hydrochloride salt.

-124-

¹H-NMR (TFA) δ 1.30-1.47 (m, 2H), 1.56-1.84 (m, 5H), 2.01-2.22 (m, 1H), 2.40-2.59 (m, 1H), 2.83-3.15 (m, 4H), 3.57-3.77 (m, 1H), 3.80-4.10 (m, 4H), 4.23-4.50 (m, 1H), 7.20-7.60 (br m, 1H), 8.16 (br d, 1H, J=13 Hz), 9.18 (s, 1H), 11.62 (m, 1H).

EXAMPLE 26

3R,1R-1-cyclopropyl-6-fluoro-7-[3-(1-N-tert-butoxycarbonyl-N-methylaminoethyl)-1-pyrrolidinyl]-8-chloro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid

From 0.99 g (3.3 mmol) of quinolone C, 0.75 g (3.3 mmol) of pyrrolidine 61, and 0.51 g (5.0 mmol) of triethylamine, there was obtained 1.66 g (99%) of the title compound after column chromatography (silica gel, dichloromethane/methanol 10:1).

[α]_D = -146° (c=0.50, EtOH).

¹H-NMR (CDCl₃) δ 0.80-1.08 (m, 2H), 1.10-1.35 (m, 2H), 1.16 (d, 3H, J=6.7 Hz), 1.48 (s, 9H), 1.67-1.85 (m, 1H), 1.90-2.15 (m, 1H), 2.30-2.50 (m, 1H), 2.70-2.83 (m, 3H), 3.42-3.60 (m, 3H), 3.75-4.16 (m, 2H), 4.18-4.37 (m, 1H), 7.91 (d, 1H, J=13.3 Hz), 8.86 (s, 1H), 14.60-14.80 (m, 1H).

Anal. Calcd. for C₂₅H₃₁ClFN₃O₅ · 0.20 H₂O:

C, 58.69; H, 6.19; N, 8.21

Found: C, 58.66; H, 5.98; N, 8.03.

3R,1R-1-cyclopropyl-6-fluoro-7-[3-(1-N-methylaminoethyl)-1-pyrrolidinyl]-8-chloro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid

Using Method B on 1.58 g (3.1 mmol) of the above protected quinolone, the title compound was obtained (0.79 g) as a solid; mp >280°C.

[α]_D = -109° (c=0.93, methanol).

¹H-NMR (CD₃OD) δ 0.89-1.10 (m, 2H), 1.16-1.45 (m, 2H),

-125-

1.40 (d, 3H, J=6.6 Hz), 1.83-2.00 (m, 1H), 2.26-
2.40 (m, 1H), 2.55-2.70 (m, 1H), 2.77 (s, 3H),
3.28-3.44 (m, 2H), 3.60-3.69 (m, 3H), 3.91-4.02
(m, 1H), 4.39-4.48 (m, 1H), 7.84 (d, 1H, J=13.3
5 Hz), 8.91 (s, 1H).

Anal. Calcd. for $C_{20}H_{23}ClFN_3O_3 \cdot 1.0 HCl \cdot 1.0 H_2O$:

C, 51.96; H, 5.67; N, 9.09; Cl, 15.34

Found: C, 52.05; H, 5.73; N, 9.22; Cl, 15.42.

EXAMPLE 27

10 3R,1S-1-cyclopropyl-6-fluoro-7-[3-(1-N-tert-butoxy-
carbonyl-N-methylaminoethyl)-1-pyrrolidinyl]-8-
trifluoromethyl-1,4-dihydro-4-oxo-3-quinolinecarboxylic
acid

15 From 1.00 g (3.0 mmol) of quinolone D, 0.71 g
(3.1 mmol) of pyrrolidine 60, and 0.61 g (6.0 mmol) of
triethylamine, there was obtained 1.31 g (81%) of the
title compound after recrystallization from
dichloromethane/heptane; mp 175-177°C.

$[\alpha]_D = -332^\circ$ (c=0.13, chloroform).

20 ^1H -NMR ($CDCl_3$) δ 0.70-0.83 (m, 1H), 0.85-1.02 (m, 1H),
1.17-1.38 (m, 2H), 1.22 (d, 3H, J=6.7 Hz), 1.46
(s, 9H), 1.65-1.80 (m, 1H), 2.05-2.19 (m, 1H),
2.37-2.50 (m, 1H), 2.75 and 2.76 (2xs, 3H), 3.50-
4.32 (m, 6H), 7.90 and 7.93 (2xd, 1H, J=14.6 Hz),
25 8.77 (s, 1H), 14.76-14.82 (m, 1H).

Anal. Calcd. for $C_{26}H_{31}F_4N_3O_5 \cdot 0.50 H_2O$:

C, 56.72; H, 5.86; N, 7.63

Found: C, 56.63; H, 5.64; N, 7.56.

-126-

3R,1S-1-cyclopropyl-6-fluoro-7-[3-(1-N-methylamino-ethyl)-1-pyrrolidinyl]-8-trifluoromethyl-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid

Using Method B on 1.10 g (2.0 mmol) of the above protected quinolone, there was obtained the title compound (0.94 g); mp 210-212°C.

$[\alpha]_D = -234^\circ$ (c=1.03, methanol).

$^1\text{H-NMR}$ (CD_3OD) δ 0.88-1.10 (m, 2H), 1.22-1.37 (m, 2H), 1.43 (d, 3H, J=6.3 Hz), 1.81-2.00 (m, 1H), 2.18-2.31 (m, 1H), 2.60-2.90 (m, 1H), 2.77 (s, 3H), 3.35-3.50 (m, 1H), 3.63-4.20 (m, 5H), 7.71 (d, 1H, J=14.3 Hz), 8.85 (s, 1H).

Anal. Calcd. for $\text{C}_{21}\text{H}_{23}\text{F}_4\text{N}_3\text{O}_3 \cdot 1.0 \text{ HCl} \cdot 1.5 \text{ H}_2\text{O}$:

C, 49.96; H, 5.39; N, 8.32; Cl, 7.02;

F, 15.05

Found: C, 49.84; H, 5.12; N, 8.56; Cl, 7.81;

F, 14.67.

EXAMPLE 28

3R,1R-1-cyclopropyl-6-fluoro-7-[3-(1-N-tert-butoxycarbonyl-N-methylaminoethyl)-1-pyrrolidinyl]-8-trifluoromethyl-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid

From 1.03 g (3.1 mmol) of quinolone D, 0.74 g (3.2 mmol) of pyrrolidine 61, and 0.61 g (6.0 mmol) of triethylamine, there was obtained 1.15 g (69%) of the title compound after successive column chromatography (silica gel, dichloromethane/methanol 40:1) and recrystallization from dichloro-methane/heptane.

$[\alpha]_D = -238^\circ$ (c=0.10, chloroform).

$^1\text{H-NMR}$ (CDCl_3) δ 0.75-1.10 (m, 2H), 1.12-1.40 (m, 2H), 1.19 (d, 3H, J=6.5 Hz), 1.49 (s, 9H), 1.70-1.94 (m, 1H), 1.97-2.10 (m, 1H), 2.36-2.50 (m, 1H), 2.77 and 2.80 (2Xs, 3H), 3.55-4.30 (m, 6H), 7.89 (d, 1H, J=14.3 Hz), 8.78 (s, 1H), 14.73-14.78 (m, 1H).

-127-

Anal. Calcd. for $C_{26}H_{31}F_4N_3O_5 \cdot 0.30 H_2O$:

C, 57.10; H, 5.82; N, 7.68; F, 13.89

Found: C, 57.14; H, 5.61; N, 7.42; F, 13.71.

5 3R,1R-1-cyclopropyl-6-fluoro-7-[3-(1-N-methylamino-ethyl)-1-pyrrolidinyl]-8-trifluoromethyl-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid

Using Method B on 1.05 g (1.93 mmol) of the above protected quinolone, there was obtained the title compound (0.93 g) as a light yellow solid; mp 261-262°C. $[\alpha]_D = -259^\circ$ (c=0.72, methanol).

10 ^1H -NMR (CD_3OD) δ 0.80-0.95 (m, 1H), 0.96-1.09 (m, 1H), 1.20-1.45 (m, 2H), 1.39 (d, 3H, J=6.6 Hz), 1.80-2.00 (m, 1H), 2.26-2.40 (m, 1H), 2.56-2.70 (m, 1H), 2.77 (s, 3H), 3.33-3.46 (m, 1H), 3.70-3.93 (m, 3H), 15 3.97-4.14 (m, 2H), 7.84 (d, 1H, J=14.4 Hz), 8.86 (s, 1H).

Anal. Calcd. for $C_{21}H_{23}F_4N_3O_3 \cdot 1.0 HCl \cdot 1.1 H_2O$:

C, 50.68; H, 5.31; N, 8.44; Cl, 7.12;

F, 15.27

20 Found: C, 50.35; H, 5.25; N, 8.52; Cl, 7.53; F, 15.43.

EXAMPLE 29

25 3S,1R-1-cyclopropyl-6-fluoro-7-[3-(1-N-tert-butoxycarbonyl-N-methylaminoethyl)-1-pyrrolidinyl]-8-trifluoromethyl-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid

From 0.90 g (2.7 mmol) of quinolone D, 0.75 g (3.3 mmol) of pyrrolidine 63, and 0.41 g (4.1 mmol) of triethylamine, there was obtained 0.88 g (60%) of the title compound. Concentration of the filtrate and washings provided additional product (0.42 g, 29%); mp 188-189°C.

30 $[\alpha]_D = +224^\circ$ (c=0.43, chloroform).

-128-

¹H-NMR (CDCl₃) δ 0.70-0.82 (m, 1H), 0.83-1.01 (m, 1H),
1.18-1.35 (m, 2H), 1.22 (d, 3H, J=6.7 Hz), 1.46
(s, 9H), 1.64-1.84 (m, 1H), 2.07-2.19 (m, 1H),
2.36-2.52 (m, 1H), 2.74 (s, 3H), 3.50-4.32 (m, 6H),
5 7.91 and 7.93 (2xd, 1H, J=14.2 and 14.7 Hz), 8.76
(s, 1H), 14.70-14.82 (m, 1H).

Anal. Calcd. for C₂₆H₃₁F₄N₃O₅ · 0.30 H₂O:

C, 57.10; H, 5.82; N, 7.68; F, 13.89

Found: C, 57.38; H, 5.67; N, 7.70; F, 13.54.

10 3S,1R-1-cyclopropyl-6-fluoro-7-[3-(1-N-methylamino-ethyl)-1-pyrrolidinyl]-8-trifluoromethyl-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid

Using Method B on 1.20 g (2.2 mmol) of the above
protected quinolone, there was obtained the title
15 compound (0.86 g); mp 218-219°C.

¹H-NMR (d₆-DMSO) δ 0.80-0.91 (m, 1H), 0.92-1.07 (m, 1H),
1.09-1.32 (m, 2H), 1.28 (d, 3H, J=6.3 Hz), 1.65-
1.73 (m, 1H), 2.02-2.21 (m, 1H), 2.42-2.69 (m, 1H),
2.51 and 2.57 (2xs, 3H), 3.20-3.40 (m, 1H), 3.62-
20 4.04 (m, 5H), 7.88 (d, 1H, J=14.4 Hz), 8.77
(s, 1H), 8.80-9.10 (m, 2H), 14.90 (br. s, 1H).

Anal. Calcd. for C₂₁H₂₃F₄N₃O₄ · 1.0 HCl · 1.0 H₂O:

C, 50.86; H, 5.28; N, 8.47

Found: C, 50.51; H, 5.27; N, 8.52.

25

EXAMPLE 30

3S,1S-1-cyclopropyl-6-fluoro-7-[3-(1-N-tert-butoxy-carbonyl-N-methylaminoethyl)-1-pyrrolidinyl]-8-trifluoromethyl-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid

30

From 0.83 g (2.5 mmol) of quinolone D, 0.70 g
(3.1 mmol) of pyrrolidine 62, and 0.40 g (4.0 mmol) of
triethylamine, there was obtained 0.39 g (26%) of the
title compound. Concentration of the filtrate and

-129-

washings provided additional product (0.36 g, 27%);
mp 196-197°C.

$[\alpha]_D = 177^\circ$ ($c=0.44$ CHCl_3).

$^1\text{H-NMR}$ (CDCl_3) δ 0.70-0.85 (m, 1H), 0.86-1.02
5 (m, 1H), 1.18 (d, 3H, $J=6.7$ Hz), 1.23-1.37 (m, 2H),
1.48 (s, 9H), 1.70-1.91 (m, 1H), 1.93-2.10
(m, 1H), 2.32-2.51 (m, 1H), 2.76 and 2.79
(2xs, 3H), 3.51-4.34 (m, 6H), 7.94 (d, 1H,
 $J=14.6$ Hz), 8.79 (s, 1H), 14.70-14.80 (m, 1H).

10 Anal. Calcd. for $\text{C}_{26}\text{H}_{31}\text{F}_4\text{N}_3\text{O}_5$:

C, 57.67; H, 5.77; N, 7.76

Found: C, 57.78; H, 5.92; N, 7.81.

3S,1S-1-cyclopropyl-6-fluoro-7-[3-(1-N-methylamino-ethyl)-1-pyrrolidinyl]-8-trifluoromethyl-1,4-dihydro-4-
15 oxo-3-quinolinecarboxylic acid

Using Method B on 0.77 g (1.4 mmol) of the above
protected quinolone, there was obtained the title
compound (0.66 g); mp 252-253°C.

$^1\text{H-NMR}$ (d_6 -DMSO) δ 0.82-0.94 (m, 1H), 0.95-1.08 (m, 1H),
20 1.11-1.35 (m, 2H), 1.28 (d, 3H, $J=6.7$ Hz), 1.72-
2.00 (m, 1H), 2.23-2.40 (m, 1H), 2.52-2.70 (m, 1H),
2.62 (s, 3H), 3.25-3.42 (m, 1H), 3.63-4.10 (m, 5H),
7.86 (d, 1H, $J=14.4$ Hz), 8.78 (s, 1H), 14.02
(br. s, 1H).

25 Anal. Calcd. for $\text{C}_{21}\text{H}_{23}\text{F}_4\text{N}_3\text{O}_3 \cdot 1.0 \text{ HCl} \cdot 2 \text{ H}_2\text{O}$:

C, 49.08; H, 5.49; N, 8.18

Found: C, 48.75; H, 5.60; N, 8.55.

EXAMPLE 31

3R,1R-1-cyclopropyl-6-fluoro-7-[3-(1-N-tert-
30 butoxycarbonyl-N-methylaminoethyl)-1-pyrrolidinyl]-1,4-
dihydro-4-oxo-3-quinolinecarboxylic acid

From 0.64 g (2.4 mmol) of quinolone B, 0.71 g
(3.1 mmol) of pyrrolidine 61, and 0.35 g (3.5 mmol) of

-130-

triethylamine, there was obtained 0.99 g (87%) of the title compound; mp 233-234°C.

$[\alpha]_D = -65^\circ$ (c=0.20, chloroform).

$^1\text{H-NMR}$ (CDCl_3) δ 1.13-1.22 (m, 5H), 1.27-1.37 (m, 2H),
5 1.49 (s, 9H), 1.75-1.94 (m, 1H), 1.96-2.14 (m, 1H),
2.39-2.56 (m, 1H), 2.77 and 2.81 (2xs, 3H), 3.32-
3.43 (m, 1H), 3.45-3.82 (m, 4H), 3.97-4.30 (m, 1H),
6.81 (d, 1H, J=7.4 Hz), 7.79 (d, 1H, J=14.1 Hz),
8.57 (s, 1H), 15.28-15.39 (m, 1H).

10 Anal. Calcd. for $\text{C}_{25}\text{H}_{32}\text{FN}_3\text{O}_5$:

C, 63.41; H, 6.81; N, 8.87; F, 4.01.

Found: C, 63.30; H, 6.86; N, 9.03; F, 4.10.

15 3R,1R-1-cyclopropyl-6-fluoro-7-[3-(1-N-methylamino-ethyl)-1-pyrrolidinyl]-1,4-dihydro-4-oxo-3-quinoline-carboxylic acid

Using Method B on 1.15 g (2.4 mmol) of the above protected quinolone, there was obtained the title compound (0.35 g). Concentration of the mother liquor provided additional product (0.57 g); mp >280°C.

20 $[\alpha]_D = -64^\circ$ (c=1.04, 1N NaOH).

$^1\text{H-NMR}$ (TFA) δ 1.30-1.48 (m, 2H), 1.55-1.80
(m, 5H), 2.03-2.27 (m, 1H), 2.52-2.70 (m, 1H),
2.86-3.16 (m, 4H), 3.57-4.38 (m, 6H), 7.20-7.53
(m, 2H), 8.13 (d, 1H, J=13.4 Hz), 9.18 (s, 1H),
25 11.51-11.69 (m, 1H).

Anal. Calcd. for $\text{C}_{20}\text{H}_{24}\text{FN}_3\text{O}_3 \cdot 1.0 \text{ HCl} \cdot 0.5 \text{ H}_2\text{O}$:

C, 57.35; H, 6.26; N, 10.03

Found: C, 57.04; H, 6.02; N, 9.91.

-131-

EXAMPLE 32

3S,1R-1-cyclopropyl-6-fluoro-7-[3-(1-N-tert-butoxycarbonyl-N-methylaminoethyl)-1-pyrrolidinyl]-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid

5 From 0.75 g (2.8 mmol) of quinolone B, 0.75 g (3.3 mmol) of pyrrolidine 63, and 0.44 g (4.3 mmol) of triethylamine, there was obtained 1.01 g (76%) of the title compound; mp 225-226°C.

$[\alpha]_D = +93^\circ$ (c=0.36, chloroform).

10 $^1\text{H-NMR}$ (CDCl_3) δ 1.11-1.32 (m, 7H), 1.45 and 1.48 (2xs, 9H), 1.66-1.87 (m, 1H), 2.06-2.20 (m, 1H), 2.41-2.59 (m, 1H), 2.79 and 2.81 (2xs, 3H), 3.28-3.82 (m, 5H), 3.99-4.32 (m, 1H), 6.77 (d, 1H, J=7.0 Hz), 7.77 (d, 1H, J=14.1 Hz), 8.55 (s, 1H),
15 15.32-15.38 (m, 1H).

Anal. Calcd. for $\text{C}_{25}\text{H}_{32}\text{FN}_3\text{O}_5 \cdot 0.20 \text{ H}_2\text{O}$:

C, 62.93; H, 6.84; N, 8.81

Found: C, 62.99; H, 6.81; N, 8.59.

20 3S,1R-1-cyclopropyl-6-fluoro-7-[3-(1-N-methylaminoethyl)-1-pyrrolidinyl]-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid

Using Method C on 1.09 g (2.3 mmol) of the above protected quinolone afforded the title compound (0.83 g); mp >280°C.

25 $[\alpha]_D = 55^\circ$ (c=1.03, 1 N NaOH).

$^1\text{H-NMR}$ ($\text{d}_6\text{-DMSO} + \text{TFA}$) δ 1.42-1.51 (m, 2H), 1.53-1.79 (m, 5H), 2.05-2.25 (m, 1H), 2.41-2.54 (m, 1H), 2.80-3.00 (m, 1H), 2.95 (s, 3H), 3.60-3.74 (m, 1H), 3.76-4.29 (m, 5H), 7.38 (d, 1H, J=7.3 Hz),
30 8.11 (d, 1H, J=14.0 Hz), 8.90 (s, 1H).

Anal. Calcd. for $\text{C}_{20}\text{H}_{24}\text{FN}_3\text{O}_3 \cdot 1.0 \text{ HCl} \cdot 0.8 \text{ H}_2\text{O}$:

C, 56.62; H, 6.32; N, 9.90; Cl, 8.36

Found: C, 56.92; H, 6.22; N, 9.89; Cl, 8.39.

-132-

EXAMPLE 33

3S,1S-1-cyclopropyl-6-fluoro-7-[3-(1-N-tert-butoxycarbonyl-N-methylaminoethyl)-1-pyrrolidinyl]-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid

5 From 0.66 g (2.5 mmol) of quinolone B, 0.70 g (3.1 mmol) of pyrrolidine 62, and 0.40 g (4.0 mmol) of triethylamine, there was obtained 1.08 g (91%) of the title compound; mp 223.5-224.5°C.

$[\alpha]_D = 69^\circ$ (c=0.81, chloroform).

10 $^1\text{H-NMR}$ (CDCl_3) δ 1.12-1.24 (m, 5H), 1.29-1.37 (m, 2H), 1.49 (s, 9H), 1.78-1.93 (m, 1H), 1.97-2.15 (m, 1H), 2.39-2.56 (m, 1H), 2.77 and 2.81 (2Xs, 3H), 3.30-3.41 (m, 1H), 3.42-3.80 (m, 4H), 3.96-4.31 (m, 1H), 6.83 (d, 1H, J=7.4 Hz), 7.83 (d, 1H, J=14.1 Hz),
15 8.60 (s, 1H), 15.30-15.38 (m, 1H).

Anal. Calcd. for $\text{C}_{25}\text{H}_{32}\text{FN}_3\text{O}_5$:

C, 63.41; H, 6.81; N, 8.87

Found: C, 63.60; H, 7.12; N, 8.92.

3S,1S-1-cyclopropyl-6-fluoro-7-[3-(1-N-methylaminoethyl)-1-pyrrolidinyl]-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid

20 Using Method B on 1.10 g (2.3 mmol) of the above protected quinolone, there was obtained the title compound (0.61 g). Concentration of the mother liquor provided additional product (0.22 g); mp >280°C.

25 $[\alpha]_D = 72^\circ$ (c=0.52, 1 N NaOH).

30 $^1\text{H-NMR}$ (d_6 -DMSO + TFA) δ 1.12-1.20 (m, 2H), 1.22-1.38 (m, 2H), 1.30 (d, 3H, J=6.6 Hz), 1.79-1.96 (m, 1H), 2.20-2.37 (m, 1H), 2.50-2.68 (m, 1H), 2.64 (s, 3H), 3.27-3.52 (m, 2H), 3.58-3.85 (m, 4H), 7.11 (d, 1H, J=7.4 Hz), 7.84 (d, 1H, J=14.2 Hz), 8.61 (s, 1H), 15.50 (s, 1H).

-133-

Anal. Calcd. for $C_{20}H_{24}FN_3O_3 \cdot 1.0 HCl \cdot 0.4 H_2O$:

C, 57.59; H, 6.23; N, 10.07; Cl, 8.50

Found: C, 57.68; H, 6.10; N, 10.07; Cl, 8.54.

EXAMPLE 34

5 3S,1R-1-cyclopropyl-5-amino-6,8-difluoro-7-[3-(1-N-tert-butoxycarbonyl-N-methylaminoethyl)-1-pyrrolidinyl]-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid

10 From 0.81 g (2.7 mmol) of quinolone L, 0.75 g (3.3 mmol) of pyrrolidine 63, and 0.44 g (4.3 mmol) of triethylamine, there was obtained 0.62 g (45%) of the title compound. Concentration of the filtrate and washings provided additional product (0.50 g, 37%); mp 198-199°C.

[α]_D = +230° (c=0.45, chloroform).

15 ¹H-NMR (CDCl₃) δ 0.98-1.25 (m, 7H), 1.46 (s, 9H), 1.60-1.75 (m, 1H), 1.98-2.12 (m, 1H), 2.27-2.44 (m, 1H), 2.76 (d, 3H, J=7.1 Hz), 3.48-3.79 (m, 5H), 3.82-4.30 (m, 1H), 6.30-6.45 (m, 2H), 8.57 (s, 1H), 14.92 and 14.95 (2xs, 1H).

20 Anal. Calcd. for $C_{25}H_{32}F_2N_4O_5 \cdot 0.4 H_2O$:

C, 58.45; H, 6.44; N, 10.91

Found: C, 58.46; H, 6.17; N, 10.88.

25 3S,1R-5-amino-1-cyclopropyl-6,8-difluoro-7-[3-(1-N-methylaminoethyl)-1-pyrrolidinyl]-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid

30 Using 1.58 g (3.1 mmol) of the above quinolone, hydrolysis of the tert-butoxycarbonyl group with hydrogen chloride in methylene chloride, followed by 6N HCl, provided the title compound (0.14 g) as the hydrochloride salt.

-134-

¹H-NMR (TFA) δ 1.25-1.55 (m, 4H), 1.57-1.70 (m, 3H),
1.92-2.11 (m, 1H), 2.30-2.51 (m, 1H), 2.70-2.88 (m,
1H), 2.93-3.10 (m, 3H), 3.58-3.72 (m, 1H),
3.80-4.20 (m, 5H), 7.10-7.60 (m, 2H), 9.14 (s, 1H).

5

EXAMPLE 35

3S,1S-5-amino-1-cyclopropyl-6,8-difluoro-7-[3-(1-N-tert-
butoxycarbonyl-N-methylaminoethyl)-1-pyrrolidinyl]-1,4-
dihydro-4-oxo-3-quinolinecarboxylic acid

From 0.78 g (2.6 mmol) of quinolone L, 0.71 g
10 (3.1 mmol) of pyrrolidine 62, and 0.51 g (5.0 mmol) of
triethylamine, there was obtained 1.06 g (80%) of the
title compound. Concentration of the filtrate and
washings provided additional product (0.21 g, 16%);
mp 207.5-208.5°C.

15 $[\alpha]_D = 198^\circ$ (c=0.42, CHCl₃).

¹H-NMR (CDCl₃) δ 0.98-1.25 (m, 7H), 1.48 (s, 9H),
1.62-1.82 (m, 1H), 1.84-2.04 (m, 1H), 2.27-2.41
(m, 1H), 2.76 and 2.79 (2xs, 3H), 3.45-3.60
(m, 1H), 3.61-3.95 (m, 4H), 3.96-4.31 (m, 1H),
20 6.30-6.48 (m, 2H), 8.58 (s, 1H), 14.90 and 14.93
(2xs, 1H).

Anal. Calcd. for C₂₅H₃₂F₂N₄O₅:

C, 59.28; H, 6.37; N, 11.06; F, 7.50

Found: C, 59.46; H, 6.54; N, 11.08; F, 6.99.

25 3S,1S-5-amino-1-cyclopropyl-6,8-difluoro-7-[3-(1-N-
methylaminoethyl)-1-pyrrolidinyl]-1,4-dihydro-4-oxo-3-
quinolinecarboxylic acid

Using 0.75 g (1.8 mmol) of the above quinolone,
hydrolysis of the tert-butoxycarbonyl group with
30 hydrogen chloride in methylene chloride, followed by 6N
HCl, provided the title compound (0.58 g) as the
hydrochloride salt; mp >250°C.

¹H-NMR (TFA) δ 1.26-1.60 (m, 4H), 1.61 (d, 3H,

-135-

J=6.2 Hz), 1.96-2.12 (m, 1H), 2.45-2.60 (m, 1H),
2.72-2.89 (m, 1H), 3.04 (s, 3H), 3.53-3.69 (m, 1H),
3.91-4.40 (m, 5H), 7.20-7.40 (m, 1H), 9.16 (s, 1H).

Anal. Calcd. for $C_{20}H_{24}F_2N_4O_3 \cdot 2.0HCl \cdot 0.60H_2O$:

5 C, 49.01; H, 5.59; N, 11.43.

Found: C, 49.09; H, 5.55; N, 1.07.

General Procedure for 8-Methoxy Quinolone Carboxylic
Acids

10 These derivatives were obtained by reaction of the
appropriate pyrrolidine side chain (2 eq) with the 7-
fluoro-8-methoxy-1,4-dihydro-4-oxo-3-quinolinecarboxylic
acid borate ester according to the general procedure,
except that no triethylamine was added to the reaction
mixture. The resulting ester was subsequently
15 hydrolyzed with triethylamine in 80% aqueous ethanol.

EXAMPLE 36

20 3R,1S-1-cyclopropyl-6-fluoro-7-[3-(1-N-tert-
butoxycarbonyl-N-methylaminoethyl)-1-pyrrolidinyl]-8-
methoxy-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid
borate ester

From 0.90 g (2.6 mmol) of 8-methoxyquinolone borate
ester, and 0.65 g (2.6 mmol) of pyrrolidine 60, there
was obtained 1.00 g (70%) of the title compound.

25 ^1H -NMR ($CDCl_3$) δ 0.80-0.92 (m, 1H), 0.93-1.08 (m, 1H),
1.10-1.29 (m, 5H), 1.46 (s, 9H), 1.61-1.80 (m, 1H),
2.05-2.20 (m, 1H), 2.32-2.49 (m, 1H), 2.75 and 2.78
(2Xs, 3H), 3.62 (s, 3H), 3.65-3.81 (m, 2H), 3.82-
4.14 (m, 2H), 4.20-4.38 (m, 2H), 7.82 (br. d, 1H,
J=13.8 Hz), 8.93 (s, 1H).

-136-

3R,1S-1-cyclopropyl-6-fluoro-7-[3-(1-N-tert-butoxycarbonyl-N-methylaminoethyl)-1-pyrrolidinyl]-8-methoxy-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid

From 0.80 g (1.5 mmol) of the above borate ester and (3.6 mmol) of triethylamine in 20 mL of 80% aqueous ethanol, there was obtained 0.56 g (74%) of the title compound after recrystallization from dichloromethane/heptane.

$^1\text{H-NMR}$ (CDCl_3) δ 0.80-0.98 (m, 1H), 1.03-1.40 (m, 6H), 1.44 (s, 9H), 1.52-1.88 (m, 1H), 1.98-2.20 (m, 1H), 2.31-2.50 (m, 1H), 2.73 and 2.75 (2Xs, 3H), 3.30-3.60 (m, 2H), 3.55 (s, 3H), 3.62-4.40 (m, 4H), 7.80 (br. d, 1H), 8.74 (s, 1H), 15.02-15.10 (m, 1H).

3R,1S-1-cyclopropyl-6-fluoro-7-[3-(1-N-methylaminoethyl)-1-pyrrolidinyl]-8-methoxy-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid

Using Method A on 0.75 g (1.5 mmol) of the above protected quinolone, there was obtained the title compound (0.40 g) as a yellow solid; mp 166-167°C.

$[\alpha]_D = -105^\circ$ (c=1.08, methanol).

$^1\text{H-NMR}$ (d_6 -DMSO + CD_3OD) δ 0.87-0.99 (m, 1H), 1.01-1.27 (m, 3H), 1.32 (d, 3H, $J=6.0$ Hz), 1.70-1.90 (m, 1H), 2.08-2.11 (m, 1H), 2.49-2.73 (m, 4H), 3.48-3.69 (m, 3H), 3.57 (s, 3H), 3.71-3.82 (m, 2H), 4.08-4.20 (m, 1H), 7.65 (d, 1H, $J=13.8$ Hz), 8.66 (s, 1H), 9.09-9.29 (m, 1H), 9.31-9.55 (m, 1H), 15.10-15.20 (br. s, 1H).

Anal. Calcd. for $\text{C}_{21}\text{H}_{26}\text{FN}_3\text{O}_4 \cdot 1.0 \text{ HCl} \cdot 1.4 \text{ H}_2\text{O}$:

C, 54.23; H, 6.46; N, 9.03; Cl, 7.62

Found: C, 54.04; H, 6.30; N, 8.99; Cl, 8.11.

-137-

EXAMPLE 37

3R,1R-1-cyclopropyl-6-fluoro-7-[3-(1-N-tert-butoxycarbonyl-N-methylaminoethyl)-1-pyrrolidinyl]-8-methoxy-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid borate ester

From 0.90 g (2.6 mmol) of 8-methoxyquinolone borate ester, and 1.16 g (5.1 mmol) of pyrrolidine 61, there was obtained 1.41 g (98%) of the title compound after recrystallization from dichloromethane/ether.

¹H-NMR (CDCl₃) δ 0.98-1.08 (m, 1H), 1.12-1.30 (m, 6H), 1.48 (s, 9H), 1.70-1.87 (m, 1H), 1.92-2.13 (m, 1H), 2.32-2.52 (m, 1H), 2.79 and 2.82 (2xs, 3H), 3.55-4.20 (m, 6H), 3.64 (s, 3H), 7.77 (d, 1H, J=13.7 Hz), 8.90 (s, 1H).

Anal. Calcd. for C₂₆H₃₃BF₃N₃O₆:

C, 56.64; H, 6.03; N, 7.62

Found: C, 56.68; H, 6.16; N, 7.55.

3R,1R-1-cyclopropyl-6-fluoro-7-[3-(1-N-tert-butoxycarbonyl-N-methylaminoethyl)-1-pyrrolidinyl]-8-methoxy-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid

From 1.35 g (2.5 mmol) of borate ester and 2.50 g (25 mmol) of triethylamine in 60 mL of 80% aqueous ethanol, there was obtained 0.63 g (50%) of the title compound after recrystallization from dichloromethane/hexane. Concentration of the mother liquor provided additional product (0.50 g, 40%); mp 140-145°C.

[α]_D = -116° (c=1.06, chloroform).

¹H-NMR (CDCl₃) δ 0.85-0.97 (m, 1H), 1.02-1.30 (m, 3H), 1.18 (d, 3H, J=6.6 Hz), 1.49 (s, 9H), 1.65-1.88 (m, 1H), 1.91-2.10 (m, 1H), 2.29-2.43 (m, 1H), 2.78 and 2.81 (2xs, 3H), 3.45-3.65 (m, 3H), 3.57 (s, 3H), 3.72-3.83 (m, 1H), 3.96-4.36 (m, 2H), 7.76

-138-

(d, 1H, $J=13.8$ Hz), 8.77 (s, 1H), 14.95-15.20 (m, 1H).

Anal. Calcd. for $C_{26}H_{34}FN_3O_6 \cdot 1.6 H_2O$:

C, 58.66; H, 7.04; N, 7.89

5 Found: C, 58.62; H, 7.02; N, 8.09.

3R,1R-1-cyclopropyl-6-fluoro-7-[3-(1-N-methylamino-ethyl)-1-pyrrolidinyl]-8-methoxy-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid

10 Using Method A on 1.20 g (2.4 mmol) of the above protected quinolone, there was obtained the title compound (0.46 g); mp 212-213°C (dec.).

$[\alpha]_D = -165^\circ$ (c=1.01, 1 N NaOH).

15 ^1H -NMR (d_6 -DMSO) δ 0.86-1.25 (m, 4H), 1.27 (d, 3H, $J=6.5$ Hz), 1.71-1.92 (m, 1H), 2.20-2.33 (m, 1H), 2.47-2.62 (m, 1H), 2.57 (s, 3H), 3.50-3.65 (m, 3H), 3.57 (s, 3H), 3.70-3.80 (m, 2H), 4.10-4.19 (m, 1H), 7.66 (d, 1H, $J=13.9$ Hz), 8.66 (s, 1H), 8.90-9.20 (m, 2H), 15.00-15.15 (m, 1H).

Anal. Calcd. for $C_{21}H_{26}FN_3O_4 \cdot 1.0 HCl \cdot 2.0 H_2O$:

20 C, 53.00; H, 6.57; N, 8.83; Cl, 7.45

Found: C, 52.69; H, 6.47; N, 8.72; Cl, 7.44.

EXAMPLE 38

25 3S,1R-1-cyclopropyl-6-fluoro-7-[3-(1-N-tert-butoxycarbonyl-N-methylaminoethyl)-1-pyrrolidinyl]-8-methoxy-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid borate ester

30 From 0.86 g (2.5 mmol) of 8-methoxyquinolone borate ester, and 1.14 g (5.0 mmol) of pyrrolidine 63, there was obtained 1.34 g (97%) of the title compound after recrystallization from dichloromethane/ether; mp 185-186°C.

$[\alpha]_D = +87^\circ$ (c=0.56, chloroform).

^1H -NMR ($CDCl_3$) δ 0.94-1.07 (m, 1H), 1.16-1.29 (m, 2H),

-139-

1.24 (d, 3H, J=6.8 Hz), 1.31-1.50 (m, 1H), 1.47 (s, 9H), 1.60-1.82 (m, 1H), 2.06-2.10 (m, 1H), 2.32-2.51 (m, 1H), 2.75 and 2.78 (2xs, 3H), 3.43-3.85 (m, 3H), 3.62 (s, 3H), 3.87-4.38 (m, 3H), 7.82 (br. d, 1H, J=13.8 Hz), 8.92 (s, 1H).

Anal. Calcd. for $C_{26}H_{33}BF_3N_3O_6$:

C, 56.64; H, 6.03; N, 7.62

Found: C, 56.61; H, 6.00; N, 7.28.

3S,1R-1-cyclopropyl-6-fluoro-7-[3-(1-N-t-butoxycarbonyl-N-methylaminoethyl)-1-pyrrolidinyl]-8-methoxy-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid

From 1.35 g (2.5 mmol) of borate ester and 2.50 g (25 mmol) of triethylamine in 50 mL of 80% aqueous ethanol, there was obtained 1.17 g (93%) of the title compound.

^1H -NMR ($CDCl_3$) δ 0.82-0.95 (m, 1H), 1.01-1.12 (m, 2H), 1.17-1.29 (m, 4H), 1.46 (s, 9H), 1.60-1.77 (m, 1H), 2.02-2.16 (m, 1H), 2.29-2.48 (m, 1H), 2.74 and 2.77 (2xs, 3H), 3.38-3.70 (m, 3H), 3.56 (s, 3H), 3.79-3.90 (m, 1H), 3.91-4.33 (m, 2H), 7.78 (d, 1H, J=13.9 Hz), 8.77 (s, 1H).

3S,1R-1-cyclopropyl-6-fluoro-7-[3-(1-N-methylaminoethyl)-1-pyrrolidinyl]-8-methoxy-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid

Using Method A on 1.10 g (2.2 mmol) of the above protected quinolone, there was obtained the title compound (0.57 g). Concentration of the mother liquor provided additional product (0.22 g); mp 190-195°C.

^1H -NMR (d_6 -DMSO) δ 1.06-1.23 (m, 4H), 1.31 (d, 3H, J=6.3 Hz), 1.69-1.87 (m, 1H), 2.04-2.10 (m, 1H), 2.48-2.64 (m, 1H), 2.55 (s, 3H), 3.00-3.12 (m, 1H), 3.45-3.65 (m, 2H), 3.57 (s, 3H), 3.66-3.80 (m, 2H), 4.08-4.19 (m, 1H), 7.66 (d, 1H, J=13.8 Hz), 8.66

-140-

(s, 1H), 8.91-9.10 (m, 1H), 9.13-9.31 (m, 1H),
15.10-15.20 (m, 1H).

Anal. Calcd. for $C_{21}H_{26}FN_3O_4 \cdot 1.0 \text{ HCl} \cdot 2.0 \text{ H}_2\text{O}$:

C, 53.00; H, 6.57; N, 8.83

5 Found: C, 52.76; H, 6.43; N, 8.71.

EXAMPLE 39

3S,1S-1-cyclopropyl-6-fluoro-7-[3-(1-N-tert-
butoxycarbonyl-N-methylaminoethyl)-1-pyrrolidinyl]-8-
methoxy-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid
borate ester

10

From 0.86 g (2.5 mmol) of 8-methoxyquinolone borate
ester, and 1.15 g (5.0 mmol) of pyrrolidine 62, there
was obtained 1.04 g (75%) of the title compound after
recrystallization from dichloromethane/ether;
15 mp 189-190°C.

$[\alpha]_D = 105^\circ$ (c=0.34, chloroform).

$^1\text{H-NMR}$ (CDCl_3) δ 0.98-1.06 (m, 1H), 1.10-1.32 (m, 6H),
1.49 (s, 9H), 1.72-1.90 (m, 1H), 1.93-2.14 (m, 1H),
2.30-2.48 (m, 1H), 2.78 and 2.82 (2xs, 3H), 3.56-
20 4.37 (m, 6H), 3.62 (s, 3H), 7.85 (d, 1H,
J=13.7 Hz), 8.94 (s, 1H).

Anal. Calcd. for $C_{26}H_{33}BF_3N_3O_6 \cdot 0.5 \text{ H}_2\text{O}$:

C, 55.73; H, 6.12; N, 7.50

Found: C, 55.61; H, 6.24; N, 7.49.

25

3S,1S-1-cyclopropyl-6-fluoro-7-[3-(1-N-tert-
butoxycarbonyl-N-methylaminoethyl)-1-pyrrolidinyl]-8-
methoxy-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid

30

From 1.00 g (1.8 mmol) of borate ester and 2.50 g
(25 mmol) of triethylamine in 50 mL of 80% aqueous
ethanol, there was obtained 0.85 g (93%) of the title
compound.

$^1\text{H-NMR}$ (CDCl_3) δ 0.85-0.95 (m, 1H), 1.03-1.30 (m, 3H),

-141-

1.18 (d, 3H, J=6.8 Hz), 1.49 (s, 9H), 1.68-1.89 (m, 1H), 1.91-2.10 (m, 1H), 2.28-2.44 (m, 1H), 2.77 and 2.81 (2xs, 3H), 3.45-3.64 (m, 3H), 3.57 (s, 3H), 3.70-3.87 (m, 1H), 3.94-4.08 (m, 1H), 4.16-4.36 (m, 1H), 7.77 (d, 1H, J=13.8 Hz), 8.77 (s, 1H).

3S,1S-1-cyclopropyl-6-fluoro-7-[3-(1-N-methylamino-ethyl)-1-pyrrolidinyl]-8-methoxy-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid

Using Method A on 1.24 g (2.5 mmol) of the above protected quinolone, there was obtained the title compound (0.18 g). Concentration of the mother liquor provided additional product (0.03 g); mp 173-174°C (dec).

¹H-NMR (d₆-DMSO + TFA) δ 0.85-1.25 (m, 4H), 1.26 (d, 3H, J=6.2 Hz), 1.72-1.90 (m, 1H), 2.15-2.31 (m, 1H), 2.42-2.60 (m, 1H), 2.63 (s, 3H), 3.25-3.43 (m, 1H), 3.45-3.68 (m, 6H), 3.70-3.88 (m, 1H), 4.09-4.20 (m, 1H), 7.64 (d, 1H, J=13.8 Hz), 8.52-8.80 (m, 2H), 12.10-12.60 (m, 1H).

EXAMPLE 40

3R,1S-1-cyclopropyl-6-fluoro-7-[3-(1-N-methylamino-ethyl)-1-pyrrolidinyl]-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid

This compound was prepared by reacting a suspension of the quinolone B (0.80 g, 3.0 mmol) and triethylamine (0.33 g, 3.3 mmol) in acetonitrile (15 mL) with the unprotected side chain 64 (0.42 g, 3.3 mmol) according to the general coupling procedure. The title compound (0.60 g) was obtained. Concentration of the filtrate and washings provided additional product (0.43 g); mp 229-230°C.

¹H-NMR (TFA) δ 1.35-1.42 (m, 2H), 1.55-1.70 (m, 2H),

-142-

1.64 (d, 3H, J=6.4 Hz), 2.05-2.19 (m, 1H), 2.41-
2.58 (m, 1H), 2.82-3.18 (m, 1H), 3.04 (br. s, 3H),
3.59-3.77 (m, 1H), 3.81-4.06 (m, 4H), 4.32-4.42
(m, 1H), 7.10-7.40 (m, 1H), 7.35 (d, 1H, J=6.8 Hz),
5 8.13 (d, 1H, J=13.5 Hz), 9.18 (s, 1H), 11.63 (br.
s, 1H).

Anal. Calcd. for $C_{20}H_{24}FN_3O_3 \cdot 2.0 \text{ HF} \cdot 0.5 \text{ H}_2\text{O}$:

C, 56.86; H, 6.44; N, 9.95

Found: C, 56.68; H, 6.11; N, 9.98.

10

EXAMPLE 41

3R,1R-5-amino-1-cyclopropyl-6,8-difluoro-7-[3-(1-N-
methylaminoethyl)-1-pyrrolidinyl]-1,4-dihydro-4-oxo-3-
quinoline carboxylic acid

15 This compound was prepared by reacting a
suspension of the quinolone L (1.19 g, 4.0 mmol) and
triethylamine (0.71 g, 5.5 mmol) in acetonitrile (50 mL)
with the unprotected side chain 65 (0.70 g, 5.5 mmol)
according to the general coupling procedure. The title
compound (1.62 g) was obtained; mp 198-199°C.

20 $^1\text{H-NMR}$ (TFA) δ 1.25-1.70 (m, 4H), 1.61 (d, 3H,
J=6.6 Hz), 1.93-2.10 (m, 1H), 2.43-2.60 (m, 1H),
2.70-2.88 (m, 1H), 3.06 and 3.07 (2xs, 3H), 3.53-
3.70 (m, 1H), 3.85-4.00 (m, 1H), 4.01-4.40 (m, 4H),
7.05-7.35 (m, 1H), 9.14 (s, 1H).

25 Anal. Calcd. for $C_{20}H_{24}F_2N_4O_3 \cdot 1.5 \text{ H}_2\text{O}$:

C, 55.42; H, 6.28; N, 12.93

Found: C, 55.70; H, 6.14; N, 12.86.

EXAMPLE 42

30 3R,1S-5-amino-1-cyclopropyl-6,8-difluoro-7-[3-(1-N-
methylaminoethyl)-1-pyrrolidinyl]-1,4-dihydro-4-oxo-3-
quinoline carboxylic acid

This compound was prepared by reacting a suspension
of the quinolone L (0.89 g, 3.0 mmol) and triethylamine

-143-

(0.46 g, 4.5 mmol) in acetonitrile (30 mL) with the unprotected side chain 64 (0.57 g, 4.4 mmol) according to the general coupling procedure. The title compound (0.59 g) was obtained;

5 $[\alpha]_D = -210^\circ$ (c=0.46, 1 N NaOH).

$^1\text{H-NMR}$ (TFA) δ 1.22-1.39 (m, 2H), 1.40-1.55 (m, 2H),
1.64 (d, 3H, J=6.6 Hz), 1.85-2.07 (m, 1H), 2.35-
2.50 (m, 1H), 2.68-2.86 (m, 1H), 3.01 and 3.03
(2xs, 3H), 3.55-3.70 (m, 1H), 3.96-4.20 (m, 5H),
10 7.03-7.42 (m, 1H), 9.13 (s, 1H), 11.58 (s, 1H).

Anal. Calcd. for $\text{C}_{20}\text{H}_{24}\text{F}_2\text{N}_4\text{O}_3 \cdot 1.5 \text{ HF} \cdot 0.7 \text{ H}_2\text{O}$:

C, 53.50; H, 6.04; N, 12.48; F, 14.81

Found: C, 53.56; H, 5.77; N, 12.51; F, 14.96.

EXAMPLE 43

15 3R,1S-7-[3-(1-aminoethyl)-1-pyrrolidinyl]-1-(2,4-
difluorophenyl)-6-fluoro-1,4-dihydro-4-oxo-1,8-
naphthyridine-3-carboxylic acid

A mixture of 7-chloro-1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid G (0.05 g, 1.52 mmol), pyrrolidine 20 (0.32 g, 1.52 mmol), Et_3N (1 mL, 7.18 mmol) in CH_3CN (20 mL) was refluxed for 18 hours. The solution was cooled and concentrated. The residue was dissolved in CH_2Cl_2 (50 mL), cooled to 0°C and treated with gaseous HCl .

25 The reaction was allowed to stir at room temperature for 18 hours and then concentrated. The residue was suspended in H_2O (10 mL) and 1 N NaOH was added until the pH of the solution was 12. The mixture was filtered and the filtrate acidified with HCl to pH 7.1. The
30 resulting solid was filtered, washed with water and dried to provide the title compound in a yield of 74%; mp $140-145^\circ\text{C}$.

-144-

EXAMPLE 44

3R,1S-7-[3-(1-aminoethyl)-1-pyrrolidinyl]-1-cyclopropyl-
6-fluoro-1,4-dihydro-8-methoxy-4-oxo-3-
quinolinecarboxylic acid

5 A solution of 0.53 g (1.55 mmol) of 1-cyclopropyl-
6,7-difluoro-1,4-dihydro-8-methoxy-4-oxo-3-
quinolinecarboxylic acid-borondifluoride complex, 0.40
(1.87 mmol) of pyrrolidine 20, 0.60 g (4.6 mmol) of
diisopropylethylamine, and 25 mL of acetonitrile was
10 stirred for 3 days at room temperature. The solution
was concentrated to an orange oil which was dissolved in
95% ethanol (20 mL) and treated with 5 mL of
triethylamine. The solution was heated at reflux for
2 hours, then cooled to room temperature and
15 concentrated. The solid that was obtained was
chromatographed (silica gel, 230-400 mesh), eluting with
CHCl₃/MeOH (9/1), to give 0.69 g of 3R,1S-7-[3-(1-t-
butoxycarbonylaminoethyl)-1-pyrrolidinyl]-1-cyclopropyl-
6-fluoro-1,4-dihydro-8-methoxy-4-oxo-3-
20 quinolinecarboxylic acid as a foam, mp 145-147°C.

 The above compound (0.69 g, 1.4 mmol) was dissolved
in 30 mL of chloroform, cooled to 5°C, and treated with
a steady stream of gaseous HCl for 15 minutes. The
solution was allowed to warm to room temperature and
25 concentrated in vacuo. The residue was triturated with
2-propanol:ethyl acetate (1:10), and the solids were
filtered, washed with ether, and dried to give 0.54 g of
the title compound as the hydrochloride salt;
mp 236-238°C.

30 Anal. Calcd. for C₂₀H₂₄FN₃O₄·1.25 HCl·H₂O:

C, 50.04; H, 6.35; N, 8.75; Cl, 9.23.

Found: C, 50.09; H, 5.97; N, 8.82; Cl, 9.44.

HPLC: 99.5%

¹H-NMR (TFA) δ 9.41 (s, 1H), 8.18 (d, 1H), 4.55 (m, 1H),
35 4.32 (m, 2H), 4.14 (m, 2H), 3.93 (bs, 4H), 2.57 (m,

-145-

1H), 3.09 (m, 1H), 2.21 (m, 1H), 1.69 (d, J=5.5 Hz, 3H), 1.61 (m, 1H), 1.50 (m, 1H), 1.33 (m, 1H), 1.21 (m, 1H).

EXAMPLE 45

5 3R,1R-7-[3-(1-aminoethyl)-1-pyrrolidinyl]-1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-4-oxo-3-quinoline-carboxylic acid

10 The procedure above was used to prepare the title compound (0.54 g) from 0.58 g (1.7 mmol) of 1-cyclopropyl-6,7-difluoro-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid-borondifluoride complex and 0.43 g (2.0 mmol) of 21. The title compound was isolated as the hydrochloride salt; mp 215-218°C.

Anal. Calcd. for $C_{20}H_{24}FN_3O_4 \cdot 1.15 HCl \cdot 2.1 H_2O$:

15 C, 51.20; H, 6.30; N, 8.95; Cl, 8.69.

Found: C, 51.20; H, 6.00; N, 8.68; Cl, 8.36.

20 ^1H -NMR (DMSO- d_6) δ 8.66 (s, 1H), 8.30 (bs, 2H), 7.66 (d, J=14 Hz, 1H), 4.14 (m, 1H), 3.77 (m, 1H), 3.56 (bs, 6H), 3.26 (m, 1H), 2.45 (m, 1H), 2.21 (m, 1H), 1.78 (m, 1H), 1.26 (d, J=6 Hz, 3H), 1.17-0.98 (m, 4H).

EXAMPLE 46

3R,1R-7-[3-(1-aminoethyl)-1-pyrrolidinyl]-1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-5-methyl-4-oxo-3-quinolinecarboxylic acid

25 A solution of 0.40 g (1.4 mmol) of 1-(2,4-difluorophenyl)-6,7-difluoro-1,4-dihydro-5-methyl-4-oxo-3-quinolinecarboxylic acid J, 0.30 g (1.4 mmol) of pyrrolidine 21, 0.36 g (3.6 mmol) of triethylamine, and 20 mL of acetonitrile was heated at
30 reflux for 4 hours. The solution was cooled to 5°C, and the solids were filtered. The product was washed with water and ether, dried, and dissolved in 30 mL of chloroform. This solution was cooled to 5°C and treated

-146-

with a steady stream of gaseous HCl for 10 minutes. The mixture was allowed to warm to room temperature, stirred for 18 hours, and filtered. The solids were collected via filtration, washed with ether, and dried in vacuo to give 0.46 g of the title compound as the hydrochloride salt; mp >300°C.

Anal. Calcd. for $C_{23}H_{22}F_3N_3O_3 \cdot HCl \cdot 2.5 H_2O$:

C, 52.42; H, 5.36; N, 7.97; Cl, 6.72.

Found: C, 52.24; H, 4.99; N, 7.80; Cl, 6.68.

^1H -NMR (DMSO- d_6) δ 8.67 (s, 1H), 8.15 (bs, 2H), 7.9 (m, 1H), 7.7 (m, 1H), 7.4 (m, 1H), 5.7 (d, 1H), 3.6-3.15 (m, 5H), 2.78 (d, 3H), 2.4 (m, 1H), 2.15 (m, 1H), 1.7 (m, 1H), 1.17 (d, 3H).

EXAMPLE 47

3R,1S-7-[3-(1-aminoethyl)-1-pyrrolidinyl]-1-cyclopropyl-6-fluoro-1,4-dihydro-5-methyl-4-oxo-3-quinoline-carboxylic acid

A solution of 0.38 g (1.4 mmol) of 1-cyclopropyl-6,7-difluoro-1,4-dihydro-5-methyl-4-oxo-3-quinolinecarboxylic acid I, 0.32 g (1.5 mmol) of pyrrolidine, 0.42 g (4.2 mmol) of triethylamine, and 25 mL of acetonitrile was heated at reflux for 4 hours, then cooled to 5°C. The mixture was diluted with ether, and the solids were filtered, washed with ether, and dried to give 3R,1S-7-[3-(1-t-butoxycarbonylaminoethyl)-1-pyrrolidinyl]-1-cyclopropyl-6-fluoro-1,4-dihydro-5-methyl-4-oxo-3-quinolinecarboxylic acid, mp 188-191°C.

The above compound was dissolved in 30 mL of chloroform, cooled to 5°C, and treated with a steady stream of gaseous HCl for 10 minutes. The solution was allowed to warm to room temperature overnight. Ether was added and the solids were filtered, washed with ether, and dried to give 0.43 g of the title compound as the hydrochloride salt; mp 266-268°C.

-147-

Anal. Calcd. for $C_{20}H_{24}FN_3O_3 \cdot 1.1 HCl \cdot 1.2 H_2O$:

C, 55.20; H, 6.37; N, 9.66; Cl, 8.96.

Found: C, 55.14; H, 6.08; N, 9.54; Cl, 8.91.

H^1 -NMR (DMSO- d_6 + TFA) δ 8.55 (s, 1H), 7.02 (d, J=7 Hz, 1H), 3.72 (m, 4H), 3.48 (m, 1H), 3.35 (m, 1H), 2.74 (d, 3H), 2.47 (m, 1H), 2.15 (m, 1H), 1.79 (m, 1H), 1.37 (m, 2H), 1.30 (d, J=6.5 Hz, 3H), 1.11 (m, 2H).

EXAMPLE 48

3R,1R-7-[3-(1-aminoethyl)-1-pyrrolidinyl]-1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid

A solution of 0.40 g (1.1 mmol) of 7-chloro-1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid G, 0.30 g (1.4 mmol) of pyrrolidine 21, 0.36 g (3.6 mmol) of triethylamine, and 15 mL of acetonitrile was heated at reflux for 5 hours. The suspension was cooled to 5°C, and the solids were filtered, washed with water and ether, and dried to give 0.48 g of 3R,1R-7-[3-(1-N-t-butoxycarbonylaminoethyl)-1-pyrrolidinyl]-1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid.

The above compound was dissolved in 20 mL of chloroform, cooled to 5°C, and treated with a steady stream of gaseous HCl for 10 minutes. The solution was warmed to room temperature and concentrated by half. Ether was added, and the solids that formed were filtered, washed with ether, and dried to give 0.38 g of the title compound as the hydrochloride salt; mp 265-268°C.

Anal. Calcd. for $C_{21}H_{19}F_3N_4O_3 \cdot 1.1 HCl \cdot 1.2 H_2O$:

C, 51.04; H, 4.59; N, 11.34; Cl, 7.89.

Found: C, 50.93; H, 4.45; N, 11.22; Cl, 7.62.

^1H -NMR (DMSO- d_6) δ 15.16 (bs, 1H), 8.83 (s, 1H), 8.20 (bs, 2H), 8.05 (d, J=12 Hz, 1H), 7.80 (m, 1H), 7.61

-148-

(m, 1H), 7.34 (m, 1H), 3.35 (m, 5H), 2.33 (m, 1H),
2.12 (m, 1H), 1.68 (m, 1H), 1.15 (bs, 3H).

EXAMPLE 49

5 3R,1S-7-[3-(1-aminoethyl)-1-pyrrolidinyl]-1-cyclopropyl-
8-ethoxy-6-fluoro-1,4-dihydro-4-oxo-3-quinoline-
carboxylic acid

A solution of 0.55 g (1.55 mmole) of 1-cyclopropyl-
8-ethoxy-6,7-difluoro-1,4-dihydro-4-oxo-3-quinoline-
carboxylic acid borondifluoride complex, 0.40 g
10 (1.9 mmol) of pyrrolidine 20, 0.60 g (4.6 mmol) of
diisopropylethylamine, and 25 mL of acetonitrile was
stirred at room temperature for 3 days. The solution
was concentrated to a yellow foam which was dissolved in
20 mL of ethanol, treated with 5 mL of triethylamine,
15 and heated at reflux for 5 hours. The mixture was
concentrated to a gold solid which was chromatographed
(silica gel, eluting with 90:10 CHCl₃:MeOH) to give
0.76 g of 3R,1S-7-[3-(1-N-t-butoxycarbonylaminoethyl)-1-
pyrrolidinyl]-1-cyclopropyl-8-ethoxy-6-fluoro-1,4-
20 dihydro-4-oxo-3-quinolinecarboxylic acid, mp 161-163°C.

The above compound (0.74 g, 1.5 mmol) was dissolved
in 30 mL of chloroform, cooled to 5°C, and treated with
a steady stream of gaseous HCl for 10 minutes. The
solution was allowed to warm to room temperature and
25 stirred for 90 minutes. The suspension was
concentrated, and the residue was triturated with ethyl
acetate. The solids were filtered, washed with ethyl
acetate, and dried to give 0.56 g of the title compound
as the hydrochloride salt; mp 222-224°C.

30 Anal. Calcd. for C₂₁H₂₆FN₃O₄·1.25 HCl·2.5 H₂O:

C, 51.05; H, 6.58; N, 8.50; Cl, 8.97.

Found: C, 51.14; H, 6.35; N, 8.49; Cl, 8.42.

¹H-NMR (DMSO-d₆) δ 15.15 (s, 1H), 8.67 (s, 1H), 8.22
(bs, 3H), 7.66 (d, J=14.0 Hz, 1H), 4.14 (m, 1H),

-149-

3.72 (m, 4H), 3.48 (m, 2H), 3.28 (m, 1H), 2.41 (m, 1H), 2.10 (m, 1H), 1.72 (m, 1H), 1.30 (m, 7H), 1.06 (m, 2H), 0.90 (m, 1H).

EXAMPLE 50

5 3R,1S-7-[3-(1-N-ethylaminoethyl)-1-pyrrolidinyl]-1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid

A solution of 0.71 g (2.0 mmol) of 7-chloro-1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid G, 0.31 g (2.2 mmol) of pyrrolidine 44, 0.61 g (6.0 mmol) of triethylamine, and 15 mL of acetonitrile was heated at reflux for 3 hours, then cooled to room temperature and concentrated. The residue was dissolved in water which was basified to pH 11 with 10% NaOH, filtered through a fiberglass pad, and neutralized to pH 7.2. The solids that formed were filtered, washed with ether, and dried in vacuo to give 0.65 g of the title compound; mp 136-138°C.

Anal. Calcd. for $C_{23}H_{23}F_3N_4O_3 \cdot 2H_2O$:

20 C, 55.64; H, 5.48; N, 11.28.

Found: C, 55.42; H, 5.22; N, 11.31.

^1H -NMR (DMSO- d_6) δ 8.78 (s, 1H), 8.00 (d, J=13 Hz, 1H), 7.80 (q, 1H), 7.56 (s, 1H), 7.32 (m, 1H), 4.0-3.3 (m, 4H), 2.61 (m, 1H), 2.39 (m, 2H), 2.02 (m, 2H), 1.55 (m, 1H), 0.98 (m, 6H).

EXAMPLE 51

3R,1R-7-[3-(1-N-ethylaminoethyl)-1-pyrrolidinyl]-1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid

30 The procedure outlined in Example 50 was used to prepare the title compound (0.71 g) from 0.71 g (2.0 mmol) of 7-chloro-1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid G,

-150-

0.31 g (2.2 mmol) of pyrrolidine 45, and 0.61 g (6.0 mmol) of triethylamine. The title compound was isolated via isoelectric precipitation at pH 7.2, mp 203-205°C.

5

EXAMPLE 52

3R,1S-1-cyclopropyl-7-[3-(1-N-ethylaminoethyl)-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-5-methyl-4-oxo-3-quinolinecarboxylic acid

10 A solution of 0.56 g (2.0 mmole) of 1-cyclopropyl-6,7-difluoro-1,4-dihydro-5-methyl-4-oxo-3-quinolinecarboxylic acid I, 0.31 g (2.2 mmol) of pyrrolidine 44, 0.61 g (6.0 mmol) of triethylamine, and 15 mL of acetonitrile was heated at reflux for 4 hours. The solution was cooled and concentrated to an orange solid.

15 The residue was dissolved in water, filtered through a fiberglass pad, acidified to pH 2.0, and lyophilized. The yellow powder was dissolved in concentrated hydrochloric acid and filtered; the filtrate was concentrated to a gold oil which was triturated with

20 2-propanol:ether (1:1). The solids were filtered, washed with 2-propanol and ether, and dried in vacuo to give 0.41 g of the title compound as the hydrochloride salt; mp >300°C.

Anal. Calcd. for $C_{22}H_{28}FN_3O_3 \cdot 1.4 HCl \cdot 1H_2O$:

25 C, 56.16; H, 6.73; N, 8.93; Cl, 10.55.

Found: C, 56.19; H, 6.45; N, 8.99; Cl, 10.38.

^1H -NMR (DMSO- d_6) δ 8.55 (s, 1H), 7.06 (d, J=2 Hz, 1H), 3.87 (m, 1H), 3.67 (m, 3H), 3.45 (m, 1H), 3.04 (m, 2H), 2.73 (d, J=3 Hz, 3H), 2.55 (m, 2H), 2.16 (m, 1H), 1.82 (m, 1H), 1.40 (m, 2H), 1.28 (m, 6H), 1.09 (m, 2H).

30

-151-

EXAMPLE 53

3R,1S-5-amino-1-cyclopropyl-7-[3-(1-N-ethylaminoethyl)-1-pyrrolidinyl]-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid

5 A solution of 0.60 g (2.0 mmol) of 5-amino-1-cyclopropyl-6,7,8-trifluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid L, 0.31 g (2.2 mmol) of pyrrolidine 44, 0.61 g (6.0 mmol) of triethylamine, and 20 mL of acetonitrile was heated at reflux for 5 hours.
10 The solution was cooled to room temperature and concentrated. The residue was taken up in water which was basified to pH 11, filtered through a fiberglass pad, and neutralized to pH 7.8. The solids that formed were filtered, washed with water and ether, and dried to
15 give 0.61 g of the title compound; mp 148-150°C.

Anal. Calcd. for $C_{21}H_{26}F_2N_4O_3 \cdot 0.5H_2O$:

C, 58.73; H, 6.34; N, 13.05.

Found: C, 58.59; H, 6.41; N, 13.45.

^1H -NMR (DMSO- d_6) δ 8.41 (s, 1H), 7.10 (bs, 2H), 3.95 (m, 1H), 3.66 (m, 3H), 3.33 (m, 1H), 2.67 (m, 1H), 2.48
20 (m, 2H), 2.00 (m, 2H), 1.58 (m, 1H), 1.04 (m, 10H).

EXAMPLE 54

3R,1S-7-[3-(1-N-ethylaminoethyl)-1-pyrrolidinyl]-1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-5-methyl-4-oxo-3-quinolinecarboxylic acid

25 A solution of 0.70 g (2.0 mmol) of 1-(2,4-difluorophenyl)-6,7-difluoro-1,4-dihydro-5-methyl-4-oxo-3-quinolinecarboxylic acid J, 0.31 g (2.2 mmol) of pyrrolidine 44, 0.61 g (6.0 mmol) of triethylamine, and
30 20 mL of acetonitrile was heated at reflux for 4 hours. The solution was cooled to room temperature and concentrated. The residue was taken up in water which was basified to pH 11.0, filtered through a fiberglass

-152-

pad, neutralized to pH 7.9, and refrigerated. The solids that formed were filtered, washed with water and ether, and dried in vacuo to give 0.51 g of the title compound; mp 187-189°C.

5 Anal. Calcd. for $C_{25}H_{26}F_{23}N_3O_3 \cdot 3.6H_2O$:

C, 55.77; H, 6.20; N, 7.80.

Found: C, 55.50; H, 6.23; N, 7.72.

^1H -NMR (DMSO- d_6) δ 8.67 (s, 1H), 7.88 (m, 1H), 7.72 (m, 1H), 7.43 (m, 1H), 5.65 (d, J=7.7 Hz, 1H), 3.35 (m, 3H), 3.2 (m, 1H), 2.75 (d, J=3.3 Hz, 3H), 2.63 (m, 1H), 2.43 (m, 2H), 2.1 (m, 1H), 1.90 (m, 1H), 1.57 (m, 1H), 0.98 (m, 6H).

EXAMPLE 55

15 3R,1S-5-amino-7-[3-(1-N-ethylaminoethyl)-1-pyrrolidinyl]-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid

A solution of 0.56 g (2.0 mmol) of 5-amino-1-cyclopropyl-6,7-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid M, 0.31 g (2.2 mmol) of pyrrolidine 44, 20 0.61 g (6.0 mmol) of triethylamine, and 20 mL of pyridine was heated at reflux for 24 hours. The solution was cooled to room temperature and concentrated. The residue was dissolved in water, acidified to pH 2.0, filtered through a fiberglass pad, 25 and lyophilized. The solids were suspended in concentrated hydrochloric acid and filtered, and the filtrate was concentrated. The residue was triturated with 2-propanol:ether (1:1); the solids were filtered, washed with chloroform and ether, and dried in vacuo to 30 give 0.68 g of the title compound as the hydrochloride salt; mp >300°C.

Anal. Calcd. for $C_{21}H_{27}FN_4O_3 \cdot 1.8HCl \cdot 1.5H_2O$:

C, 50.94; H, 6.47; N, 11.31; Cl, 12.91.

Found: C, 50.71; H, 6.19; N, 11.25; Cl, 12.63.

-153-

$^1\text{H-NMR}$ (DMSO-d_6) δ 8.42 (s, 1H), 6.38 (d, $J=8$ Hz, 1H), 3.83 (m, 1H), 3.65 (m, 2H), 3.51 (m, 2H), 3.33 (m, 1H), 2.99 (m, 2H), 2.62 (m, 1H), 2.13 (m, 1H), 1.81 (m, 1H), 1.30 (m, 8H), 1.04 (m, 2H).

5

EXAMPLE 56

3R,1S-5-amino-1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[3-(1-N-methylaminoethyl)-1-pyrrolidinyl]-4-oxo-3-quinolinecarboxylic acid

10 A solution of 0.71 g (2.3 mmol) of 5-amino-1-cyclopropyl-6,7-difluoro-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid K, 0.80 g (3.0 mmol) of pyrrolidine 60, 0.93 g (9.2 mmol) of triethylamine, 15 mL of acetonitrile, and 15 mL of DMSO was refluxed for 18 hours. The mixture was cooled to room
15 temperature, and the acetonitrile was evaporated in vacuo. The solution was poured into water, and the solids that formed were filtered, washed with water and ether, and dried.

The above compound (1.07 g, 2.1 mmol) was dissolved
20 in 30 mL of chloroform, cooled to 5°C , and treated with a steady stream of gaseous HCl for 5 minutes. The mixture was stirred overnight at room temperature. The solution was then concentrated to a paste which was taken up in a small amount of chloroform, diluted with
25 ethyl acetate, cooled to 5°C , and filtered. The solids were washed with ethyl acetate and dried to give 0.95 g of the title compound as the hydrochloride salt; mp $258-260^\circ\text{C}$.

Anal. Calcd. for $\text{C}_{21}\text{H}_{27}\text{FN}_4\text{O}_4 \cdot 2\text{HCl} \cdot 2\text{H}_2\text{O}$:

30 C, 47.82; H, 6.31; N, 10.62; Cl, 13.44.

Found: C, 47.81; H, 5.99; N, 10.78; Cl, 13.77.

$^1\text{H-NMR}$ (DMSO-d_6) δ 8.52 (s, 1H), 4.02 (m, 1H), 3.74 (m, 2H), 3.58 (m, 2H), 3.42 (s, 3H), 3.30 (m, 1H), 2.5 (m, 4H), 2.08 (m, 1H), 1.75 (m, 1H), 1.30 (d,

-154-

J=6.5 Hz, 3H), 1.14 (m, 1H), 0.96 (m, 2H), 0.76 (m, 1H).

EXAMPLE 57

5 3R,1S-1-cyclopropyl-8-ethoxy-6-fluoro-1,4-dihydro-7-[3-
(1-N-methylaminoethyl)-1-pyrrolidinyl]-4-oxo-3-
quinolinecarboxylic acid

A solution of 0.35 g (1.0 mmol) of 1-cyclopropyl-8-ethoxy-6,7-difluoro-1,4-dihydro-4-oxo-3-quinoline-carboxylic acid borondifluoride complex, 0.27 g
10 (1.2 mmol) of pyrrolidine 60, 0.46 g (3.6 mmol) of diisopropylethylamine, and 15 mL of acetonitrile was stirred at room temperature for 18 hours. The solution was concentrated to an oil which was chromatographed (silica gel 230-400 mesh, eluting with 90:10
15 CHCl₃:MeOH). The product that was isolated was dissolved in 20 mL of ethanol, treated with 5 mL of triethylamine, and heated at reflux for 3 hours. The solution was cooled to 5°C and diluted with ether. The solids were filtered, washed with ether, and dried to
20 give 0.47 g of 3R,1S-7-[3-(1-N-t-butoxycarbonyl-N-methylaminoethyl)-1-pyrrolidinyl]-1-cyclopropyl-8-ethoxy-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid.

¹H-NMR (CDCl₃) δ 15.0 (br s, 1H), 3.77 (s, 1H), 7.76 (d, J=14 Hz, 1H), 4.25 (m, 1H), 4.00 (m, 1H), 3.80 (m, 2H), 3.63 (m, 3H), 3.40 (m, 1H), 2.75 (d, J=10 Hz, 3H), 2.35 (m, 1H), 2.10 (m, 1H), 1.7 (m, 1H), 1.46 (s, 9H), 1.33 (m, 4H), 1.22 (d, J=6.7 Hz, 3H), 1.05 (m, 2H), 0.85 (m, 1H).

30 A solution of the above compound in 30 mL of chloroform was cooled to 5°C and treated with a steady stream of gaseous HCl for 10 minutes. The mixture was warmed to room temperature and concentrated. The residue was triturated with isopropanol:ether 1:10, and

-155-

the solids were filtered and washed with ether to give 0.37 g of the title compound as the hydrochloride salt; mp 210-212°C.

Anal. Calcd. for $C_{22}H_{28}FN_3O_4 \cdot 1.2HCl \cdot 1.15H_2O$:

5 C, 54.83; H, 6.59; N, 8.72; Cl, 8.83.

Found: C, 54.93; H, 6.99; N, 9.09; Cl, 8.90.

^1H -NMR (DMSO- d_6) δ 15.1 (bs, 1H), 9.0 (bs, 1H), 8.67 (s, 1H), 7.66 (d, $J=13.8$ Hz, 1H), 4.14 (m, 1H), 3.74-3.4 (m, 4H), 3.07 (m, 3H), 2.56 (bs, 3H), 2.12 (m, 1H), 1.75 (m, 1H), 1.28 (m, 4H), 1.20 (m, 4H), 1.17 (m, 2H), 0.90 (m, 1H).

EXAMPLE 58

15 3R,1S-5-amino-7-[3-(1-aminoethyl)-1-pyrrolidinyl]-1-cyclopropyl-6,8-difluoro-1,4-dihydro-4-oxo-3-quinoline-carboxylic acid

A solution of 0.32 g (1.1 mmol) of 5-amino-1-cyclopropyl-6,7,8-trifluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid L, 0.26 g (1.2 mmol) of pyrrolidine 20, 0.32 g (3.2 mmol) of triethylamine, and 15 mL of acetonitrile was heated at reflux for 6 hours. The suspension was cooled to room temperature and filtered. The solids were washed with water and ether, dried, and then dissolved in 20 mL of chloroform. The solution was cooled in an ice bath and treated with a steady stream of gaseous HCl for 10 minutes. The mixture was allowed to warm to room temperature. The solvent was evaporated and the residue was triturated with 30 mL of ethyl acetate. The solids were filtered, washed with ether, and dried in vacuo to give 0.33 g of the title compound as the hydrochloride salt, mp 251-254°C.

-156-

EXAMPLE 59

3R,1S-5-amino-7-[3-(1-aminoethyl)-1-pyrrolidinyl]-1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid

5 A solution of 0.34 g (1.1 mmol) of 5-amino-1-cyclopropyl-6,7-difluoro-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid K, 0.26 g (1.2 mmol) of pyrrolidine 20, 0.32 g (3.2 mmol) of triethylamine, 10 mL of DMSO, and 10 mL of acetonitrile was heated at
10 reflux for 18 hours. The acetonitrile was evaporated in vacuo, and the solution was poured into water and extracted with chloroform. The organic layer was dried and concentrated. The residue was chromatographed (silica gel, 230-400 mesh, eluting with 90:10
15 CHCl₃:MeOH) to give 0.37 g of 5-amino-7-[(3R,1'S)-3-(1'-N-t-butoxycarbonylaminoethyl)-1-pyrrolidinyl]-1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid.

¹H-NMR (CDCl₃) δ 15.08 (s, 1H), 8.64 (s, 1H), 6.39 (bs, 2H), 4.44 (m, 1H), 3.90-3.70 (m, 3H), 3.64 (m, 3H),
20 3.43 (s, 3H), 2.19 (m, 1H), 2.03 (m, 1H), 1.69 (m, 1H), 1.45 (s, 9H), 1.23 (d, J=6.8 Hz, 3H), 1.20 (m, 1H), 0.97 (m, 2H), 0.74 (m, 1H).

 The above compound was dissolved in 20 mL of
25 chloroform, cooled to 5°C, and treated with gaseous HCl for 10 minutes. The mixture was allowed to warm to room temperature and stirred at that temperature for 3 hours. The solution was concentrated to a paste which was
30 trituated with ethyl acetate and filtered. The solids were washed with ether and dried in vacuo to give 0.27 g of the title compound as the hydrochloride salt;
 mp 234-237°C.

¹H-NMR (DMSO-d₆) δ 8.51 (s, 1H), 8.23 (bs, 2H), 4.04 (m, 1H), 3.70 (m, 2H), 3.58 (m, 2H), 3.42 (s, 3H), 3.25
35 (m, 1H), 2.40 (m, 1H), 2.10 (m, 1H), 1.70 (m, 1H),

-157-

1.30 (d, J=6.5 Hz, 3H), 1.15 (m, 1H), 0.96 (m, 2H),
0.86 (m, 1H).

EXAMPLE 60

5 3R,1S-7-[3-(1-aminoethyl)-1-pyrrolidinyl]-1-cyclopropyl-
6-fluoro-1,4-dihydro-4-oxo-8-trifluoromethyl-3-
quinolinecarboxylic acid

A solution of 0.36 g (1.1 mmol) of 1-cyclopropyl-
6,7-difluoro-1,4-dihydro-4-oxo-8-trifluoromethyl-3-
quinolinecarboxylic acid D, 0.25 g (1.2 mmol) of
10 pyrrolidine 20, 0.32 g (3.2 mmol) of triethylamine, and
15 mL of acetonitrile was heated at reflux for 3 hours,
then cooled to room temperature and concentrated. The
residue was chromatographed (silica gel, 230-400 mesh,
eluting with 90:10 CHCl₃:MeOH) to give 0.53 g of 3R,1S-
15 7-[3-(1-N-t-butoxycarbonylaminoethyl)-1-pyrrolidinyl]-1-
cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-8-
trifluoromethyl-3-quinolinecarboxylic acid.

¹H-NMR (CDCl₃) δ 8.78 (s, 1H), 7.94 (d, J=14.3 Hz, 1H),
4.40 (bd, 1H), 3.98 (m, 2H), 3.76 (m, 4H), 2.30 (m,
20 1H), 2.10 (m, 1H), 1.75 (m, 1H), 1.45 (bs, 9H),
1.24 (d, J=6.7 Hz, 3H), 1.21 (m, 2H), 1.05 (m, 1H),
0.8 (m, 1H).

The above compound was dissolved in 20 mL of
chloroform, cooled to 5°C, and treated with a steady
25 stream of gaseous HCl for 10 minutes. The solution was
allowed to warm to room temperature and concentrated by
half. The suspension was diluted with ether and
filtered; the solids were washed with ether and dried in
vacuo to give 0.42 g of the title compound as the
30 hydrochloride salt, mp >300°C.

Anal. Calcd. for C₂₀H₂₁F₄N₃O₃·1.8HCl·1.3H₂O:

C, 46.51; H, 4.95; N, 8.14; Cl, 12.36.

Found: C, 46.48; H, 4.79; N, 8.15; Cl, 12.40.

-158-

¹H-NMR (DMSO-d₆) δ 8.76 (s, 1H), 8.32 (bs, 3H), 7.86 (d, J=14.6 Hz, 1H), 3.93 (m, 3H), 3.73 (m, 2H), 3.27 (m, 1H), 2.50 (m, 1H), 2.11 (m, 1H), 1.75 (m, 1H), 1.27 (d, 3H), 1.20 (m, 2H), 1.02 (m, 1H), 0.87 (m, 1H).

5

EXAMPLE 61

3R,1S-1-cyclopropyl-6-fluoro-7-[3-(1-N-methylamino-ethyl)-1-pyrrolidinyl]-5-methyl-8-methoxy-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid

10 From 1.0 g (2.8 mmol) of 7-fluoro-5-methyl-8-methoxyquinoline borate ester (from quinolone N), and 0.84 g (3.2 mmol) of pyrrolidine 60, and diisopropylethylamine (11.2 mmol) in acetonitrile was obtained 1.38 g (87%) of the desired product.

15 ¹H-NMR (DMSO-d₆) δ 0.9-1.28 (m, 10H), 1.38 (s, 9H), 1.60-1.68 (m, 1H), 2.1-2.8 (m, 1H), 2.40-2.58 (m, 1H), 2.60-2.70 (d, 6H), 3.48 (s, 3H), 3.5-4.2 (m, 3H), 4.23-4.38 (m, 1H), 8.9 (s, 1H). M+1 566.

20 From 1.3 g (2.3 mmol) of the borate ester obtained above, 2.6 mmol of triethylamine and 60 mL of 80% ethanol was obtained 0.92 g (78%) of the ester which was purified by chromatography (silica gel, 10% CH₃OH/CHCl₃).

25 ¹H-NMR (DMSO-d₆) δ 0.65-0.99 (m, 3H), 1.05-1.30 (m, 4H), 1.37 (s, 9H), 1.46-1.55 (m, 1H), 1.98-2.10 (m, 1H), 2.37-2.50 (m, 1H), 2.66 (d, 6H), 3.45 (s, 3H), 3.38-3.62 (m, 2H), 3.70-3.90 (m, 1H), 3.9-4.2 (m, 2H), 8.62 (s, 1H), 15.61 (s, 1H).

Anal. Calcd. for C₂₇H₃₆F₁N₃O₆·0.5H₂O:

30 C, 61.56; H, 7.08; N, 7.98.

Found: C, 61.51; H, 6.80; N, 8.12.

-159-

From 0.90 g (1.74 mmol) of the ester above, using Method C and recrystallizing from ethanol, the title compound was obtained (0.51 g, 70%); mp 238-241°C (dec).

¹H-NMR (TFA) δ 1.02-1.38 (dm, 2H), 1.39-1.76 (m, 2H),
1.68 (d, J=6.57 Hz, 3H), 2.22-2.42 (m, 1H),
2.48-2.70 (m, 1H), 2.94 (s, 3H), 3.05 (s, 3H),
3.18-3.38 (m, 1H), 3.62-3.82 (m, 1H), 3.94 (s, 3H),
4.10-4.61 (m, 5H), 9.46 (s, 1H), 11.6 (s, 1H).

Anal. Calcd. for C₂₂H₂₈N₃F₁O₄·HCl:

C, 58.21; H, 6.44; N, 9.26.

Found: C, 58.08; H, 6.41; N, 9.39.

EXAMPLE 62

3R,1S-1-difluorophenyl-6-fluoro-7-[3-(1-N-methylamino-ethyl)-1-pyrrolidinyl]-1,4-dihydro-4-oxo-3-quinoline-carboxylic acid

From 0.46 g (1.07 mmol) of 1-(2,4-difluorophenyl)-6,7-difluoro-5-methyl-8-methoxy quinoline borate ester (from quinolone N), 0.29 g (1.12 mmol) of pyrrolidine 60, and 4.28 mmol of diisopropylethylamine was obtained the coupled product. The resulting borate ester was carried on as described above to provide 0.17 g (61%) of the N-t-butoxycarbonyl derivative after chromatography (10% CH₃OH/CHCl₃).

¹H-NMR (CDCl₃) δ 1.12-1.70 (m, 3H), 1.42 (d, 3H), 1.59 (s, 9H), 2.69, 2.73 (2d, 3H), 2.81 (d, J=3.19 Hz, 3H), 3.02, 3.14 (2s, 3H), 3.20-4.30 (m, 7H), 6.8-7.5 (m, 3H), 8.40-8.45 (m, 1H).

From 0.16 g (0.27 mmol) of the above compound, the protecting group was removed using Method C. After recrystallizing from isopropanol, the title compound was obtained, 0.09 g (70%) as an off-white solid; mp 233-238°C (dec).

Anal. Calcd. for C₂₅H₂₆F₃N₃O₄·HCl·0.5H₂O:

-160-

C, 56.13; H, 5.28; N, 7.85.

Found: C, 56.21; H, 0.18; N, 7.89.

¹H-NMR (TFA) δ 1.62 (d, J=5.5 Hz, 3H), 2.09 (m, 1H), 2.4 (m, 1H), 2.98 (m, 1H), 2.97 (s, 3H), 3.01 (s, 3H), 3.28, 3.39 (2s, 3H), 3.65 (m, 1H), 4.09 (m, 5H), 7.18 (m, 2H), 7.72 (m, 1H), 8.99 (s, 1H), 11.63 (s, 1H).

EXAMPLE 63

3R,1R-1-(2,4-difluorophenyl)-5-methyl-7-[3-(1-N-tert-butoxycarbonyl-N-methylaminoethyl)-1-pyrrolidinyl]-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid

From 0.70 g (2.0 mmol) of 1-(2,4-difluorophenyl)-5-methyl-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid, J, 0.57 g (2.5 mmol) of pyrrolidine 61, and 1.03 g (8.0 mmol) of diisopropylethylamine, there was obtained the title compound (0.93 g).

¹H-NMR (CDCl₃) δ 1.07-1.15 (m, 3H), 1.45 (s, 9H), 1.65-1.79 (m, 1H), 1.82-2.01 (m, 1H), 2.25-2.40 (m, 1H), 2.68-2.73 (m, 3H), 2.80 (d, 3H), 3.11-3.40 (m, 3H), 3.50-3.63 (m, 1H), 3.80-4.20 (2xm, 1H), 5.60 (br d, 1H), 7.07-7.21 (m, 2H), 7.40-7.52 (m, 1H), 8.47 (s, 1H), 15.60-15.72 (m, 1H).

Anal. Calcd. for C₂₉H₃₂F₃N₃O₅:

C, 62.25; H, 5.76; N, 7.51.

Found: C, 61.90; H, 5.66; N, 7.51.

3R,1R-1-(2,4-difluorophenyl)-5-methyl-7-[3-(1-N-methylaminoethyl)-1-pyrrolidinyl]-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid

From 0.80 g (1.4 mmol) of 3R,1R-1-(2,4-difluorophenyl)-5-methyl-7-[3-(1-N-tert-butoxycarbonyl-N-methylaminoethyl)-1-pyrrolidinyl]-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid, hydrolysis of the tert-butoxycarbonyl group with trifluoroacetic acid in

-161-

dichloromethane provided the title compound (0.72 g);
mp 140-143°C.

¹H-NMR (DMSO-d₆) δ 1.16 (d, 3H, J=6.1 Hz), 1.63-1.78 (m, 1H), 2.02-2.18 (m, 1H), 2.32-2.60 (m, 1H), 2.50 (s, 3H), 2.78 (d, 3H, J=3.1 Hz), 3.14-3.40 (m, 4H), 3.50-3.65 (m, 1H), 5.71 (d, 1H, J=7.9 Hz), 7.37-7.49 (m, 1H), 7.65-7.79 (m, 1H), 7.82-7.95 (m, 1H), 8.20-8.70 (m, 2H), 8.69 (s, 1H).

Anal. Calcd. for C₂₄H₂₄F₃N₃O₃·1.0CF₃CO₂H·0.6H₂O:

C, 53.45; H, 4.52; N, 7.19.

Found: C, 53.47; H, 4.32; N, 7.45.

EXAMPLE 64

3R,1S-1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-7-[3-[1-(methylamino)ethyl]-1-pyrrolidinyl]-4-oxo-1,8-naphthyridine-3-carboxylic acid, monohydrochloride

A mixture of 7-chloro-1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid G (0.50 g, 1.41 mmol), compound 60 (0.38 g, 1.66 mmol), Et₃N (1 mL, 7.18 mmol) in CH₃CN (20 mL) was heated at reflux for 3 hours. The mixture was cooled and concentrated. The residue was dissolved in CH₂Cl₂ (50 mL), cooled to 0°C and HCl was bubbled into the solution for 2 minutes. The reaction was allowed to warm to room temperature for 18 hours and concentrated. The residue was recrystallized from EtOH/H₂O to provide 0.56 g (82%) of the desired product; mp 278-280°C (dec).
NMR (DMSO-d₆) δ 1.21 (d, 3H), 1.66 (m, 1H), 2.01 (m, 1H), 3.22 (m, 2H), 3.34 (s, 3H), 7.34 (t, 1H), 7.59 (t, 1H), 7.82 (q, 1H), 8.06 (d, 1H), 8.81 (s, 1H), 8.98 (bs, 2H).

-162-

EXAMPLE 65

3R,1S-7-[3-(1-aminoethyl)-1-pyrrolidinyl]-1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-5-methyl-4-oxo-3-quinolinecarboxylic acid, monohydrochloride

5 A mixture of 6,7-difluoro-1-(2,4-difluorophenyl)-1,4-dihydro-5-methyl-4-oxo-3-quinolinecarboxylic acid J (0.41 g, 1.20 mmol), compound 20 (0.36 g, 1.44 mmol), Et_3N (1 mL, 7.18 mmol) in CH_3CN (25 mL) was heated at reflux for 3 hours. The reaction was worked up as
10 described previously to provide 0.51 g (87%) of the desired product; mp $>250^\circ\text{C}$.
NMR (DMSO-d_6) δ 1.22 (d, 3H), 1.75 (, 1H), 2.03 (m, 1H), 2.37 (m, 1H), 2.77 (m, 3H), 3.78 (m, 1H), 5.75 (d, 1H), 7.43 (t, 1H), 7.73 (t, 1H), 7.90 (t, 1H), 8.19 (bs, 2H),
15 8.66 (s, 1H).

EXAMPLE 66

3R,1S-1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-5-methyl-7-[3-(methylamino)ethyl]-1-pyrrolidinyl]-4-oxo-3-quinolinecarboxylic acid, monohydrochloride

20 A mixture of 6,7-difluoro-1-(2,4-difluorophenyl)-1,4-dihydro-5-methyl-4-oxo-3-quinolinecarboxylic acid J (0.50 g, 1.47 mmol), compound 60 (0.38 g, 1.66 mmol), Et_3N (1 mL, 7.18 mmol) in CH_3CN 920 mL) was heated at reflux for 5 hours. The mixture was then cooled and
25 concentrated. The residue was dissolved in CH_2Cl_2 (50 mL), cooled to 0°C and HCl was bubbled into the solution for 2 minutes. The reaction was then allowed to stir at room temperature for 18 hours, and then concentrated. The residue was recrystallized from
30 $\text{EtOH}/\text{H}_2\text{O}$ to provide 0.58 g (78%) of the desired product; mp $>300^\circ\text{C}$ (dec.).

NMR (DMSO-d_6) δ 1.24 (d, 3H), 1.69 (m, 1H), 2.01 (m, 1H), 2.77 (d, 3H), 3.33 (m, 6H), 3.67 (m, 1H), 5.73 (d,

-163-

1H), 7.42 (t, 1H), 7.70 (t, 1H), 7.89 (q, 1H), 8.66 (s, 1H).

EXAMPLE 67

5 3R,1S-1-cyclopropyl-6-fluoro-1,4-dihydro-5-methyl-7-[3-[1-(methylamino)ethyl]-1-pyrrolidinyl]-4-oxo-3-quinolinecarboxylic acid, monohydrochloride

A mixture of 1-cyclopropyl-6,7-difluoro-1,4-dihydro-5-methyl-4-oxo-3-quinolinecarboxylic acid I (0.41 g, 1.47 mmol), compound 60 (0.41 g, 1.55 mmol),
10 Et₃N (1 mL, 7.13 mmol) and CH₃CN (20 mL) was heated at reflux for 3 hours. Workup was performed as described above to provide 0.49 g (79%) of the desired product; mp >250°C.

15 NMR (DMSO-d₆-TFA) δ 1.11 (m, 2H), 1.31 (d, 3H), 1.38 (m, 2H), 1.79 (m, 1H), 2.52 (s, 2H), 2.71 (d, 3H), 3.34 (t, 1H), 3.48 (t, 1H), 3.67 (m, 3H), 3.86 (m, 1H), 7.01 (d, 1H), 8.53 (s, 1H).

EXAMPLE 68

20 3R,1S-5-amino-1-cyclopropyl-6-fluoro-7-[3-[1-(methylamino)ethyl]-1-pyrrolidinyl]-4-oxo-3-quinolinecarboxylic acid, monohydrochloride

A mixture of 5-amino-1-cyclopropyl-6,7-difluoro-4-oxo-3-quinolinecarboxylic acid M (0.40 g, 1.42 mmol), compound 60 (0.42 g, 1.68 mmol), Et₃N (1 mL, 7.18 mmol)
25 in pyridine (20 mL) was heated at reflux for 7 hours and then stirred at room temperature for 12 hours. The mixture was concentrated and chromatographed (silica gel, 5% MeOH/CHCl₃) to provide 0.60 g of material.

30 NMR (CDCl₃) δ 1.07 (m, 2H), 1.23 (m, 5H), 1.45 (m, 9H), 2.15 (m, 1H), 2.56 (m, 1H), 2.78 (m, 3H), 3.28-3.85 (m, 6H), 6.14 (d, 1H), 6.46 (bs, 2H), 8.52 (s, 1H).

This material was dissolved in CHCl₂ (25 mL), cooled to 0°C and HCl was bubbled in for 2 minutes. The

-164-

mixture was allowed to warm to room temperature, stirred for 18 hours, and concentrated. The residue was recrystallized from EtOH/H₂O to provide 0.28 g (45%) of the desired product; mp >250°C.

5 NMR (DMSO-d₆) δ 1.05 (6s, 2H), 1.30 (m, 6H), 1.73 (m, 1H), 2.15 (m, 1H), 2.56 (s, 3H), 3.28-3.85 (m, 6H), 6.37 (d, 1H), 7.18 (bs, 1H), 8.41 (s, 1H), 9.11 (bs, 2H).

EXAMPLE 69

10 3S,1R-1-cyclopropyl-7-[3-[1-(dimethylamino)ethyl]-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid

The title compound was prepared from naphthyridine A, pyrrolidine 35, and triethylamine using the procedure outlined in Example 50; mp 231-234°C.

15

EXAMPLE 70

3S,1S-1-cyclopropyl-7-[3-[1-(dimethylamino)ethyl]-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid

20

The title compound was prepared from naphthyridine A, pyrrolidine 34, and triethylamine using the procedure outlined in Example 50; mp 226-228°C.

EXAMPLE 71

25

3R,1S-1-cyclopropyl-7-[3-[1-(dimethylamino)ethyl]-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid

The title compound was prepared from naphthyridine A, pyrrolidine 32, and triethylamine using the procedure outlined in Example 50; mp 231-233°C.

-165-

EXAMPLE 72

3R,1R-1-cyclopropyl-7-[3-[1-(dimethylamino)ethyl]-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid

5 The title compound was prepared from naphthyridine A, pyrrolidine 33, and triethylamine using the procedure outlined in Example 50; mp 228-230°C.

EXAMPLE 73

10 3R,1S-1-cyclopropyl-7-[3-[1-(dimethylamino)ethyl]-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid

 The title compound was prepared from quinolone B, pyrrolidine 32, and triethylamine as outlined in Example 14; mp 273-275°C.

15 EXAMPLE 74

3R,1R-1-cyclopropyl-7-[3-[1-(dimethylamino)ethyl]-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid

20 The title compound was prepared from quinolone B, pyrrolidine 33, and triethylamine as outlined in Example 14; mp 263-265°C.

EXAMPLE 75

25 3S,1R-1-cyclopropyl-7-[3-[1-(dimethylamino)ethyl]-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid

 The title compound was prepared from quinolone B, pyrrolidine 35, and triethylamine as outlined in Example 14; mp 262-264°C.

-166-

EXAMPLE 76

3S,1S-1-cyclopropyl-7-[3-[1-(dimethylamino)ethyl]-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid

- 5 The title compound was prepared from quinolone B, pyrrolidine 34, and triethylamine as outlined in Example 14; mp 271-274°C.

EXAMPLE 77

10 3R,1R-1-cyclopropyl-7-[3-[1-(ethylamino)ethyl]-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid

 The title compound was prepared from naphthyridine A, pyrrolidine 45, and triethylamine using the procedure outlined in Example 50.

- 15 Anal. Calcd. for $C_{20}H_{25}FN_4O_3 \cdot 0.05 \text{ HF}$:
 C, 59.75; H, 6.63; N, 13.94; F, 4.96.
 Found: C, 59.72; H, 6.75; N, 14.23; F, 5.18.

EXAMPLE 78

20 3R,1S-1-cyclopropyl-7-[3-[1-(ethylamino)ethyl]-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid

 The title compound was prepared from naphthyridine A, pyrrolidine 44, and triethylamine using the procedure outlined in Example 50.

- 25 Anal. Calcd. for $C_{20}H_{25}FN_4O_3 \cdot 0.1 \text{ HF} \cdot 0.4 \text{ H}_2\text{O}$:
 C, 60.41; H, 6.57; N, 14.09; F, 5.26.
 Found: C, 60.75; H, 6.52; N, 13.61; F, 5.19.

-167-

EXAMPLE 79

3S,1R-1-cyclopropyl-7-[3-[1-(ethylamino)ethyl]-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid

5 The title compound was prepared from naphthyridine A, pyrrolidine 47, and triethylamine using the procedure outlined in Example 50.

Anal. Calcd. for $C_{20}H_{25}FN_4O_3 \cdot 0.45 H_2O$:

C, 60.58; H, 6.58; N, 14.13; F, 4.79.

10 Found: C, 60.57; H, 6.47; N, 14.29; F, 5.01.

EXAMPLE 80

3S,1S-1-cyclopropyl-7-[3-[1-(ethylamino)ethyl]-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid

15 The title compound was prepared from naphthyridine A, pyrrolidine 46, and triethylamine using the procedure outlined in Example 50.

Anal. Calcd. for $C_{20}H_{25}FN_4O_3 \cdot 0.5 H_2O$:


C, 60.44; H, 6.59; N, 14.10; F, 4.78.

20 Found: C, 60.83; H, 6.40; N, 14.15; F, 4.86.

-168-

CLAIMS

1. An individual stereoisomer of a compound of the formula



wherein

- * denotes an asymmetric carbon atom;
- X is C-H, C-F, C-Cl, C-OR, C-CF₃ or N;
- R₁ is ethyl, cyclopropyl, or 2,4-difluorophenyl;
- R₂ is hydrogen, alkyl of 1-4 carbon atoms or a cation;
- R₃ is hydrogen, amino, or methyl;
- R and R' are each independently hydrogen or alkyl of 1-3 carbon atoms, or a pharmaceutically acceptable acid addition salt thereof; with the proviso that when X is C-F, R₃ is amino or R¹ is 2,4-difluorophenyl.

2. The individual stereoisomers of Claim 1 wherein X is C-H, C-Cl, C-OR, C-CF₃ or N and R₁ is cyclopropyl.

-169-

3. The stereoisomers of Claim 1 wherein X is C-F, C-H and N, and R₁ is 2,4-difluorophenyl.
4. The stereoisomers of Claim 1 wherein X is C-F and R₃ is amino.
5. The stereoisomers of Claim 1 wherein X is CH, R₃ is methyl.
6. The stereoisomer of Claim 1 and being 3R,1S-7-[3-(1-aminoethyl)-1-pyrrolidinyl]-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid.
7. The stereoisomer of Claim 1 and being 3R,1S-7-[3-(1'-aminoethyl)-1-pyrrolidinyl]-8-chloro-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid.
8. The stereoisomer of Claim 1 and being 3R,1S-7-[3-(1'-aminoethyl)-1-pyrrolidinyl]-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid.
9. The stereoisomer of Claim 1 and being 3R,1S-5-amino-7-[3-(1-aminoethyl)-1-pyrrolidinyl]-1-cyclopropyl-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid.
10. The stereoisomer of Claim 1 and being 3R,1S-7-[3-(1-aminoethyl)-1-pyrrolidinyl]-1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid.

-170-

11. The stereoisomer of Claim 1 and being 3R,1S-5-amino-7-[3-(1-aminoethyl)-1-pyrrolidinyl]-1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid.
12. The stereoisomer of Claim 1 and being 3R,1S-7-[3-(1-aminoethyl)-1-pyrrolidinyl]-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-8-trifluoromethyl-3-quinolinecarboxylic acid.
13. The stereoisomer of Claim 1 and being 3R,1S-7-[3-(1-aminoethyl)-1-pyrrolidinyl]-1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-5-methyl-4-oxo-3-quinolinecarboxylic acid.
14. The stereoisomer of Claim 1 and being 3R,1S-7-[3-(1-aminoethyl)-1-pyrrolidinyl]-1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid.
15. The stereoisomer of Claim 1 and being 3R,1S-7-[3-(1-aminoethyl)-1-pyrrolidinyl]-1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid.
16. The stereoisomer of Claim 1 and being 3R,1S-1-cyclopropyl-6-fluoro-1,4-dihydro-7-[3-[1-(methylamino)ethyl]-1-pyrrolidinyl]-1,8-naphthyridine-3-carboxylic acid.
17. The stereoisomer of Claim 1 and being 3R,1S-8-chloro-1-cyclopropyl-6-fluoro-1,4-dihydro-7-[3-[1-(methylamino)ethyl]-1-pyrrolidinyl]-4-oxo-3-quinolinecarboxylic acid.

-171-

18. The stereoisomer of Claim 1 and being 3R,1S-5-amino-1-cyclopropyl-6,8-difluoro-1,4-dihydro-7-[3-[1-(methylamino)ethyl]-1-pyrrolidinyl]-4-oxo-3-quinolinecarboxylic acid.
19. The stereoisomer of Claim 1 and being 3R,1S-1-cyclopropyl-6-fluoro-1,4-dihydro-7-[3-[1-(methylamino)ethyl]-1-pyrrolidinyl]-4-oxo-3-quinolinecarboxylic acid.
20. The stereoisomer of Claim 1 and being 3R,1S-1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[3-[1-(methylamino)ethyl]-1-pyrrolidinyl]-4-oxo-3-quinolinecarboxylic acid.
21. The stereoisomer of Claim 1 and being 3R,1S-5-amino-1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[3-[1-(methylamino)ethyl]-1-pyrrolidinyl]-4-oxo-3-quinolinecarboxylic acid.
22. The stereoisomer of Claim 1 and being 3R,1S-1-cyclopropyl-6-fluoro-1,4-dihydro-7-[3-[1-(methylamino)ethyl]-1-pyrrolidinyl]-4-oxo-8-trifluoromethyl-3-quinolinecarboxylic acid.
23. The stereoisomer of Claim 1 and being 3R,1S-1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-5-methyl-7-[3-[1-(methylamino)ethyl]-1-pyrrolidinyl]-4-oxo-3-quinolinecarboxylic acid.
24. The stereoisomer of Claim 1 and being 3R,1S-1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-7-[3-[1-(methylamino)ethyl]-1-pyrrolidinyl]-4-oxo-1,8-naphthyridine-3-carboxylic acid.

-172-

25. The stereoisomer of Claim 1 and being 3R,1S-1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-7-[3-[1-(methylamino)ethyl]-1-pyrrolidinyl]-4-oxo-3-quinolinecarboxylic acid.
26. The stereoisomer of Claim 1 and being 3R,1S-1-cyclopropyl-7-[3-[1-(ethylamino)ethyl]-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid.
27. The stereoisomer of Claim 1 and being 3R,1S-8-chloro-1-cyclopropyl-7-[3-[1-(ethylamino)ethyl]-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid.
28. The stereoisomer of Claim 1 and being 3R,1S-1-cyclopropyl-7-[3-[1-(ethylamino)ethyl]-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid.
29. The stereoisomer of Claim 1 and being 3R,1S-5-amino-1-cyclopropyl-7-[3-[1-(ethylamino)ethyl]-1-pyrrolidinyl]-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid.
30. The stereoisomer of Claim 1 and being 3R,1S-1-cyclopropyl-7-[3-[1-(ethylamino)ethyl]-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid.
31. The stereoisomer of Claim 1 and being 3R,1S-5-amino-1-cyclopropyl-7-[3-[1-(ethylamino)ethyl]-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid.

-173-

32. The stereoisomer of Claim 1 and being 3R,1S-1-(2,4-difluorophenyl)-7-[3-[1-(ethylamino)ethyl]-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-5-methyl-4-oxo-3-quinolinecarboxylic acid.
33. The stereoisomer of Claim 1 and being 3R,1S-1-cyclopropyl-7-[3-[1-(ethylamino)ethyl]-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-4-oxo-8-trifluoromethyl-3-quinolinecarboxylic acid.
34. The stereoisomer of Claim 1 and being 3R,1S-1-(2,4-difluorophenyl)-7-[3-[1-(ethylamino)ethyl]-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid.
35. The stereoisomer of Claim 1 and being 3R,1S-1-(2,4-difluorophenyl)-7-[3-[1-(ethylamino)ethyl]-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid.
36. The stereoisomer of Claim 1 and being 3R,1S-1-cyclopropyl-7-[3-[1-(dimethylamino)ethyl]-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid.
37. The stereoisomer of Claim 1 and being 3R,1S-1-cyclopropyl-7-[3-[1-(dimethylamino)ethyl]-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid.
38. The stereoisomer of Claim 1 and being 3R,1S-5-amino-1-cyclopropyl-7-[3-[1-(dimethylamino)ethyl]-1-pyrrolidinyl]-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid.

-174-

39. The stereoisomer of Claim 1 and being 3R,1S-1-cyclopropyl-7-[3-[1-(dimethylamino)ethyl]-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid.
40. The stereoisomer of Claim 1 and being 3R,1S-8-chloro-1-cyclopropyl-7-[3-[1-(dimethylamino)ethyl]-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid.
41. The stereoisomer of Claim 1 and being 3R,1S-1-cyclopropyl-7-[3-[1-(dimethylamino)ethyl]-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid.
42. The stereoisomer of Claim 1 and being 3R,1S-1-cyclopropyl-7-[3-[1-(dimethylamino)ethyl]-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-8-trifluoromethyl-4-oxo-3-quinolinecarboxylic acid.
43. The stereoisomer of Claim 1 and being 3R,1S-1-(2,4-difluorophenyl)-7-[3-[1-(dimethylamino)ethyl]-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid.
44. The stereoisomer of Claim 1 and being 3R,1S-1-(2,4-difluorophenyl)-7-[3-[1-(dimethylamino)ethyl]-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid.
45. The stereoisomer of Claim 1 and being 3R,1S-1-(2,4-difluorophenyl)-7-[3-[1-(dimethylamino)ethyl]-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-5-methyl-4-oxo-3-quinolinecarboxylic acid.

-175-

46. The stereoisomer of Claim 1 and being 3S,1R-7-[3-(1-aminoethyl)-1-pyrrolidinyl]-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid.
47. The stereoisomer of Claim 1 and being 3S,1R-7-[3-(1-aminoethyl)-1-pyrrolidinyl]-8-chloro-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid.
48. The stereoisomer of Claim 1 and being 3S,1R-7-[3-(1-aminoethyl)-1-pyrrolidinyl]-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid.
49. The stereoisomer of Claim 1 and being 3S,1R-5-amino-7-[3-(1-aminoethyl)-1-pyrrolidinyl]-1-cyclopropyl-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid.
50. The stereoisomer of Claim 1 and being 3S,1R-7-[3-(1-aminoethyl)-1-pyrrolidinyl]-1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid.
51. The stereoisomer of Claim 1 and being 3S,1R-5-amino-7-[3-(1-aminoethyl)-1-pyrrolidinyl]-1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid.
52. The stereoisomer of Claim 1 and being 3S,1R-7-[3-(1-aminoethyl)-1-pyrrolidinyl]-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-8-trifluoromethyl-3-quinolinecarboxylic acid.

-176-

53. The stereoisomer of Claim 1 and being 3S,1R-7-[3-(1-aminoethyl)-1-pyrrolidinyl]-1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-5-methyl-4-oxo-3-quinolinecarboxylic acid.
54. The stereoisomer of Claim 1 and being 3S,1R-7-[3-(1-aminoethyl)-1-pyrrolidinyl]-1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid.
55. The stereoisomer of Claim 1 and being 3S,1R-7-[3-(1-aminoethyl)-1-pyrrolidinyl]-1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid.
56. The stereoisomer of Claim 1 and being 3S,1R-1-cyclopropyl-6-fluoro-1,4-dihydro-7-[3-[1-(methylamino)ethyl]-1-pyrrolidinyl]-1,8-naphthyridine-3-carboxylic acid.
57. The stereoisomer of Claim 1 and being 3S,1R-8-chloro-1-cyclopropyl-6-fluoro-1,4-dihydro-7-[3-[1-(methylamino)ethyl]-1-pyrrolidinyl]-4-oxo-3-quinolinecarboxylic acid.
58. The stereoisomer of Claim 1 and being 3S,1R-5-amino-1-cyclopropyl-6,8-difluoro-1,4-dihydro-7-[3-[1-(methylamino)ethyl]-1-pyrrolidinyl]-4-oxo-3-quinolinecarboxylic acid.
59. The stereoisomer of Claim 1 and being 3S,1R-1-cyclopropyl-6-fluoro-1,4-dihydro-7-[3-[1-(methylamino)ethyl]-1-pyrrolidinyl]-4-oxo-3-quinolinecarboxylic acid.

-177-

60. The stereoisomer of Claim 1 and being 3S,1R-1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[3-[1-(methylamino)ethyl]-1-pyrrolidinyl]-4-oxo-3-quinolinecarboxylic acid.
61. The stereoisomer of Claim 1 and being 3S,1R-5-amino-1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[3-[1-(methylamino)ethyl]-1-pyrrolidinyl]-4-oxo-3-quinolinecarboxylic acid.
62. The stereoisomer of Claim 1 and being 3S,1R-1-cyclopropyl-6-fluoro-1,4-dihydro-7-[3-[1-(methylamino)ethyl]-1-pyrrolidinyl]-4-oxo-8-trifluoromethyl-3-quinolinecarboxylic acid.
63. The stereoisomer of Claim 1 and being 3S,1R-1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-5-methyl-7-[3-[1-(methylamino)ethyl]-1-pyrrolidinyl]-4-oxo-3-quinolinecarboxylic acid.
64. The stereoisomer of Claim 1 and being 3S,1R-1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-7-[3-[1-(methylamino)ethyl]-1-pyrrolidinyl]-4-oxo-1,8-naphthyridine-3-carboxylic acid.
65. The stereoisomer of Claim 1 and being 3S,1R-1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-7-[3-[1-(methylamino)ethyl]-1-pyrrolidinyl]-4-oxo-3-quinolinecarboxylic acid.
66. The stereoisomer of Claim 1 and being 3S,1R-1-cyclopropyl-7-[3-[1-(ethylamino)ethyl]-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid.

-178-

67. The stereoisomer of Claim 1 and being 3S,1R-8-chloro-1-cyclopropyl-7-[3-[1-(ethylamino)ethyl]-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid.
68. The stereoisomer of Claim 1 and being 3S,1R-1-cyclopropyl-7-[3-[1-(ethylamino)ethyl]-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid.
69. The stereoisomer of Claim 1 and being 3S,1R-5-amino-1-cyclopropyl-7-[3-[1-(ethylamino)ethyl]-1-pyrrolidinyl]-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid.
70. The stereoisomer of Claim 1 and being 3S,1R-1-cyclopropyl-7-[3-[1-(ethylamino)ethyl]-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid.
71. The stereoisomer of Claim 1 and being 3S,1R-5-amino-1-cyclopropyl-7-[3-[1-(ethylamino)ethyl]-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid.
72. The stereoisomer of Claim 1 and being 3S,1R-1-(2,4-difluorophenyl)-7-[3-[1-(ethylamino)ethyl]-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-5-methyl-4-oxo-3-quinolinecarboxylic acid.
73. The stereoisomer of Claim 1 and being 3S,1R-1-cyclopropyl-7-[3-[1-(ethylamino)ethyl]-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-4-oxo-8-trifluoromethyl-3-quinolinecarboxylic acid.

-179-

74. The stereoisomer of Claim 1 and being 3S,1R-1-(2,4-difluorophenyl)-7-[3-[1-(ethylamino)ethyl]-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid.
75. The stereoisomer of Claim 1 and being 3S,1R-1-(2,4-difluorophenyl)-7-[3-[1-(ethylamino)ethyl]-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid.
76. The stereoisomer of Claim 1 and being 3S,1R-1-cyclopropyl-7-[3-[1-(dimethylamino)ethyl]-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid.
77. The stereoisomer of Claim 1 and being 3S,1R-1-cyclopropyl-7-[3-[1-(dimethylamino)ethyl]-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid.
78. The stereoisomer of Claim 1 and being 3S,1R-5-amino-1-cyclopropyl-7-[3-[1-(dimethylamino)ethyl]-1-pyrrolidinyl]-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid.
79. The stereoisomer of Claim 1 and being 3S,1R-1-cyclopropyl-7-[3-[1-(dimethylamino)ethyl]-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid.
80. The stereoisomer of Claim 1 and being 3S,1R-8-chloro-1-cyclopropyl-7-[3-[1-(dimethylamino)ethyl]-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid.

-180-

81. The stereoisomer of Claim 1 and being 3S,1R-1-cyclopropyl-7-[3-[1-(dimethylamino)ethyl]-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid.
82. The stereoisomer of Claim 1 and being 3S,1R-1-cyclopropyl-7-[3-[1-(dimethylamino)ethyl]-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-8-trifluoromethyl-3-quinolinecarboxylic acid.
83. The stereoisomer of Claim 1 and being 3S,1R-1-(2,4-difluorophenyl)-7-[3-[1-(dimethylamino)ethyl]-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid.
84. The stereoisomer of Claim 1 and being 3S,1R-1-(2,4-difluorophenyl)-7-[3-[1-(dimethylamino)ethyl]-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid.
85. The stereoisomer of Claim 1 and being 3S,1R-1-(2,4-difluorophenyl)-7-[3-[1-(dimethylamino)ethyl]-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-5-methyl-4-oxo-3-quinolinecarboxylic acid.
86. The stereoisomer of Claim 1 and being 3R,1R-7-[3-(1-aminoethyl)-1-pyrrolidinyl]-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid.
87. The stereoisomer of Claim 1 and being 3R,1R-7-[3-(1-aminoethyl)-1-pyrrolidinyl]-8-chloro-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid.

-181-

88. The stereoisomer of Claim 1 and being 3R,1R-7-[3-(1-aminoethyl)-1-pyrrolidinyl]-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid.
89. The stereoisomer of Claim 1 and being 3R,1R-5-amino-7-[3-(1-aminoethyl)-1-pyrrolidinyl]-1-cyclopropyl-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid.
90. The stereoisomer of Claim 1 and being 3R,1R-7-[3-(1-aminoethyl)-1-pyrrolidinyl]-1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid.
91. The stereoisomer of Claim 1 and being 3R,1R-5-amino-7-[3-(1-aminoethyl)-1-pyrrolidinyl]-1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid.
92. The stereoisomer of Claim 1 and being 3R,1R-7-[3-(1-aminoethyl)-1-pyrrolidinyl]-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-8-trifluoromethyl-3-quinolinecarboxylic acid.
93. The stereoisomer of Claim 1 and being 3R,1R-7-[3-(1-aminoethyl)-1-pyrrolidinyl]-1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-5-methyl-4-oxo-3-quinolinecarboxylic acid.
94. The stereoisomer of Claim 1 and being 3R,1R-7-[3-(1-aminoethyl)-1-pyrrolidinyl]-1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid.

-182-

95. The stereoisomer of Claim 1 and being 3R,1R-7-[3-(1-aminoethyl)-1-pyrrolidinyl]-1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid.
96. The stereoisomer of Claim 1 and being 3R,1R-1-cyclopropyl-6-fluoro-1,4-dihydro-7-[3-[1-(methylamino)ethyl]-1-pyrrolidinyl]-1,8-naphthyridine-3-carboxylic acid.
97. The stereoisomer of Claim 1 and being 3R,1R-8-chloro-1-cyclopropyl-6-fluoro-1,4-dihydro-7-[3-[1-(methylamino)ethyl]-1-pyrrolidinyl]-4-oxo-3-quinolinecarboxylic acid.
98. The stereoisomer of Claim 1 and being 3R,1R-5-amino-1-cyclopropyl-6,8-difluoro-1,4-dihydro-7-[3-[1-(methylamino)ethyl]-1-pyrrolidinyl]-4-oxo-3-quinolinecarboxylic acid.
99. The stereoisomer of Claim 1 and being 3R,1R-1-cyclopropyl-6-fluoro-1,4-dihydro-7-[3-[1-(methylamino)ethyl]-1-pyrrolidinyl]-4-oxo-3-quinolinecarboxylic acid.
100. The stereoisomer of Claim 1 and being 3R,1R-1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[3-[1-(methylamino)ethyl]-1-pyrrolidinyl]-4-oxo-3-quinolinecarboxylic acid.
101. The stereoisomer of Claim 1 and being 3R,1R-5-amino-1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[3-[1-(methylamino)ethyl]-1-pyrrolidinyl]-4-oxo-3-quinolinecarboxylic acid.

-183-

102. The stereoisomer of Claim 1 and being 3R,1R-1-cyclopropyl-6-fluoro-1,4-dihydro-7-[3-[1-(methylamino)ethyl]-1-pyrrolidinyl]-4-oxo-8-trifluoromethyl-3-quinolinecarboxylic acid.
103. The stereoisomer of Claim 1 and being 3R,1R-1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-5-methyl-7-[3-[1-(methylamino)ethyl]-1-pyrrolidinyl]-4-oxo-3-quinolinecarboxylic acid.
104. The stereoisomer of Claim 1 and being 3R,1R-1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-7-[3-[1-(methylamino)ethyl]-1-pyrrolidinyl]-4-oxo-1,8-naphthyridine-3-carboxylic acid.
105. The stereoisomer of Claim 1 and being 3R,1R-1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-7-[3-[1-(methylamino)ethyl]-1-pyrrolidinyl]-4-oxo-3-quinolinecarboxylic acid.
106. The stereoisomer of Claim 1 and being 3R,1R-1-cyclopropyl-7-[3-[1-(ethylamino)ethyl]-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid.
107. The stereoisomer of Claim 1 and being 3R,1R-8-chloro-1-cyclopropyl-7-[3-[1-(ethylamino)ethyl]-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid.
108. The stereoisomer of Claim 1 and being 3R,1R-1-cyclopropyl-7-[3-[1-(ethylamino)ethyl]-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid.

-184-

109. The stereoisomer of Claim 1 and being 3R,1R-5-amino-1-cyclopropyl-7-[3-[1-(ethylamino)ethyl]-1-pyrrolidinyl]-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid.
110. The stereoisomer of Claim 1 and being 3R,1R-1-cyclopropyl-7-[3-[1-(ethylamino)ethyl]-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid.
111. The stereoisomer of Claim 1 and being 3R,1R-5-amino-1-cyclopropyl-7-[3-[1-(ethylamino)ethyl]-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid.
112. The stereoisomer of Claim 1 and being 3R,1R-1-(2,4-difluorophenyl)-7-[3-[1-(ethylamino)ethyl]-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-5-methyl-4-oxo-3-quinolinecarboxylic acid.
113. The stereoisomer of Claim 1 and being 3R,1R-1-cyclopropyl-7-[3-[1-(ethylamino)ethyl]-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-4-oxo-8-trifluoromethyl-3-quinolinecarboxylic acid.
114. The stereoisomer of Claim 1 and being 3R,1R-1-(2,4-difluorophenyl)-7-[3-[1-(ethylamino)ethyl]-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid.
115. The stereoisomer of Claim 1 and being 3R,1R-1-(2,4-difluorophenyl)-7-[3-[1-(ethylamino)ethyl]-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid.

-185-

116. The stereoisomer of Claim 1 and being 3R,1R-1-cyclopropyl-7-[3-[1-(dimethylamino)ethyl]-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid.
117. The stereoisomer of Claim 1 and being 3R,1R-1-cyclopropyl-7-[3-[1-(dimethylamino)ethyl]-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid.
118. The stereoisomer of Claim 1 and being 3R,1R-5-amino-1-cyclopropyl-7-[3-[1-(dimethylamino)ethyl]-1-pyrrolidinyl]-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid.
119. The stereoisomer of Claim 1 and being 3R,1R-1-cyclopropyl-7-[3-[1-(dimethylamino)ethyl]-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid.
120. The stereoisomer of Claim 1 and being 3R,1R-8-chloro-1-cyclopropyl-7-[3-[1-(dimethylamino)ethyl]-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid.
121. The stereoisomer of Claim 1 and being 3R,1R-1-cyclopropyl-7-[3-[1-(dimethylamino)ethyl]-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid.
122. The stereoisomer of Claim 1 and being 3R,1R-1-cyclopropyl-7-[3-[1-(dimethylamino)ethyl]-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-8-trifluoromethyl-3-quinolinecarboxylic acid.

-186-

123. The stereoisomer of Claim 1 and being 3R,1R-1-(2,4-difluorophenyl)-7-[3-[1-(dimethylamino)ethyl]-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid.
124. The stereoisomer of Claim 1 and being 3R,1R-1-(2,4-Difluorophenyl)-7-[3-[1-(dimethylamino)ethyl]-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid.
125. The stereoisomer of Claim 1 and being 3R,1R-1-(2,4-difluorophenyl)-7-[3-[1-(dimethylamino)ethyl]-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-5-methyl-4-oxo-3-quinolinecarboxylic acid.
126. The stereoisomer of Claim 1 and being 3R,1S-5-amino-7-[3-(1-aminoethyl)-1-pyrrolidinyl]-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid.
127. The stereoisomer of Claim 1 and being 3R,1S-7-[3-(1-aminoethyl)-1-pyrrolidinyl]-1-cyclopropyl-6-fluoro-1,4-dihydro-5-methyl-4-oxo-3-quinolinecarboxylic acid.
128. The stereoisomer of Claim 1 and being 3R,1S-7-[3-(1-aminoethyl)-1-pyrrolidinyl]-1-cyclopropyl-8-ethoxy-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid.
129. The stereoisomer of Claim 1 and being 3R,1S-5-amino-1-cyclopropyl-6-fluoro-1,4-dihydro-7-[3-[1-(methylamino)ethyl]-1-pyrrolidinyl]-4-oxo-3-quinolinecarboxylic acid.

-187-

130. The stereoisomer of Claim 1 and being 3R,1S-1-cyclopropyl-6-fluoro-1,4-dihydro-5-methyl-7-[3-[1-(methylamino)ethyl]-1-pyrrolidinyl]-4-oxo-3-quinolinecarboxylic acid.
131. The stereoisomer of Claim 1 and being 3R,1S-1-cyclopropyl-8-ethoxy-6-fluoro-1,4-dihydro-7-[3-[1-(methylamino)ethyl]-1-pyrrolidinyl]-4-oxo-3-quinolinecarboxylic acid.
132. The stereoisomer of Claim 1 and being 3R,1S-5-amino-1-cyclopropyl-7-[3-[1-(ethylamino)ethyl]-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid.
133. The stereoisomer of Claim 1 and being 3R,1S-1-cyclopropyl-7-[3-[1-(ethylamino)ethyl]-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-5-methyl-4-oxo-3-quinolinecarboxylic acid.
134. The stereoisomer of Claim 1 and being 3R,1S-1-cyclopropyl-8-ethoxy-7-[3-[1-(ethylamino)ethyl]-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid.
135. The stereoisomer of Claim 1 and being 3R,1S-5-amino-1-cyclopropyl-7-[3-[1-(dimethylamino)ethyl]-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid.
136. The stereoisomer of Claim 1 and being 3R,1S-1-cyclopropyl-7-[3-[1-(dimethylamino)ethyl]-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-5-methyl-4-oxo-3-quinolinecarboxylic acid.

-188-

137. The stereoisomer of Claim 1 and being 3R,1S-1-cyclopropyl-7-[3-[1-(dimethylamino)ethyl]-1-pyrrolidinyl]-8-ethoxy-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid.
138. The stereoisomer of Claim 1 and being 3S,1R-5-amino-7-[3-(1-aminoethyl)-1-pyrrolidinyl]-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid.
139. The stereoisomer of Claim 1 and being 3S,1R-7-[3-(1-aminoethyl)-1-pyrrolidinyl]-1-cyclopropyl-6-fluoro-1,4-dihydro-5-methyl-4-oxo-3-quinolinecarboxylic acid.
140. The stereoisomer of Claim 1 and being 3S,1R-7-[3-(1-aminoethyl)-1-pyrrolidinyl]-1-cyclopropyl-8-ethoxy-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid.
141. The stereoisomer of Claim 1 and being 3S,1R-5-amino-1-cyclopropyl-6-fluoro-1,4-dihydro-7-[3-[1-(methylamino)ethyl]-1-pyrrolidinyl]-4-oxo-3-quinolinecarboxylic acid.
142. The stereoisomer of Claim 1 and being 3S,1R-1-cyclopropyl-6-fluoro-1,4-dihydro-5-methyl-7-[3-[1-(methylamino)ethyl]-1-pyrrolidinyl]-4-oxo-3-quinolinecarboxylic acid.
143. The stereoisomer of Claim 1 and being 3S,1R-1-cyclopropyl-8-ethoxy-6-fluoro-1,4-dihydro-7-[3-[1-(methylamino)ethyl]-1-pyrrolidinyl]-4-oxo-3-quinolinecarboxylic acid.

-189-

144. The stereoisomer of Claim 1 and being 3S,1R-5-amino-1-cyclopropyl-7-[3-[1-(ethylamino)ethyl]-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid.
145. The stereoisomer of Claim 1 and being 3S,1R-1-cyclopropyl-7-[3-[1-(ethylamino)ethyl]-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-5-methyl-4-oxo-3-quinolinecarboxylic acid.
146. The stereoisomer of Claim 1 and being 3S,1R-1-cyclopropyl-8-ethoxy-7-[3-[1-(ethylamino)ethyl]-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid.
147. The stereoisomer of Claim 1 and being 3S,1R-5-amino-1-cyclopropyl-7-[3-[1-(dimethylamino)ethyl]-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid.
148. The stereoisomer of Claim 1 and being 3S,1R-1-cyclopropyl-7-[3-[1-(dimethylamino)ethyl]-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-5-methyl-4-oxo-3-quinolinecarboxylic acid.
149. The stereoisomer of Claim 1 and being 3S,1R-1-cyclopropyl-7-[3-[1-(dimethylamino)ethyl]-1-pyrrolidinyl]-8-ethoxy-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid.
150. The stereoisomer of Claim 1 and being 3R,1R-5-amino-7-[3-(1-aminoethyl)-1-pyrrolidinyl]-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid.


-190-

151. The stereoisomer of Claim 1 and being 3R,1R-7-[3-(1-aminoethyl)-1-pyrrolidinyl]-1-cyclopropyl-6-fluoro-1,4-dihydro-5-methyl-4-oxo-3-quinolinecarboxylic acid.
152. The stereoisomer of Claim 1 and being 3R,1R-7-[3-(1-aminoethyl)-1-pyrrolidinyl]-1-cyclopropyl-8-ethoxy-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid.
153. The stereoisomer of Claim 1 and being 3R,1R-5-amino-1-cyclopropyl-6-fluoro-1,4-dihydro-7-[3-[1-(methylamino)ethyl]-1-pyrrolidinyl]-4-oxo-3-quinolinecarboxylic acid.
154. The stereoisomer of Claim 1 and being 3R,1R-1-cyclopropyl-6-fluoro-1,4-dihydro-5-methyl-7-[3-[1-(methylamino)ethyl]-1-pyrrolidinyl]-4-oxo-3-quinolinecarboxylic acid.
155. The stereoisomer of Claim 1 and being 3R,1R-1-cyclopropyl-8-ethoxy-6-fluoro-1,4-dihydro-7-[3-[1-(methylamino)ethyl]-1-pyrrolidinyl]-4-oxo-3-quinolinecarboxylic acid.
156. The stereoisomer of Claim 1 and being 3R,1R-5-amino-1-cyclopropyl-7-[3-[1-(ethylamino)ethyl]-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid.
157. The stereoisomer of Claim 1 and being 3R,1R-1-cyclopropyl-7-[3-[1-(ethylamino)ethyl]-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-5-methyl-4-oxo-3-quinolinecarboxylic acid.


-191-

158. The stereoisomer of Claim 1 and being 3R,1R-1-cyclopropyl-8-ethoxy-7-[3-[1-(ethylamino)ethyl]-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid.
159. The stereoisomer of Claim 1 and being 3R,1R-5-amino-1-cyclopropyl-7-[3-[1-(dimethylamino)ethyl]-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid.
160. The stereoisomer of Claim 1 and being 3R,1R-1-cyclopropyl-7-[3-[1-(dimethylamino)ethyl]-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-5-methyl-4-oxo-3-quinolinecarboxylic acid.
161. The stereoisomer of Claim 1 and being 3R,1R-1-cyclopropyl-7-[3-[1-(dimethylamino)ethyl]-1-pyrrolidinyl]-8-ethoxy-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid.
162. A pharmaceutical composition comprising an antibacterially effective amount of a compound of Claim 1 in admixture with a pharmaceutically acceptable carrier.
163. A method of treating bacterial infections in mammals which comprises administering to said mammal in need thereof a pharmaceutical composition of Claim 162.
164. A process for the preparation of a compound of Claim 1 which comprises reacting a compound of the formula

-192-



wherein L is fluorine or chlorine with an individual stereoisomeric amine of the formula



wherein


* denotes an asymmetric carbon atom;

R is hydrogen or alkyl of 1-3 carbon atoms;
and

R'' is hydrogen, alkyl of 1-3 carbon atoms or an amino protecting group, and removing, if necessary, the amino protecting group according to known methods.

-193-

165. An individual stereoisomer of the formula



wherein

* denotes asymmetric carbon atoms;


R is hydrogen or alkyl of 1-3 carbon atoms;
and

R' is alkyl of 1-3 carbon atoms.

166. The stereoisomer of Claim 165, wherein R is hydrogen, methyl or ethyl, and R' is methyl or ethyl.

167. The 3R,1S, 3S,1R, or 3R,1R stereoisomer of Claim 166.

168. An individual stereoisomer of the formula



wherein

* and *' denote asymmetric carbon atoms;

-194-

R is hydrogen or alkyl of 1-3 carbon atoms;
and


R" is hydrogen, alkyl of 1-3 carbon atoms or
t-butyloxycarbonyl.

169. The stereoisomer of Claim 168 wherein *' is of the
R or S configuration.

170. The stereoisomer of Claim 169 wherein R is
hydrogen, methyl or ethyl, and R" hydrogen is
methyl, ethyl or t-butyloxycarbonyl.

171. The 3R,1S, 3S,1R, or 3R,1R stereoisomer of
Claim 170 wherein *' is R or S.

172. An individual stereoisomer of the formula




wherein

* and *' denote asymmetric carbon atoms;
R is hydrogen or alkyl of 1-3 carbon atoms;
and
R" is hydrogen, alkyl of 1-3 carbon atoms,
acetyl, trifluoroacetyl or t-butyloxycarbonyl.

173. The stereoisomer of Claim 172 wherein *' is of the
R or S configuration.

-195-

174. The stereoisomer of Claim 173 wherein R is hydrogen, methyl or ethyl, and R" is hydrogen, methyl, ethyl, acetyl, trifluoroacetyl or t-butyloxycarbonyl.
175. The 3R,1S, 3S,1R, or 3R,1R stereoisomer of Claim 174 wherein *' is R or S.
176. An stereoisomer of the formula




wherein * and *' denote asymmetric carbon atoms.

177. The stereoisomer of Claim 176 wherein *' is of the R or S configuration.
178. 3-(Acetyl)-1-(S- α -methylbenzyl)pyrrolidin-5-one.
179. 3-(2'-(Ethoxycarbonyl)acetyl)-1-(S- α -methylbenzyl)pyrrolidin-5-one.


-196-

180. A process for the preparation of the individual stereoisomers of the formula




wherein * denotes asymmetric carbon atoms and R is hydrogen or alkyl of 1-3 carbon atoms which comprises:

- (a) converting a chirally fixed pyrrolidin-5-one-3-carboxylic acid of the formula




-197-

wherein *' is either R or S by known methods to a diastereomeric pair of oximes of the formula



wherein * is an asymmetric carbon atom;

- 5 (b) separating the diastereomers by column chromatography;
- (c) reducing each diastereomeric oxime by known means to a diastereomeric pair of amines of the formula



- 10 (d) separating each diastereomeric pair of amines into the individual diastereomers by column chromatography;
- (e) reducing the 5-pyrrolidinone by known methods and protecting the free amino group with a suitable protecting group by known methods, if
- 15 desired, and


-198-

- (f) removing the fixed chiral α -methylbenzyl group by hydrogenolysis, and converting, if desired, by known means the resulting compounds where R is hydrogen to those where R is independently hydrogen or alkyl of 1-3 carbon atoms.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 91/08419

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) ⁶		
According to International Patent Classification (IPC) or to both National Classification and IPC		
Int.Cl.5	C 07 D 401/04	C 07 D 471/04
A 61 K 31/435	C 07 D 207/09	C 07 D 207/26
II. FIELDS SEARCHED		
Minimum Documentation Searched ⁷		
Classification System	Classification Symbols	
Int.Cl.5	C 07 D 401/00 C 07 D 471/00 C 07 D 207/00	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched ⁸		
III. DOCUMENTS CONSIDERED TO BE RELEVANT⁹		
Category ¹⁰	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
A	EP,A,0207420 (DAIICHI SEIYAKU CO., LTD) 7 January 1987, see claims (cited in the application) ---	1,162
A	US,A,4780468 (WARNER-LAMBERT CO.) 25 October 1988, see claims 6,7 ---	1,162
A	EP,A,0393400 (WAKUNAGA SEIYAKU K.K.) 24 October 1990, see page 30, compounds 152,153; page 35, compound 181; page 39, compounds 183-184; page 45, compounds 120,121; page 49, compound 147; page 53, compound 191 -----	1,162
¹⁰ Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "&" document member of the same patent family		
IV. CERTIFICATION		
Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report	
10-03-1992	16.04.92	
International Searching Authority	Signature of Authorized Officer	
EUROPEAN PATENT OFFICE	 Els Vonk	

FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET

V. ☒ OBSERVATION WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE ¹

This International search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claim numbers because they relate to subject matter not required to be searched by this Authority, namely:

Remark: Although claim 163 is directed to a method of treatment of (diagnostic method practised on) the human/animal body the search has been carried out and based on the alleged effects of the compound/composition.

2. ☐ Claim numbers because they relate to parts of the International application that do not comply with the prescribed requirements to such an extent that no meaningful International search can be carried out, specifically:

3. ☐ Claim numbers because they are dependent claims and are not drafted in accordance with the second and third sentences of PCT Rule 6.4(a).

VI. ☐ OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING ²

This International Searching Authority found multiple inventions in this International application as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International search report covers all searchable claims of the International application
2. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims of the International application for which fees were paid, specifically claims:
3. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claim numbers:
4. ☐ As all searchable claims could be searched without effort justifying an additional fee, the International Searching Authority did not invite payment of any additional fee.

Remark on Protest

- ☐ The additional search fees were accompanied by applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

**ANNEX TO THE INTERNATIONAL SEARCH REPORT
ON INTERNATIONAL PATENT APPLICATION NO.**

US 9108419

SA 54359

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the European Patent Office EDP file on 08/04/92
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A- 0207420	07-01-87	AU-B- 589978	26-10-89
		AU-A- 5924586	08-01-87
		JP-A- 62234082	14-10-87

US-A- 4780468	25-10-88	AU-B- 616422	31-10-91
		AU-A- 2006088	09-02-89
		AU-A- 8374391	14-11-91
		EP-A- 0302525	08-02-89
		JP-A- 1066180	13-03-89
		US-A- 4803205	07-02-89
		US-A- 4933335	12-06-90

EP-A- 0393400	24-10-90	AU-A- 5228190	04-10-90
		CN-A- 1045971	10-10-90
		JP-A- 3188074	16-08-91
